The Journal — Dr. Natasha Ryan

Does Birth Control Mask Perimenopause? What to Know in Your 40s

2026-10-04T00:00:00.000Z

She has been on the pill, or a hormonal IUD, for fifteen years. Her bleeding is light and predictable, or gone entirely. She is 43 and sleeping badly, her moods are harder to manage, and she wonders whether it could be perimenopause. Her cycle can't tell her, because her cycle hasn't been hers for a long time.

How hormonal birth control hides it

The usual first sign of perimenopause is a change in your cycle. Hormonal contraception removes that signal.

Combined pill, patch, or ring. The bleeding you have is a withdrawal bleed, not a natural period. These methods can also mask or control hot flashes and night sweats, and some women notice symptoms for the first time when they stop.
Progestin-only methods. The implant, the progestin-only pill, and the injection can cause irregular bleeding or stop periods completely for as long as you use them.
Hormonal IUD. It commonly makes periods lighter or stops them.
Copper IUD. It has no hormones, so it doesn't mask the cycle. It can make periods heavier.

Combined hormonal contraception also makes FSH testing unreliable. UK guidance (NICE) specifically advises against using FSH to diagnose menopause in women on combined estrogen and progestogen contraception or high-dose progestogen. If a clinician orders an FSH while you are on the pill, the result doesn't answer the question.

What still shows up

Contraception doesn't suppress everything. Sleep changes, early-morning waking, brain fog, joint aches, and new anxiety can all continue or begin while you are on it. Because hormonal methods can also cause mood and sleep effects of their own, it is hard to know which is which, and that is a fair reason to look at the whole picture rather than guess. Track symptoms rather than bleeding, as described in Perimenopause With Regular Periods, and check the other usual causes in the earlier article on telling them apart.

You can still get pregnant

This is the part that gets missed. According to the UK Faculty of Sexual and Reproductive Healthcare, women aged 40 to 44 who have unprotected sex over a year have a 10 to 20% chance of pregnancy, falling to about 12% at 45 to 49. Pregnancy after 50 is rare but possible.

The usual guidance for when you can stop contraception is:

12 months after your last period if you are 50 or older.
Two years after your last period if you are under 50.
Or at age 55, when natural conception is considered exceptionally rare.

Women whose method stops their periods can't use bleeding to know when that is. Many continue until 55. Some clinicians check FSH at 50 after pausing a method, with the caveat above.

Guidelines differ by country, and what I have described is mostly UK and Australian guidance. Your own situation matters more than any age cutoff, so ask your clinician where you fall.

Which methods suit your 40s

UK and Australian guidance says combined pills, patches, and rings should be reserved for low-risk women in their 40s and stopped at 50 because of clot risk. Progestin-only methods, including the implant and hormonal IUD, and the copper IUD can generally continue. A copper IUD placed in your 40s can often stay until 55, depending on the device and where you live. Smoking, high blood pressure, a history of clots, and migraine with aura all change the picture.

If you start menopausal hormone therapy, it is not contraception. Some clinicians pair a contraceptive implant, a drospirenone pill, or a hormonal IUD with hormone therapy. The IUD can also supply the progestogen that protects the uterine lining. That is a decision to make with someone who prescribes both.

The AMH test question

AMH (anti-Müllerian hormone) tests are marketed online as a way to predict when you will reach menopause. The research is not supportive. A study of the Doetinchem cohort concluded that AMH is associated with age at menopause, but individual predictions from a single measurement are unreliable, and it could not advocate AMH as a screening method for timing of menopause. An individual-patient meta-analysis of 2,596 women found that AMH added little to age alone for predicting time to menopause. It added more for early menopause, but individual predictions remained imprecise.

AMH can tell you something about egg supply, which matters for fertility planning. It can't tell you when your periods will stop.

What I would do

Track sleep, mood, night sweats, and headaches, and write down what happens in the pill-free week if you have one.
Don't stop your method on your own to find out. Plan the change first, so you are not unprotected.
If you are 45 or older with symptoms, talk to a clinician who handles both contraception and menopause care.
Skip AMH for menopause timing.

Birth control works well for what it does. It also quietly removes the signals that tell you what your hormones are doing. In your 40s, that is worth knowing and worth planning around.

Postpartum Depletion or Perimenopause? Why You're Still Exhausted After Baby

2026-10-04T00:00:00.000Z

Her youngest is three. She had her first baby at 34 and her second at 37. She is now 40, and she has never felt quite right since the second pregnancy. She is exhausted, her memory is poor, her hair is thinning, and her patience is gone. She assumed it was just what motherhood does. It may be, or it may be one of several things that are checkable.

Many millennial women had children in their mid-30s or later, so the aftermath of pregnancy and the start of perimenopause now overlap. The symptoms are nearly identical, which makes it easy to blame the wrong thing or nothing at all.

What pregnancy can leave behind

Postpartum thyroiditis. According to the American Thyroid Association, this autoimmune inflammation of the thyroid affects roughly 5 to 10% of women in the US after delivery. It typically brings a hyperthyroid phase, sometimes with anxiety and a racing heart, followed by an underactive phase with fatigue, dry skin, constipation, and low mood. Most women recover within 12 to 18 months. But one review estimated that about 25% of women with a history of it develop permanent hypothyroidism in the following ten years, and annual TSH checks are recommended afterward. If you had unexplained exhaustion or mood changes after a baby and nobody tested your thyroid, it is worth checking now, with antibodies. See Plateau Patty for the full panel.
Low iron. Pregnancy and delivery use up iron, and many women start pregnancy with low stores. A literature review found that low ferritin in the postpartum period was associated with higher risk of postpartum depression, and iron supplementation after delivery lowered the risk in four of five studies. Iron deficiency causes fatigue, hair shedding, poor concentration, and restless legs whether or not you are anemic.
Low B12 and vitamin D. Both have been associated with perinatal depression in observational studies. That does not prove they cause it, but they are cheap to test and easy to correct.
Sleep debt. Years of broken sleep are an effective cause of exhaustion, anxiety, and low mood on their own, and they are a trigger for the early-morning waking that also marks perimenopause.

You will also see "postnatal depletion" used for the cluster of fatigue, fog, and low mood after pregnancy. It is not a formal diagnosis. Iron, and possibly B12 and vitamin D, have the most evidence behind them. I would treat the term as a useful description, not a proven syndrome.

Where perimenopause comes in

Perimenopause can begin in the late 30s and 40s, and it can start earlier in some women. If you are over 38 and your cycles, sleep, or mood have shifted, it belongs on the list. It can also coexist with any of the above, and treating only one leaves you partly better.

Breastfeeding complicates the picture. Cycles and hormone levels can be altered while you nurse and for a while afterward, so hormone testing and cycle changes are harder to interpret in the first months after you stop.

If you had postpartum depression or anxiety

A large registry study found that women with a history of postpartum depression had about twelve times the risk of a depression diagnosis in perimenopause compared with women with no depression history. The risk was just as high for women who had depression earlier that was not postpartum, so the finding is that any prior depression raises risk, not that postpartum depression is uniquely predictive. If you have had it, tell your clinician, and take new low mood or anxiety seriously early. Don't read this as inevitable. It is a reason to watch and treat early.

What I would check

Thyroid: TSH, free T4, free T3, and TPO antibodies.
Iron: blood count and ferritin.
B12 and vitamin D.
A1c. Gestational diabetes raises the risk of type 2 diabetes later.
A pregnancy test, if you are unsure.
A depression and anxiety screen. A short questionnaire is fine.

What helps

Replace what is low, and only what is low. Iron should be taken only when ferritin is low, since excess iron isn't harmless. Professional-grade iron, B12, and vitamin D are in my Fullscript dispensary.
Protect sleep like a prescription. That may mean splitting nights with a partner or asking for help. It has more effect than any supplement.
Lift weights and eat enough protein. Both help energy, mood, and muscle.
Treat the mood symptoms if they are there. Therapy and medication work, and nobody should wait for a hormone explanation first. See Perimenopause Anxiety vs. Generalized Anxiety Disorder.
Reassess after three months. If fatigue persists with normal labs, look at perimenopause, sleep apnea, and ADHD.

If you are having thoughts of harming yourself, call or text 988 in the US.

Being tired for years after a baby is common. It is not always normal, and some of the causes are simple to find.

ADHD and Perimenopause: Why Symptoms Worsen and What to Do About It

2026-10-04T00:00:00.000Z

She has always been organized, or at least she thought so. Now she loses her train of thought in meetings, misses deadlines she used to hit easily, and feels overwhelmed by tasks that were routine. She has started to wonder about ADHD. Her doctor says it is probably perimenopause. A friend with ADHD says it sounds exactly like her.

It could be either, and it could be both. This is a topic where the honest answer is that the evidence is early.

What the research shows

A 2025 population-based cohort study from Iceland, published in European Psychiatry, compared perimenopausal symptoms in women aged 35 to 55 with and without ADHD. Women with ADHD had higher total symptom scores across psychological, somatic, and urogenital symptoms, and about 54% reported severe perimenopausal symptoms compared with about 30% of women without ADHD. The gap was widest in the late 30s: symptoms peaked at ages 35 to 39 in women with ADHD and 45 to 49 in women without. The authors interpreted that as possibly indicating an earlier onset of perimenopause in ADHD.

There are real limits. The study was cross-sectional, ADHD was self-reported, symptoms overlap between the two conditions, and there was no information on treatment. A narrative review published in 2026 summarized the broader picture: hormonal changes in midlife can worsen ADHD symptoms and reduce treatment response, but it also noted that a systematic review had found no empirical studies of ADHD during menopause, and that one cross-sectional analysis in an Icelandic study found no significant difference in menopausal symptoms between women with and without ADHD. The same review pointed out that ADHD in women is frequently underdiagnosed, especially in midlife, when hormonal change can exacerbate or unmask symptoms.

The proposed mechanism is plausible. Estrogen influences dopamine signaling, and dopamine is central to attention and executive function. But plausible is not proven, and nobody has shown in controlled trials that stabilizing estrogen treats ADHD.

Why the two get confused

Both cause forgetfulness, trouble focusing, disorganization, emotional reactivity, poor sleep, and anxiety. Perimenopause alone can reduce learning and memory performance temporarily. In the SWAN study, women in perimenopause showed a subtle reduction in how well they learned on repeat testing, which rebounded after menopause.

Many women with inattentive-type ADHD were never diagnosed as girls because they were quiet and did well enough in school. They built systems and worked harder to compensate. When sleep deteriorates, anxiety rises, and hormones swing, the compensation can stop working, and the first diagnosis arrives in the 40s.

Clues that point in each direction

Toward ADHD: difficulties going back to childhood or school years (ADHD requires symptoms before age 12), a pattern of disorganization or impulsivity across many settings, and a family history.
Toward perimenopause: new onset in your late 30s or 40s with no earlier history, symptoms that worsen with poor sleep, hot flashes, or the days before your period, and other changes such as cycle shifts or night sweats.
Toward both: a lifelong tendency that got dramatically worse in the last few years.

What to do

Rule out the fixable causes first. Thyroid, ferritin, B12, vitamin D, and sleep apnea all cause poor focus. See what to rule out first.
Get evaluated by a clinician who diagnoses adult ADHD. A psychiatrist or psychologist experienced with adult women is ideal. Bring a written history of when the symptoms started.
Treat sleep and hot flashes. Poor sleep makes attention worse in everyone, and it is often the biggest single lever.
Don't stop an ADHD medication on your own. The review found no randomized trials of ADHD medication in perimenopausal women, so there are no validated dosing protocols. If your medication seems to work less well than before, tell your prescriber and track how it changes with your cycle.
Hormone therapy is not an ADHD treatment. It can treat hot flashes, sleep disruption, and other perimenopause symptoms, which may help focus indirectly. I would not start it based on ADHD symptoms alone, and it needs to be discussed with whoever manages your ADHD.
Use external structure. Written task lists, calendar alerts, and fixed routines work whether the cause is ADHD, perimenopause, or both.
Move regularly and limit alcohol. Exercise helps attention and mood, and alcohol worsens sleep.

If your focus has changed, you deserve a clear answer, not a guess in either direction. The evidence is early, but the workup is straightforward, and it separates what is fixable from what needs treatment.

Perimenopause at Work: Brain Fog, Meetings, and What Actually Helps

2026-10-04T00:00:00.000Z

She is good at her job and has been for fifteen years. Now she loses a word in the middle of a presentation, forgets what she walked into a room to say, and feels a hot flush rise during a video call. She stays late to make up for it and wonders whether she is losing her edge.

She isn't, and she is not unusual.

What the research shows

A Mayo Clinic study published in Mayo Clinic Proceedings surveyed about 4,400 employed women aged 45 to 60. It found that 13% reported at least one adverse work outcome related to menopause symptoms, and about 11% had missed at least one day of work in the past year because of them. The researchers estimated the cost of lost work time at about $1.8 billion a year in the US, and $26.6 billion once medical costs were added. The severity of symptoms strongly predicted whether a woman had an adverse work outcome. The authors also noted that women often fear bias or stigma and are reluctant to disclose symptoms to managers.

In an industry survey, 42% of women reported that perimenopause or menopause symptoms had hurt their ambition, rising to 46% of women aged 40 to 49. Treat that as a directional figure, since it comes from a brand survey.

Is the brain fog real?

Yes. The Study of Women's Health Across the Nation (SWAN) tested women repeatedly through the menopause transition. It found that perimenopause was associated with a subtle reduction in learning: women did not improve with repeated testing in the way they had earlier, on both processing speed and verbal memory. In the postmenopausal stage, learning rebounded to premenopausal levels. About 60% of women in the study reported memory problems during the transition. The researchers concluded the effect appears temporary, though the findings should be interpreted with caution.

This fits what women describe: word-finding trouble, losing track of conversations, and slower learning of new material, in a person whose underlying ability has not changed. It also means it is worth looking at the things that make it worse, which are often more fixable than hormones themselves.

What makes it worse

Poor sleep. Night sweats and 3 AM waking are the most common cause of daytime fog. See Waking at 3 AM.
Hot flashes and anxiety that pull attention in meetings.
Blood sugar crashes in the afternoon. See Why You Crash at 3 PM.
Other conditions. Low thyroid, low iron, low B12, and sleep apnea cause the same symptoms. See what to rule out first.
Alcohol and heavy caffeine, both of which worsen sleep and anxiety.

What helps at work

Use an external memory. Write down what happens in meetings, send a short follow-up email with decisions and owners, and set calendar reminders for anything you can't afford to forget. It works for everyone and it protects you.
Put your hardest thinking at your best time of day. Schedule demanding work when you are sharpest, usually mid-morning, and routine tasks for the afternoon dip.
Prepare for meetings. A written outline of your main points makes a lost word less costly.
Plan for hot flashes. Dress in layers, keep a fan or cool water at your desk, and sit near a vent or window if you can. A sudden flush passes within minutes, and most colleagues won't notice it.
Eat protein at lunch and avoid a high-sugar meal. It reduces the afternoon crash.
Take a ten-minute walk after lunch. It helps glucose, mood, and attention.
Treat the underlying symptoms. If hot flashes and poor sleep are affecting your work, effective treatments exist, including hormonal and nonhormonal prescription options. This is worth a visit rather than gritting your teeth through it.

Talking to your manager

You are not required to share a diagnosis. It is often easier to ask for specific things. Examples are a cooler workspace, a flexible start time after a bad night, the option to turn your camera off briefly, or written agendas before meetings. Frame it around what helps you do the job. Whether any legal protections apply depends on where you live and your situation, so check with HR or an employment attorney if you want formal accommodation. I am not offering legal advice here.

When it is not just perimenopause

Burnout, depression, and ADHD can all look like this. If the fog is severe, getting worse, or accompanied by low mood or loss of interest, get evaluated. See ADHD and Perimenopause and Perimenopause Anxiety vs. Generalized Anxiety Disorder.

Your ability hasn't gone anywhere. Most of the fog tracks sleep and symptoms, and both can be treated. In the meantime, a few small systems protect your work while your body sorts itself out.

Can Oura or Apple Watch Detect Perimenopause? What Wearable Data Shows

2026-10-04T00:00:00.000Z

You wear a ring or a watch. It shows your sleep, your resting heart rate, and your temperature trend. Lately the numbers have changed: more night waking, a higher resting heart rate, a temperature line that looks erratic. You wonder whether the device is telling you something about perimenopause.

It may be showing you something real. It can't tell you what it means by itself.

What the evidence says

No wearable has been validated to diagnose perimenopause or to tell you what stage you are in. Companies describe their devices as helpful for tracking the metrics that change with hormones: sleep quality, skin temperature, heart rate, and heart rate variability. Oura, for example, reports that its ovulation estimate matched the calendar method 96.4% of the time and that its four-stage sleep classification is 79% accurate against a sleep lab. Those are company-reported figures from regular-cycle and sleep-lab settings, not from perimenopausal women.

Research in this area is just starting. A registered observational study is enrolling women aged 35 to 55 to use an Oura Ring and a Fitbit daily, with a subgroup providing daily urine hormone samples across three cycles, to learn whether wearable signals can detect things like hot flashes and night sweats. That is the stage the field is at: asking the question.

What your data can usefully show

Night waking and sleep fragmentation. Seeing that you wake at 3 AM five nights a week is a clearer record than memory.
Temperature spikes at night, which may line up with night sweats.
A change in resting heart rate or heart rate variability over weeks.
Links to cycle days or behavior. Many women find the data worsens after alcohol, a late meal, or a stressful day, and in the days before a period.

That is useful. It turns a vague complaint into specifics you can bring to an appointment.

What it can't tell you

Whether you are in perimenopause. That is a clinical judgment, as described in the earlier article.
Your hormone levels. Skin temperature and heart rate respond to many things, including illness, alcohol, room temperature, and stress.
Cycle phase when cycles are irregular. Temperature-based ovulation estimates work best when cycles are regular, which is not the pattern in much of perimenopause.
Anything accurate about night sweats if the device is not designed to detect them.

Sleep stage numbers should be read as trends, not measurements. Chasing a perfect sleep score can also backfire. If checking your score makes you anxious about sleep, the tracking is costing you more than it gives.

What about a CGM?

Continuous glucose monitors have become popular among women without diabetes. In my view they can be useful for a short stretch, two weeks at most, to see how you respond to particular meals and whether you have overnight dips or afternoon crashes. There are no established targets for glucose in people without diabetes, normal readings vary, and watching numbers closely can create its own anxiety. Use it to learn a pattern, not to chase a flat line. See Sugar Sherry.

How I would use your data

Track for at least three months so you have patterns, not single nights.
Tag symptoms and behaviors. Log hot flashes, night sweats, alcohol, mood, and your period if you have one. The tagging matters more than the score.
Review once a week, not daily.
Bring a summary to your appointment: the number of nights you wake, how often, any link to your cycle, and when it started. Screenshots of a few weeks are enough.
Combine it with the standard workup for thyroid, iron, and sleep apnea. Some wearables flag breathing disturbances, but a sleep study is the way to check.

A wearable is a good notebook and a poor diagnostician. Used that way, it can help you and your clinician see what is happening in the nights and in the days before your period.

Perimenopause Symptoms in Your Late 30s and 40s: What to Rule Out First

2026-10-04T00:00:00.000Z

You are somewhere between 35 and 45. You are tired in a way sleep doesn't fix, your sleep has gotten worse, your moods are less predictable, and your periods have changed. You have searched your symptoms and perimenopause came up. You may also have been told you are too young for that, or that it is probably stress.

Either could be right. Perimenopause can begin in the late 30s or early 40s, and several other common conditions cause the same symptoms in the same decade. The useful question is not "is it perimenopause?" It is "what else could this be, and have we checked?"

What the age ranges mean

The median age at which perimenopause begins is 45, and it lasts a median of 4 to 8 years. Many women notice symptoms earlier, and in surveys of US women over 35, more than a third said they were unsure what stage they were in. Women in their late 30s more often cite not knowing what to look for.

How a clinician approaches it depends on your age. UK guidance (NICE) says that in healthy women over 45 with menopausal symptoms, perimenopause can be diagnosed from symptoms and cycle changes without blood tests. For women aged 40 to 45 with symptoms and a change in their cycle, an FSH test can be considered. For women under 40 where menopause is suspected, FSH testing is appropriate, and a diagnosis of premature ovarian insufficiency needs elevated FSH on two samples taken four to six weeks apart.

FSH is also not valid if you are on combined hormonal birth control or high-dose progestogen.

What else looks like perimenopause

Thyroid disease. Underactive thyroid causes fatigue, weight gain, hair thinning, cold intolerance, constipation, low mood, and heavier or irregular periods. Overactive thyroid causes anxiety, palpitations, heat intolerance, and lighter or irregular periods. Thyroid problems are common in women in this age range, and they can follow pregnancy. See Is It Your Thyroid or Your Hormones?
Low iron. Fatigue, hair shedding, poor concentration, restless legs, and a racing heart can occur with low iron stores even before anemia shows up on a blood count. Heavy periods make it more likely.
Low B12 or vitamin D. Both cause fatigue and low mood, and B12 deficiency also causes tingling and brain fog.
Postpartum changes. Postpartum thyroiditis, nutrient depletion, and years of broken sleep can all persist well beyond the first year, especially for women who had children in their mid to late 30s.
Sleep apnea. It becomes more common through midlife, and it causes daytime exhaustion, morning headaches, anxiety, and poor concentration. Snoring or waking gasping are clues.
PCOS or insulin resistance. Irregular cycles, acne, extra hair growth, and weight gain at the waist. PCOS can be diagnosed in the 30s and beyond.
Chronic stress and sleep loss. A stressed, under-slept body can lengthen or skip cycles and cause fatigue, anxiety, and cravings. This is covered in Bossy Betty and Wired Wendy.
Anxiety, depression, and ADHD. Each can begin or become obvious in midlife, and perimenopause can also make existing ones worse.
Pregnancy, and high prolactin, both of which are worth ruling out when periods are late or irregular.

These can also overlap. A woman can have perimenopause and low iron and a sluggish thyroid, and treating only one leaves her feeling only partly better.

Clues that point toward perimenopause

Cycle changes: shorter or more variable cycles, heavier or lighter flow, more intense PMS, or spotting before the period.
Night sweats or waking between 2 and 4 AM in someone who used to sleep well.
Mood or anxiety that is worse in the days before a period.
Symptoms that are new in your 40s with no history of them earlier.

None of these is specific. Thyroid disease can change cycles too. That is why the workup matters.

What I would ask for

Thyroid: TSH, free T4, free T3, and TPO antibodies.
Blood count and ferritin.
B12 and vitamin D.
A1c and fasting insulin.
A pregnancy test, and prolactin if periods are irregular.
FSH and estradiol in the situations above, and with realistic expectations. Hormone levels swing from month to month in perimenopause, and a study following women through the transition found single FSH measurements tell you little about menopausal status. A normal result does not rule it out.

Two to three months of notes are worth as much as the blood work. Record cycle length, flow, sleep, night sweats, and mood by cycle day. The pattern often shows more than a single lab result does. More on testing in Your Labs Are Normal.

See someone promptly if

Your periods stop for three months or more and you are under 40. That needs a premature ovarian insufficiency workup, because it affects bone and heart health.
You are soaking a pad or tampon every hour, passing large clots, or bleeding between periods or after sex.
You have chest pain, fainting, or severe shortness of breath.
You are having thoughts of harming yourself. In the US, call or text 988.

If you are in your late 30s or early 40s and something has changed, it is reasonable to look at perimenopause. It is also reasonable to check the thyroid, iron, B12, and blood sugar at the same visit, because those are the ones that are quickest to find and fix.

Can You Be in Perimenopause With Regular Periods? Yes, and Here's What's Happening

2026-10-04T00:00:00.000Z

Her periods come every 28 days, as they always have. But her PMS has become hard to ignore, she wakes in the early morning in the week before her period, and her moods have a sharper edge than they used to. She has been told that regular periods mean it can't be perimenopause.

That conclusion is common, and it is not accurate. Hormone patterns can change while cycle length still looks normal.

How perimenopause is staged

The standard staging system, STRAW+10, defines the early menopausal transition by a persistent difference of seven days or more in the length of consecutive cycles. By that definition, a woman with regular cycles is not yet in perimenopause. That is a bleeding-pattern definition, and it describes when cycles become variable, not when the underlying hormone changes begin.

Before that point is a stage the system calls late reproductive, when cycles are still regular but may show subtle changes in flow or length. Hormone changes can already be underway.

What the research shows

In a small study comparing women across the STRAW stages, FSH, LH, and estradiol in ovulatory cycles rose as women moved through the stages, while luteal-phase progesterone fell. Anovulatory cycles were uncommon in the earlier stages. In other words, women can still be ovulating and still have a changing hormonal pattern.

The researcher Jerilynn Prior has argued that perimenopause often involves higher and more erratic estrogen with lower progesterone, especially during regular cycles. Her framework describes the ovaries working harder in response to rising FSH while the luteal phase becomes shorter and progesterone falls. She also noted that research is needed to establish how to diagnose perimenopause in regularly cycling women. That caveat matters: this is an area where the physiology is better described than the diagnosis.

The practical point is that a woman can have symptoms driven by falling progesterone and swinging estrogen before her cycles are irregular enough to count.

What it can look like

PMS that is new or much worse: irritability, anxiety, breast tenderness, bloating, or low mood in the week or two before your period.
Sleep that falls apart before your period, often with waking in the early morning.
Shorter cycles, such as 28 days becoming 25 or 26, or spotting a few days before the period.
Heavier or clotty periods.
Migraines or headaches that cluster around your period.
Night sweats in the days before bleeding.

These line up with the Moody Maven and Anxious Annie patterns.

What else to check

Regular periods do not protect you from the look-alikes. Thyroid disease, low iron, B12 deficiency, and sleep problems all cause similar symptoms and should be checked, as described in the earlier article on telling them apart. Heavy periods in particular make low iron likely.

What to track

Cycle length and flow for at least three cycles.
Symptoms by cycle day. A simple note each evening is enough. You are looking for what clusters in the second half.
Ovulation and luteal phase length. Luteal phase is the number of days from ovulation to your period. About ten days or fewer is generally considered short. You can estimate ovulation with ovulation test strips or with basal or wearable temperature data.
Progesterone testing, if you want a lab check. Progesterone drawn about a week after ovulation, not on a fixed cycle day, shows whether ovulation happened and how strong it was. A random-day hormone test tells you very little.

What helps

Protect sleep first. It affects mood, anxiety, appetite, and cycle regularity. Cut alcohol for a few weeks to see what changes, since it is a common cause of early-morning waking and worsens PMS.
Eat enough and lift weights. Under-eating and overtraining can suppress ovulation and make symptoms worse. Steady blood sugar helps mood.
Support the luteal phase. Magnesium glycinate and vitamin B6 are commonly used for premenstrual symptoms, and professional-grade versions are in my Fullscript dispensary.
Ask about cyclic progesterone. Many clinicians use it for premenstrual sleep and mood symptoms in perimenopause. The trial evidence is limited, so treat it as a reasonable option to discuss rather than a guaranteed fix.

If you use hormonal birth control

If you are on the pill, patch, ring, or a hormonal IUD, you may not be able to read your cycle at all. Combined hormonal contraception also makes FSH testing unreliable, so NICE advises against using it to diagnose menopause in that situation. In this case, tracking symptoms and sleep matters more than tracking bleeding. Birth control is also not optional just because you suspect perimenopause. You can still become pregnant.

When to get checked

See a clinician for periods that last longer than seven days, soak through protection hourly, come closer than 21 days apart, or occur between cycles or after sex.

Regular periods mean you are still ovulating most months. They do not tell you that your hormones are steady. If your symptoms follow a pattern through the month, it is reasonable to take them seriously.

Perimenopause Anxiety vs. Generalized Anxiety Disorder: How to Tell the Difference

2026-10-04T00:00:00.000Z

She was told it was anxiety, and she was handed a prescription. Nobody asked about her cycle, her sleep, or whether it had a pattern. Or the reverse happened: she has had an anxiety disorder for years, and she has been told her worsening symptoms are just perimenopause.

Both mistakes happen. In one industry survey, 22% of women aged 40 to 49 said a provider had attributed their perimenopause symptoms to anxiety. This article is about how to tell what you are dealing with, and why the answer is often "both."

What the research shows

The Study of Women's Health Across the Nation (SWAN) followed 2,956 women who were 42 to 52 at the start, for ten years. Among women with low anxiety at baseline, the odds of high anxiety were about 1.6 times higher in early perimenopause, late perimenopause, and postmenopause than before menopause. Women who already had high anxiety stayed high throughout, and their risk did not differ by stage.

That fits the clinical picture. For women with no prior anxiety, the menopause transition looks like a window of new vulnerability. For women who were already anxious, perimenopause may not be the cause.

The picture is not uniform. Some studies have not found a consistent rise in anxiety by menopausal stage. Hot flashes and night sweats, however, have been consistently associated with anxiety, which makes it hard to separate the two.

A second SWAN analysis found that anxiety symptoms emerging during the transition predicted later major depressive episodes, with about 1.5 times the odds at the next annual visit. That is one reason new anxiety in midlife should be taken seriously rather than dismissed.

On mechanism, progesterone is converted to allopregnanolone, which acts on the same brain receptors as anti-anxiety medications. As progesterone falls with less frequent ovulation, that calming signal drops. A study of late perimenopause and early postmenopause found that allopregnanolone levels were related to depressive symptoms. More on this in Anxious Annie.

Clues it may be perimenopause

It is new, beginning in your late 30s or 40s with no real history of anxiety.
It follows your cycle. It is worse in the week or so before your period and eases when bleeding starts.
It comes with other changes: waking at 3 AM, night sweats, changing cycles, or a pounding heart.
It is physical more than mental. You feel a surge of adrenaline, internal shakiness, or dread without a clear thought behind it.
Irritability or rage is a big part of it, out of proportion to what set it off, and it feels unlike you.

Clues it may be an anxiety disorder

Anxiety on and off since your teens or twenties.
Persistent, hard-to-control worry about many things, on most days, for at least six months. That is the clinical threshold for generalized anxiety disorder.
No relationship to your cycle.
A family history of anxiety.

Many women fit both lists. Perimenopause can make an existing anxiety disorder much harder to control, which is the pattern the SWAN data point to for women who were already anxious.

What else to check

Several things cause anxiety that are easy to test and fix: an overactive thyroid, low iron, low B12, blood sugar swings, sleep apnea, and too much caffeine or alcohol. Alcohol acts on the same calming receptors and rebounds in the early morning hours. ADHD can also look like anxiety in midlife, especially when it was never diagnosed. See how to tell these apart.

What treatment has evidence

This is not either-or, and nobody should withhold treatment for anxiety while waiting to see whether it is hormonal.

Therapy and medication work. Cognitive behavioral therapy and SSRIs or SNRIs are effective for anxiety whether or not hormones are involved. If anxiety is interfering with work, sleep, or relationships, or you are having panic attacks, treating it is appropriate. Some of these medications also reduce hot flashes.
Hormone therapy may help in some women, but it is not a standalone anxiety treatment. Systematic reviews presented at The Menopause Society's 2025 meeting found that estrogen-based therapy did not consistently reduce anxiety or depression, though effects varied with whether hot flashes were present. A European expert statement concluded that hormone therapy may improve depressive symptoms in perimenopausal women, especially those with hot flashes, though it is not approved for that purpose. My read is that it makes the most sense when hot flashes and poor sleep are driving the mood symptoms.
Fix sleep. Poor sleep makes anxiety worse, and the 3 AM waking pattern has its own article: Waking at 3 AM.
Cut alcohol and trim caffeine for a few weeks and see how you feel.
Keep blood sugar steady with protein at each meal, and lift weights regularly. Both have good evidence for mood and anxiety.
Calm the stress response. The nervous system article covers what works in practice.
Consider magnesium glycinate or L-theanine. The evidence is modest, but both are low-risk. Professional-grade versions are in my Fullscript dispensary.

When to get help right away

If you are having thoughts of harming yourself, call or text 988 in the US. Seek urgent care for panic symptoms with chest pain or trouble breathing, because those need to be checked rather than assumed to be anxiety.

If you were told it is only anxiety, or only hormones, ask whether anyone looked at both. The answer changes the treatment, and women usually do better when it is addressed from both sides.

Lesser-Known Menopause Symptoms: 14 Signs Nobody Warns You About

2026-10-04T00:00:00.000Z

Most women know the headline symptoms: hot flashes, night sweats, irregular periods. Far fewer are told that menopause can also show up as a burning tongue, a shoulder that won't lift, or a feeling of electric shocks under the skin. So they go to a dentist, an orthopedist, or a neurologist, get told everything looks fine, and never connect any of it to their hormones.

Estrogen receptors are found throughout the body, not just in the reproductive tract. That is why the menopause transition can affect the mouth, ears, eyes, skin, joints, and heart. The National Menopause Foundation's symptom checklist lists 36 symptoms. Menopause specialists describe seeing the pattern repeat: most women have the typical symptoms, and a smaller group arrives with the unexpected ones, and it only makes sense once someone looks at the whole picture through the lens of menopause.

Here are fourteen of the ones women most often miss. Six have their own full article.

Mouth, ears, and eyes

1. Burning mouth. A burning, scalding, or numb feeling in the tongue, lips, or palate with nothing visibly wrong. Reported in a large minority of postmenopausal women, with estimates varying widely between studies. Read the full article.

2. Dizziness and vertigo. Spinning when you roll over in bed or tip your head back. Benign paroxysmal positional vertigo is more common around perimenopause, and it is one of the most treatable symptoms on this list. Read the full article.

3. Ringing in the ears. The research on hormones and tinnitus is mixed, but new or worsening tinnitus in the transition is common enough that it belongs on the list. It is covered in the same article as dizziness.

4. Dry, gritty eyes. Up to 60% of perimenopausal and menopausal women report dry eyes or other vision changes. The hormone story is more complicated than "low estrogen," and the standard fix doesn't always work. Read the full article.

Joints and muscle

5. Frozen shoulder. It peaks in women aged 40 to 60, the same years as perimenopause. Read the full article.

6. Widespread joint aches and muscle tension. The National Menopause Foundation reports that up to 60% of women have joint aches during menopause. Also covered in the frozen shoulder article, along with the conditions that look the same and need different treatment.

Skin and nerves

7. Itchy skin with no rash. Skin gets drier and thinner as collagen production falls, and the skin barrier repairs itself more slowly. Read the full article.

8. Crawling or prickling skin. A feeling of insects on or under the skin, called formication. Same article.

9. Electric shock sensations. Brief "body zaps," usually over in a second or two. Some women notice them with hot flashes. Same article.

10. Brittle nails and changing hair. Hair can become drier, thinner, and slower-growing, and nails can split or peel. Hair loss and nail changes also point to thyroid problems and low iron, so they are worth a lab check before you assume it is hormonal.

Heart, nose, and everything else

11. Heart palpitations. Fluttering, skipped beats, or a racing heart. Up to 42% of perimenopausal women report them, and they are common enough that the question is not whether they happen but how to make sure they are what you think they are. Read the full article.

12. New or worse allergies. Hormone changes can make existing allergies worse or bring on new ones, and they can cause vasomotor rhinitis, a nasal inflammation with congestion and a runny nose that looks like allergies but isn't. If antihistamines do nothing, that is a clue.

13. Body odor. Hot flashes and night sweats mean more sweat, and sweat mixing with skin bacteria produces odor. It is common and has nothing to do with hygiene.

14. Urinary urgency and recurrent UTIs. Thinning of the vaginal and urinary tissues can cause urgency, leaking, and repeated urinary infections. This falls under genitourinary syndrome of menopause, and it is one of the few menopause symptoms that does not improve on its own. Low-dose local vaginal estrogen is an effective treatment, and it is worth asking about by name.

Why these get missed

Each of these has other possible causes, and they are usually investigated one at a time by different specialists. A dentist looks at the mouth. An ophthalmologist looks at the eyes. Nobody asks whether the burning tongue, the dry eyes, and the crawling skin might share a cause.

The reverse is also true. Not everything that shows up in your forties is hormonal. Several of these symptoms can be caused by low B12, low iron, thyroid disease, diabetes, medications, or autoimmune conditions, and a few need to be checked before they are put down to menopause. That is why each article in this series lists what to rule out first.

What to do with this list

If three or more of these sound familiar, and especially if you also have changing cycles, poor sleep, or mood shifts, you are very likely in the menopause transition and worth a proper evaluation. Write down the symptoms and when they started. Ask for a basic panel: thyroid, ferritin, B12, A1c, and vitamin D. Then talk to a clinician who treats menopause, not one who treats each symptom in isolation.

These symptoms are real, they are common, and most of them have something that helps. The first step is knowing they may be connected.

Burning Mouth Syndrome in Menopause: Why Your Tongue Burns and What Helps

2026-10-04T00:00:00.000Z

She has been to the dentist twice and her primary care doctor once. The tip and sides of her tongue burn, worse by evening. Her mouth is dry, there is a metallic taste, and everything looks normal on exam. She has been told it is stress, or given a rinse for thrush she doesn't have.

This is burning mouth syndrome, and it is more common in menopausal women than almost anyone is told.

What it is

Burning mouth syndrome (BMS) is a burning, scalding, tingling, or numb sensation in the mouth with no visible cause. It most often affects the tip of the tongue, but it can involve the lips, palate, and gums. It can be mild or severe, constant or intermittent, and some women also have dry mouth, a bitter or metallic taste, or reduced taste.

It mostly affects women, and mostly women past menopause. Reviews describe it as predominantly affecting women between 50 and 70, rarely diagnosed under 30. Estimates of how many menopausal women have it range from about 10% to 40% depending on the study, and the numbers vary because researchers have used different definitions. One frequently cited figure is up to 33% of postmenopausal women. The overall rate in the general population is much lower.

Why menopause is involved

Estrogen receptors are present in the lining of the mouth and in the salivary glands. When estrogen falls, saliva production can drop and the oral lining can become thinner and more sensitive. Studies of people with BMS also show altered pain and sensory thresholds, which suggests a nerve component rather than just irritated tissue. Poor sleep and anxiety, both common in the transition, are associated with it too.

The honest summary is that the cause is not settled. Hormones are one contributor among several, which is why the workup matters.

What to rule out first

True BMS is a diagnosis of exclusion. Before it is attributed to menopause, these should be checked:

Nutrient deficiencies: B12, folate, iron (ferritin), and zinc.
Thyroid disease and diabetes: an underactive thyroid and high blood sugar can both cause oral burning.
Oral thrush: a yeast infection can burn without obvious white patches.
Dry mouth from medications or Sjögren's syndrome: antihistamines and antidepressants are common culprits. Dry mouth together with dry eyes and joint pain is worth testing for Sjögren's.
Blood pressure medication: ACE inhibitors have been associated with oral burning.
Reflux, dental materials, or flavorings: acid reflux and sensitivity to toothpaste ingredients or cinnamon and mint flavorings can all mimic it.

I would want a basic panel before accepting a hormonal explanation: ferritin, B12, folate, zinc, thyroid, and A1c. If any of them are low, replacing them is the first step, and professional-grade forms are in my Fullscript dispensary.

What helps

Protect your saliva and your mouth. Sip water through the day, use xylitol lozenges, skip alcohol-based mouthwash, and try a toothpaste without sodium lauryl sulfate. Cut back on acidic and spicy foods while it flares.
Ask a dentist or oral medicine specialist about the options with some trial evidence. These include alpha-lipoic acid, prescription topical clonazepam, and capsaicin rinses. The trials are small and the evidence quality is low, so none is a sure thing, but they are worth discussing.
Consider cognitive behavioral therapy for the pain. It has been studied in BMS and can help with how the pain is processed, even when the cause is partly hormonal.
Hormone therapy is reasonable to consider if you have other menopause symptoms. It may relieve oral burning in some women, but there are no clear studies showing how well it works, so it is not a proven fix for BMS on its own.

Don't skip the dentist

The mouth is affected by menopause in other ways too: reduced saliva, more gum disease, more oral yeast infections, and jaw bone loss when osteoporosis develops. Dry mouth raises the risk of cavities, so the visit has value beyond the burning. If you have not had a bone density scan, this is another reason to get one.

One thing needs prompt attention: any sore, white or red patch, or lump in the mouth that has not healed in two weeks should be examined, whether or not you think it is menopause.

Burning mouth is frustrating because it is invisible and easy to dismiss. But it has a recognized link to menopause, a defined list of things to rule out, and options that help.

Dizziness, Vertigo, and Tinnitus in Menopause: The Estrogen–Inner Ear Connection

2026-10-04T00:00:00.000Z

The first time it happened she rolled over in bed and the room spun for thirty seconds. Since then it has come back when she looks up at a shelf or bends to tie a shoe. She has also noticed a high-pitched ringing in the evenings. Her primary care doctor said it was probably an ear thing and to see how it goes.

Dizziness is one of the symptoms that surprises women most in perimenopause, and it is more connected to hormones than most doctors mention.

Three different problems with one name

"Dizzy" covers very different things, and the right treatment depends on which one you have.

Positional vertigo (BPPV). Brief spinning, usually under a minute, triggered by head movement such as rolling over, looking up, or bending down. It happens when tiny calcium crystals in the inner ear come loose and drift into the wrong canal.
Ménière's-type episodes. Attacks of vertigo that last longer, together with fluctuating hearing loss, ringing, and a feeling of fullness in the ear.
General lightheadedness or unsteadiness. A floaty, off-balance feeling that is often not coming from the inner ear at all.

What the research shows

The inner ear contains estrogen receptors. In lab studies, estrogen helps regulate calcium handling in the fluid of the vestibular system, and estrogen deficiency changes the crystals that BPPV involves.

In people, the pattern fits. Perimenopausal women make up a large share of the patients seen in dizziness clinics for BPPV. Postmenopausal women with unexplained BPPV have been found to have lower estradiol than comparison women. A population study in Taiwan found that the age-related rise in BPPV was reversed in women taking estrogen therapy. Separately, studies have found low bone density to be more common in women with BPPV, which fits with a calcium-handling problem.

For Ménière's disease, postmenopausal women with the condition have been found to have lower estrogen levels, and a small preliminary study has tested hormone therapy alongside vestibular rehabilitation. That is early data, not a treatment recommendation.

Hearing and tinnitus are less clear. Reviews describe the findings as inconsistent. Some studies, including a nationwide one, suggest hormone therapy lowers the risk of tinnitus, and others have not found a benefit. I would not choose hormone therapy based on tinnitus alone.

What to do

Get BPPV identified and treated. A clinician can confirm it with a simple positional test, and a repositioning maneuver (the Epley maneuver) often resolves it in one to a few sessions. A vestibular physical therapist is ideal. Do not just wait for it to pass, and do not try YouTube versions without knowing which ear is involved.
Rule out the common contributors. Ferritin and a blood count, B12, A1c, thyroid, and blood pressure including a standing reading. Dehydration, low iron, and blood sugar swings all cause lightheadedness. So do some medications, including blood pressure drugs and certain antidepressants.
Look at sleep and anxiety. Dizziness in peri- and postmenopausal women has been linked to anxiety in both directions: dizziness is frightening, and anxiety makes dizziness worse. If your symptoms are worse after bad nights or during stress, the nervous system piece and the Anxious Annie pattern may be relevant.
Check your bone density. Given the link between BPPV and low bone density, a DEXA scan is worth having if you have not had one.
For tinnitus, get a hearing test. Protect your ears from loud noise, treat poor sleep, and avoid anything that clearly worsens it, such as heavy caffeine or alcohol.
Talk about hormone therapy for the right reasons. If you have other menopause symptoms, treating them may also help dizziness. It is not a replacement for the repositioning maneuver.

When it is not menopause

Some dizziness needs urgent attention:

Sudden hearing loss in one ear is a same-day medical problem. Treatment works best when started within days.
Dizziness with facial droop, slurred speech, arm or leg weakness, double vision, a sudden severe headache, or trouble walking needs emergency care.
Ringing in only one ear, or a pulsing sound that matches your heartbeat, should be evaluated.

If you are spinning in bed at forty-seven, there is a good chance it is BPPV, there is a decent chance your hormones are part of the story, and it is among the most fixable symptoms on the whole menopause list.

Frozen Shoulder and Joint Pain in Menopause: Why Your Joints Hurt After 40

2026-10-04T00:00:00.000Z

It started as an ache she blamed on sleeping wrong. A few weeks later she couldn't reach behind her to fasten a bra or lift her arm to wash her hair, and the pain at night was waking her. There had been no fall, no injury, and no heavy lifting.

This is adhesive capsulitis, usually called frozen shoulder. It is more common in women than men, it peaks between 40 and 60, and that is exactly the age range of the menopause transition.

What frozen shoulder is

The shoulder joint is surrounded by a capsule of connective tissue. In frozen shoulder, that capsule becomes inflamed, thickens, and tightens, and the joint loses range of motion. It usually moves through three stages: a painful "freezing" stage where stiffness builds, a "frozen" stage where the pain eases but the stiffness remains, and a "thawing" stage where motion slowly returns. The whole process commonly takes one to three years, sometimes longer.

A useful sign: if someone else gently tries to move your arm, it does not go any further than you can move it yourself. That points to a stiff capsule rather than a torn tendon, where the arm usually moves passively but you cannot lift it on your own.

The estrogen connection

The link is not proven, but it is getting more attention. Estrogen is involved in how bone, muscle, and connective tissue function, and the loss of estrogen is associated with joint and muscle symptoms often grouped as the musculoskeletal syndrome of menopause. The National Menopause Foundation reports that up to 60% of women have joint aches during menopause.

For frozen shoulder specifically, a study presented at the 2022 annual meeting of the North American Menopause Society looked at about 2,000 women. The women who were not receiving hormone therapy had greater odds of adhesive capsulitis. That was an observational study of risk, and it does not tell us whether hormone therapy would loosen a shoulder that is already frozen.

What else to rule out

Joint pain after 40 is not always menopause, and some causes need different treatment.

Diabetes and prediabetes. Diabetes is one of the strongest known risk factors for frozen shoulder. If you have shoulder stiffness and any blood sugar signs, check A1c and fasting insulin. This is where the Sugar Sherry pattern shows up.
Thyroid disease. An underactive thyroid is associated with frozen shoulder and with generalized aches. See the Plateau Patty article for the full panel.
Inflammatory arthritis. Morning stiffness lasting more than 30 to 60 minutes, swollen or warm joints, or symmetrical pain in the small joints of the hands should prompt inflammatory markers and rheumatoid testing. Rheumatoid arthritis often starts in these same decades.
Low vitamin D and low iron. Both are common and both contribute to aches and fatigue.
Statin muscle pain, if you take one.

What helps

Move early, gently, and within pain limits. Do not immobilize a painful shoulder. A physical therapist can show you a range-of-motion program. Forcing it makes things worse.
Ask about an injection in the early painful stage. A corticosteroid injection can reduce pain, particularly early on. If you have diabetes, tell whoever does it, because it raises blood sugar for several days.
Position your sleep. Sleep on the unaffected side with a pillow supporting the sore arm, or on your back with the arm propped.
Build and protect muscle. Resistance training and adequate protein protect the joints and counter the muscle loss of menopause. The approach is covered in the muscle-protection article and applies whether or not you take a GLP-1.
Check vitamin D, and consider creatine. Vitamin D should be replaced if low. Creatine has real evidence for muscle and strength in postmenopausal women. Neither has been shown to treat frozen shoulder itself. Professional-grade versions are in my Fullscript dispensary.
Discuss hormone therapy if you have other symptoms. The shoulder alone is not a reason to start it, but if you already have hot flashes, poor sleep, or other symptoms, the possible benefit to joints is a point in its favor.

When to get it looked at

See someone if shoulder stiffness is getting steadily worse, if you cannot lift the arm at all, or if pain wakes you regularly. Seek urgent care for sudden severe shoulder pain with chest pressure, shortness of breath, or sweating, because left shoulder and arm pain can be cardiac.

Frozen shoulder is slow, but it is treatable, and the earlier you start moving and get the right workup, the shorter the process tends to be.

Itchy, Crawling Skin and Electric Shock Sensations in Menopause: What's Going On

2026-10-04T00:00:00.000Z

She itches, but there is no rash. At night it feels like something is crawling on her legs, and she has started to wonder if she is imagining it. Last week she felt a sudden jolt, like a small electric shock, run down her arm while she was standing in the kitchen. It was over in a second.

Women often don't mention these sensations because they sound strange. They are recognized menopause symptoms, and knowing the names helps.

Four sensations, often confused

Itching (pruritus). Generalized itch without a visible rash, often worse at night and on the legs, arms, and scalp.
Formication. A feeling of insects crawling on or under the skin, or a prickling that cannot be scratched away.
Paresthesia. Pins-and-needles, tingling, or numbness, most often in the hands, feet, arms, and legs. It usually passes quickly.
"Body zaps." Brief electric-shock-like jolts, a type of neuropathic sensation thought to relate to estrogen changes. They are usually fleeting, and some women notice them with hot flashes.

Why this happens

Estrogen supports collagen production and skin hydration. There is a strong correlation between skin collagen loss and estrogen deficiency at menopause, and estrogen use after menopause has been associated with higher skin collagen, greater thickness, and less dry skin. As estrogen falls, skin gets drier and thinner, and the skin barrier replaces itself more slowly, which makes itching, stinging, and irritation more likely.

Estrogen also plays a role in nerve function, which is the likely reason for tingling, crawling, and zaps. I want to be clear about the limits here: these sensations appear on menopause symptom checklists but have been studied far less than hot flashes, so some of the explanation is inferred from how estrogen acts on skin and nerves rather than demonstrated in trials.

What to rule out first

Several common conditions cause the same sensations, and they are worth checking before assuming menopause.

B12 deficiency. A common cause of tingling and numbness, particularly if you take metformin or an acid blocker, or eat little animal protein.
Low iron. Itching without a rash, restless legs, and crawling sensations at night are all associated with low ferritin.
Thyroid disease and diabetes. Both can cause itching and nerve symptoms. Check TSH and A1c.
Liver or kidney problems. Generalized itching without a rash can come from either, so a metabolic panel is reasonable if the itch is persistent.
Medications. New itching or tingling after starting a medication is worth reviewing with your prescriber.
Neck or wrist problems. Tingling in the hands can come from a pinched nerve at the neck or wrist.

A reasonable starting panel is a blood count, ferritin, B12, TSH, A1c, and a metabolic panel.

What helps

Treat the skin barrier. Use lukewarm showers instead of hot ones, fragrance-free cleanser, and a ceramide moisturizer applied within a few minutes of bathing. A humidifier helps in dry months.
Use a targeted itch product. Menthol or pramoxine lotions can quiet an itch without steroids.
Be careful with antihistamines. A sedating antihistamine can help you sleep through a bad night, but it is not a good nightly habit in your fifties and beyond.
Treat vulvar itching as its own problem. Itching in the vulvar area often reflects genitourinary syndrome of menopause, and low-dose local vaginal estrogen is the treatment.
Consider hormone therapy if you have other symptoms. Many menopause clinicians find it eases these sensations, but there are no good trials specifically on crawling skin or zaps, so it is a reasonable option, not a guarantee.
Work on stress and sleep. These sensations tend to flare with poor sleep and high stress. The nervous system article covers the practical side.

When it needs more attention

Get evaluated promptly for numbness or tingling on one side of the body, especially with weakness, vision changes, or trouble speaking, which need emergency care. Electric sensations that shoot down the spine when you bend your neck should be checked by a neurologist. An itch that lasts more than a couple of weeks, especially with fatigue, weight loss, or yellowing of the skin or eyes, warrants labs.

These symptoms feel alarming because they are unfamiliar. In most women they are benign, they overlap with several fixable conditions, and a short list of lab tests usually tells you whether menopause is the explanation.

Heart Palpitations in Perimenopause: When It's Hormones and When to Get Checked

2026-10-04T00:00:00.000Z

She is sitting on the couch in the evening when her heart suddenly flips, skips, or starts to race for no reason. It lasts a few seconds or a few minutes, and then it is gone. It is frightening, and it is easy to wonder whether something is seriously wrong.

Palpitations are among the most common surprises of perimenopause, and also among the symptoms most likely to be brushed off, so it is worth being clear about both sides.

How common it is

A scoping review of palpitations in the menopause transition found that up to 42% of perimenopausal women and up to 54% of postmenopausal women report them. The same review noted that although many women aged 40 to 59 believed their palpitations needed treatment, a systematic review found no top-tier evidence for how to manage them.

Menopause palpitations are also associated with worse insomnia, worse depressive symptoms, and poorer quality of life, so they are not a trivial symptom even when the heart is structurally normal.

Why it happens

The likely driver is the drop and fluctuation of estrogen. Estrogen influences the autonomic nervous system, which controls heart rate and rhythm, but the exact mechanism in women is not settled. Several things commonly make it worse:

Hot flashes and night sweats, which often come with a racing heart.
Poor sleep.
Caffeine and alcohol, which many women find they tolerate less well in perimenopause.
Blood sugar dips, especially after skipped meals or high-sugar meals (the Sugar Sherry pattern).
Anxiety and a stuck-on stress response, covered in Anxious Annie and Wired Wendy.

Get it checked, even if you think it's hormonal

Menopause palpitations are a diagnosis of exclusion. The scoping review also points out that there is a documented history of women's cardiac symptoms being trivialized, which leads to missed or delayed diagnoses. Perimenopause is also when cholesterol and blood pressure start to shift and atrial fibrillation becomes more likely with age. So I would want these checked:

An ECG at minimum.
A rhythm monitor if the palpitations are intermittent. A one- or two-week patch monitor is more likely to catch an episode than a single ECG or a 24-hour monitor.
Thyroid tests. An overactive thyroid causes palpitations, and thyroid problems become more common in these years.
Blood count and ferritin. Anemia and low iron both cause a racing heart.
Electrolytes including potassium and magnesium, and blood sugar.
Blood pressure and a lipid panel. You are there anyway, and this is the decade these start to move.

If everything comes back normal and the monitor shows only harmless extra beats, you can attribute it to hormones with much more confidence.

When to go now

Seek urgent care for palpitations with any of these:

Chest pain or pressure
Fainting or near-fainting
Shortness of breath
Palpitations that start during exertion
A fast heartbeat that does not settle after several minutes
A family history of sudden cardiac death or cardiomyopathy

What helps

Track your triggers. Note the time of day, what you had to eat and drink, how you slept, and whether a hot flash came with it. Alcohol and caffeine are the most common avoidable triggers.
Keep blood sugar steady. Eat regular meals with protein if episodes cluster after long gaps or sugary meals.
Use slow breathing. A long, slow exhale can settle the rhythm and calm the stress response, and there is more on this in the nervous system article.
Correct deficiencies. If ferritin or magnesium is low, replace it. Professional-grade options are in my Fullscript dispensary. If your levels are normal, extra magnesium is not proven to help.
Know what the evidence says about treatment. A systematic review of treatments for menopausal palpitations concluded that no therapy can be fully recommended. Estradiol had some positive evidence and can be considered with caution, and the review did not find enough support to recommend other drugs or supplements. Treat it as a reason to be careful, not to give up.

Most perimenopausal palpitations are not dangerous. But "most" is not the same as "yours," and a short workup is what lets you stop worrying about it.

Dry Eyes in Menopause: Why Hormone Therapy Isn't the Simple Fix

2026-10-04T00:00:00.000Z

Her eyes feel gritty by mid-afternoon. They burn, her vision blurs until she blinks, and her contacts, which she wore for twenty years, have become unbearable. Eye drops help for twenty minutes. Someone told her it was screen time.

Dry eye is one of the most common menopause-era symptoms and one of the least connected to menopause in most people's minds. It also has a twist that most articles skip.

How common it is

Cleveland Clinic reports that up to 60% of perimenopausal and menopausal women have symptoms such as dry, scratchy eyes, blurred vision, light sensitivity, and swollen, red eyelids.

Why it happens, and why it isn't just estrogen

Tears have three layers: a watery layer, a mucus layer, and an oily outer layer that stops the tear from evaporating. The oil comes from the meibomian glands in the eyelids, which are large oil glands. When those glands underperform, tears evaporate too fast, and that evaporative dry eye is the most common type.

Both estrogen and androgens are reduced at menopause, and both affect the tear-producing and oil-producing glands. But a review of dry eye in postmenopausal women found that low androgen levels are the more consistent factor, while both low and high estrogen levels have been linked to dry eye.

The hormone therapy twist

You might expect estrogen to fix it. The largest study on the question suggests otherwise. In the Women's Health Study, which followed more than 25,000 postmenopausal women, those using estrogen alone had about 69% higher odds of dry eye or severe dry eye symptoms than women who used no hormone therapy, and those using estrogen plus a progestogen had about 29% higher odds. The risk rose with longer use.

That was an observational study with self-reported outcomes, and it began in the 1990s, so it reflects the formulations of that era. Later research is mixed, and reviews describe hormone therapy as having limited benefit for dry eye symptoms and possibly worsening meibomian gland dysfunction. Dose and the age when treatment starts seem to matter. Androgen treatment, systemic or local, has shown promising early results, but it is not an established treatment.

My position is that your eyes alone are not a reason to start hormone therapy, and they are not a reason to avoid it either. I would not start testosterone for dry eye. The androgen data are early, and testosterone is not FDA-approved for any indication in women, as I covered in the testosterone article.

What to rule out

Sjögren's syndrome. An autoimmune condition that mainly affects women and often appears in midlife. Dry eyes together with dry mouth, joint pain, or unexplained fatigue is worth testing for.
Medications. Antihistamines, many antidepressants, some blood pressure drugs, and isotretinoin can all dry the eyes.
Thyroid disease and vitamin A deficiency. Both can cause eye symptoms.
Eyelid inflammation (blepharitis), allergies, and contact lens problems. All common and all treatable.

What helps

Preservative-free artificial tears. Use them regularly, not only when the eyes are bad. Preservatives can irritate with frequent use.
Warm compresses and lid hygiene. A warm compress for about ten minutes, followed by gentle lid cleaning, helps the oil glands flow. This is the most useful daily habit for evaporative dry eye.
Cut down on evaporation. Take screen breaks and blink fully, use a humidifier, and keep fans and car vents from blowing on your face.
See an eye doctor if it persists. Prescription drops that reduce inflammation, in-office treatments that open blocked oil glands, and tiny plugs that keep tears in the eye are all options.
Be realistic about omega-3 supplements. The evidence here is clearer than for most supplements. In the DREAM trial, 535 people with moderate to severe dry eye took a high dose of fish oil or an olive-oil placebo for a year, and the fish oil did no better. Omega-3 may be worth taking for other reasons, but I would not rely on it for dry eye.

When to see an eye doctor urgently

Same-day evaluation is warranted for eye pain, sudden vision changes, marked redness with light sensitivity, or seeing halos around lights. Those are not dry eye.

Dry eye in menopause is real, it is common, and the answer is rarely a single hormone. It usually comes from sorting out the cause and treating the eyelids and tear film directly.

Testosterone Therapy for Women: What the FDA’s 2026 Workshop Means for Menopause

2026-10-04T00:00:00.000Z

On September 17 the FDA did something it had never done before: it held a public workshop devoted entirely to testosterone use in menopausal women. If you've been on hormone therapy and wondered whether testosterone belongs in it, or you've asked about it and been told no, or you're one of the women who's been quietly getting it from a wellness clinic, this is the most important regulatory conversation about your hormones in years. Here's what actually happened, what the evidence supports today, and how I'd think about it if I were you.

First, the facts

There is no FDA-approved testosterone product for women in the United States. There never has been. Every woman using it here is using it off-label — typically a fraction of a dose of a gel or cream approved for men, or a compounded preparation, or a pellet.

That hasn't slowed demand. An analysis released this month found testosterone prescriptions for women rose 146% between January 2023 and July 2026, alongside reports of pharmacies delaying or refusing to fill them. The FDA's own framing is that despite growing off-label use, critical knowledge gaps remain — around sexual function, cognition, mood, and musculoskeletal health, around how to measure testosterone in women at all, and around long-term cardiovascular and breast cancer safety.

The workshop was hosted jointly by the FDA's Office of Women's Health and its drug-evaluation center, with endocrinologists, urologists, gynecologists, and patient advocates presenting. The agency opened a public docket that stays open through October 19, 2026, and more than 1,300 comments had come in by the time the meeting convened.

What the FDA said

Three things, and they matter in different ways.

The agency wants a product to exist. This is the headline. FDA officials said they stand ready to review applications, urged manufacturers to run the studies, and suggested that data from products already approved overseas — testosterone is approved for postmenopausal women in Australia, New Zealand, the United Kingdom, and South Africa — might be leveraged, case by case, though the U.S. approval standard would still have to be met. The closing line from the agency was that menopause is inevitable but women should not have to suffer. That is not the tone of a regulator planning to shut something down.

The evidence is strongest for one thing. Every expert in the room agreed that the best data supports testosterone for hypoactive sexual desire disorder — low desire that causes distress — in postmenopausal women. That matches the 2019 Global Consensus Position Statement, endorsed by eleven medical societies including the Endocrine Society and the North American Menopause Society, which concluded that HSDD is the only evidence-based indication and that recommendations apply to physiologic doses only. For the other reasons women ask for it — energy, mood, brain fog, muscle, bone — presenters were direct: testosterone may well turn out to help, but the trials to prove it haven't been done.

The gaps are real, and so is the alarm about high dosing. The FDA named cardiovascular disease, breast cancer, and safety beyond 24 months as the areas where robust trial data is required before approval. And both the agency and the clinicians raised specific concern about supraphysiologic dosing — levels of 500 ng/dL and above, which some pellet and injection protocols produce — where long-term effects are unknown, estradiol rises, and informed consent is often thin. Pellets came in for particular scrutiny because once one is placed, it can't be removed if side effects appear.

What I take from it

I've watched testosterone go from a hormone nobody would discuss with women to one being marketed as the missing piece of every midlife problem, and neither extreme is right. The workshop landed close to where I sit.

Testosterone is the most abundant sex hormone in a premenopausal woman's body — produced at roughly three times the rate of estrogen — and it declines gradually from the thirties rather than dropping off a cliff at menopause. Low levels are associated with loss of muscle and bone, and with changes in mood, cognition, energy, and desire. Women are not wrong that something is missing. What they're often wrong about, because someone sold it to them, is that a high dose fixes it. The dose that has evidence is the one that returns a woman to the normal premenopausal range — not above it.

The measurement problem the FDA flagged is one I run into constantly. Standard testosterone assays were built for men's concentrations, and they are imprecise at the levels women actually have. There is no blood value that diagnoses "testosterone deficiency" in a woman. So the decision is clinical: the history, the symptoms, what estrogen and progesterone have and haven't resolved, and then a baseline level using the most sensitive assay available, mostly so we have something to monitor against rather than to justify the prescription.

And this belongs in a hormone conversation, not a standalone one. The compelling cases presented at the workshop were women already on estrogen and progesterone whose symptoms didn't fully resolve — where adding testosterone made the difference. In my experience that order matters: get the foundation assessed and treated first, and testosterone earns its place afterward, or it doesn't.

If you're considering it

Be clear about what you're treating. If it's low desire with distress, the evidence is on your side. If it's energy, mood, or muscle, you're in the "plausible but unproven" territory the FDA described, and you should hear that from whoever is prescribing it.
Insist on physiologic dosing and monitoring. Transdermal cream or gel at a female dose, a level checked before starting and again at three to six weeks, and a target within the normal premenopausal range. If a provider isn't measuring, or is aiming high on purpose, that's your answer.
Be cautious about pellets. They deliver doses that can't be adjusted or reversed, and they are the formulation the workshop singled out. This is a personal judgment call, but it's mine.
Know the side effects. Acne and increased facial or body hair are the common ones and reverse if the dose comes down. Voice deepening and scalp hair loss are rarer and may not.
Expect access friction. Testosterone is a Schedule III controlled substance, which limits telehealth prescribing across state lines and lets pharmacies cap the supply they'll dispense. Several workshop participants called for that designation to be lifted for physiologic doses in women; it hasn't been yet.

If you've already been on it

Nothing in the workshop suggests women on physiologic-dose testosterone should stop. The 2019 consensus found no evidence of serious adverse events in trials at those doses over their duration. What it does suggest is worth acting on: if you've never had a level checked, get one; if your levels were pushed high on purpose, have a conversation about why; and if you were started on testosterone without estrogen and progesterone ever being evaluated, that evaluation is still the more important one.

The honest summary is that the FDA has opened the door, the evidence for one indication is solid, the evidence for the rest is promising and incomplete, and the danger isn't testosterone — it's testosterone without measurement, without context, and without a physician who'll say "not yet" when that's the true answer. The docket is open until October 19. I'll update this piece when the agency responds.

Oral GLP-1 vs. Injection: Wegovy Pill, Foundayo, and What Women Over 40 Should Know

2026-10-04T00:00:00.000Z

For four years the GLP-1 conversation had one shape: a weekly injection, a pen in the fridge, and a price that put it out of reach for most women without insurance. That era ended quietly over the past nine months. There are now two GLP-1 pills approved for weight management in the United States, a third generation of molecules is posting results that make today's drugs look modest, and the pricing has shifted enough that women who dismissed this category are asking about it again.

I've written before about semaglutide and tirzepatide for women specifically. This is the update — what the pills change, what they don't, and the question a woman in her forties or fifties should be asking that a twenty-eight-year-old doesn't have to.

What's actually available now

Oral Wegovy (semaglutide 25 mg). Approved December 22, 2025, in pharmacies from January 2026. Same molecule as the injection, taken as a once-daily pill. In its phase 3 trial it produced roughly 16% average weight loss over about 64 weeks in adults who stayed on treatment — in the same range as the injection. The catch is how it has to be taken: first thing in the morning, on an empty stomach, with no more than a few ounces of water, and then a thirty-minute wait before anything else. That's because only a small fraction of oral semaglutide is absorbed, and food destroys even that.

Foundayo (orforglipron). Approved April 1, 2026. This one is different in kind — it's a small-molecule, non-peptide GLP-1 agonist, which means it doesn't need the absorption tricks. It can be taken any time of day, with or without food or water. In its main trial, the highest dose produced about 12.4% average weight loss versus under 1% on placebo — a step below oral Wegovy and well below injectable tirzepatide, but with a convenience profile nothing else in the class matches. It comes in six dose strengths, escalated gradually.

What's coming. CagriSema, a combination of semaglutide with an amylin analog, is under FDA review with a decision expected this year. Retatrutide, a triple agonist from Lilly, reported 28.3% weight loss in its first phase 3 trial — the strongest result the class has produced. Neither is a pill yet, but both are where the injectables are heading.

Pill or shot: how I'd think about it

If you're new to GLP-1s and the needle was the barrier, Foundayo is the easiest entry point ever offered in this class, and for a woman with fifteen to twenty-five pounds to lose, its numbers are enough. If you have more to lose or a strong insulin-resistance picture, oral Wegovy's higher efficacy is worth the morning ritual.

If you're already on injectable tirzepatide and it's working, I would not switch. Nothing oral matches it yet, and the dual-receptor mechanism has particular advantages for women in midlife that I covered in the tirzepatide piece. Switching for convenience usually costs you results.

If you're on injectable semaglutide and considering the pill, it's a reasonable lateral move — same drug, similar efficacy — provided the empty-stomach timing fits your life. If you take thyroid medication in the morning, this needs thought: both want an empty stomach and a wait, and stacking them requires a plan.

On cost: the pricing announced alongside the pill launches put the lowest doses at roughly $150 a month for self-pay, a fraction of what injections cost at launch. Prices change fast in this category, so treat that as a snapshot and check current cash-pay pricing directly.

The question that doesn't change with the formulation

Here is what the marketing for every one of these products leaves out. Somewhere between a quarter and forty percent of the weight lost on GLP-1 therapy is lean tissue, not fat — muscle, bone, connective tissue. In a thirty-year-old that's a problem. In a woman whose estrogen is already declining, whose muscle mass and bone density are already trending down every year, it's a different order of problem. You can lose thirty pounds and be metabolically worse off: lighter, weaker, more insulin-resistant per pound of muscle, with a skeleton that has lost ground it won't easily recover.

The pill doesn't change this. Neither does the injection. What changes it is what you do around the medication — and I've written a companion piece on protecting muscle on a GLP-1 because it deserves its own space. The short version: deliberate protein, progressive strength training, and body composition measured instead of scale weight, built in from the first dose rather than added when the loss of strength becomes obvious.

Before you start any of them

I still want the foundation assessed first. A full thyroid panel, fasting insulin, ferritin, vitamin D, and — for a woman in her forties or fifties — hormone levels, because a share of what brings women to GLP-1s is a thyroid or estrogen problem wearing a weight-loss costume. That doesn't disqualify the medication. It means the medication works better and the weight stays off when the system underneath it is working.

And the class-wide cautions apply to the pills exactly as they do to the injections: the thyroid C-cell tumor boxed warning, pancreatitis and gallbladder risk, and — the one women are least often told — reduced absorption of oral contraceptives during dose escalation, which I detailed in the tirzepatide article.

The pill era makes GLP-1s more accessible than they have ever been. It doesn't make them simpler. The women who do best on these medications in midlife are the ones who treat the prescription as one part of a plan for a body that is losing muscle and bone with or without the drug — and who choose the formulation second, after they've decided what they're protecting.

How to Prevent Muscle Loss on Wegovy, Zepbound, or Ozempic: A Guide for Women

2026-09-26T00:00:00.000Z

The number on the scale is the least interesting thing about GLP-1 weight loss. I say that to every woman who starts one, and most of them think I'm being contrarian until we run a body composition scan three months in. The scale says she's lost twenty-two pounds. The scan says seven of them were muscle. She feels it, too — the stairs are harder, the grocery bags are heavier, and she's tired in a way the weight loss was supposed to fix.

This is the part of the GLP-1 story that has finally reached the research community, which is why two muscle-preserving drugs designed to be taken alongside GLP-1s produced headline results this year. But you don't need to wait for those. The protocol that protects muscle and bone during rapid weight loss exists now, it's not complicated, and in a woman over forty it is not optional.

Why this is a midlife problem specifically

When anyone loses weight quickly, some of it comes from lean tissue. Trials of GLP-1 medications have generally found that roughly 25 to 40 percent of the weight lost is lean mass rather than fat. The body is in a large caloric deficit, protein intake usually drops because appetite is gone, and without a reason to keep muscle — a load on it — the body treats it as expendable.

A woman in perimenopause or beyond is already losing muscle and bone on her own. Estrogen supports both; as it declines, the rate of loss accelerates, and after fifty most women are losing muscle every year without a medication speeding it along. Add rapid GLP-1 weight loss on top of that trajectory and you can produce a body that is lighter, weaker, and more fragile — with lower bone density, a lower resting metabolic rate, and less of the tissue that clears glucose from the blood. That last point is the irony: muscle is the main site of insulin sensitivity, and losing it undermines the metabolic improvement the drug was meant to deliver.

What the new drugs showed

Two trials this year put numbers on what's possible when muscle is deliberately protected. The BELIEVE study, published in Nature Medicine in March, combined semaglutide with bimagrumab, an antibody that blocks the signaling that limits muscle growth. In the high-dose combination group, roughly 92 percent of the weight lost was fat — compared with about 72 percent on semaglutide alone — and total weight loss was greater with the combination than with either drug by itself. Bimagrumab on its own actually increased lean mass while reducing fat.

The EMBRAZE trial, published in June, paired tirzepatide with apitegromab, a selective myostatin inhibitor, and found the combination preserved about 55 percent of the lean mass that would otherwise have been lost, with total weight loss essentially unchanged. Notably, more than 80 percent of the participants were women.

Neither drug is approved, both are given by infusion or injection, and both are years from a pharmacy. What they prove is the principle: when you stop the muscle from being lost, the weight loss is better in every way that matters. And there is a version of that intervention you can do yourself, starting on day one.

The protocol I build around every GLP-1 prescription

Protein: roughly 1.2 to 1.6 grams per kilogram of body weight daily, spread across meals. For a 165-pound woman that's about 90 to 120 grams — and it's the hardest part, because the medication removes the appetite that would normally get you there. Eat protein first at every meal, before anything else fills you up, and treat a protein shake as medicine on days when food doesn't appeal. Under-eating protein on a GLP-1 is the single most common way women lose muscle on it.
Resistance training two to three times a week, progressively heavier. Muscle stays when it's asked to work. Walking is excellent for glucose and mood, but it is not a signal to keep muscle; lifting is. If you've never lifted, this is the moment to learn with someone who can teach form — the goal is compound movements, real load, and adding weight over time.
Measure body composition, not weight. A DEXA scan before starting and every three to four months tells you what you're actually losing. If lean mass is dropping faster than a modest share of the total, the protein and training need adjusting before you go up another dose. A bioimpedance scale is a rougher tool but better than a bathroom scale.
Get a bone density baseline. If you're over forty-five, or have any risk factor for osteopenia, a DEXA bone scan before starting is the reference point you'll want in two years.
Slow the escalation if you're losing too fast. The dose schedules were written to reach a target dose, not to protect your skeleton. Losing more than about one percent of body weight a week for weeks on end is where lean-mass loss accelerates. A slower titration, held at a dose that produces steady rather than dramatic loss, is often the better plan in midlife.
Creatine, vitamin D, and omega-3s. Creatine monohydrate has real evidence for preserving muscle and strength in post-menopausal women and is inexpensive; vitamin D with K2 supports the bone side; the professional-grade versions are in my Fullscript dispensary. These are supports for the protein and the training, not substitutes.
Check the hormones. A woman whose estrogen and testosterone are at the floor will struggle to hold muscle no matter how well she eats and trains. If you're post-menopausal and on a GLP-1, the hormone therapy conversation belongs in the same appointment.

What to watch for

Strength going down while the scale goes down is the warning sign. So is a resting heart rate that climbs, fatigue that worsens as weight drops, hair shedding beyond the first few weeks, and a face or arms that look older rather than leaner. None of those are the drug working. They're the protocol failing, and they respond to more protein, more load, and a slower dose.

The GLP-1 medications are remarkable tools, and the muscle-preserving drugs coming behind them will make them better. But the thing those trials demonstrated — that protecting muscle turns weight loss into fat loss — is available to you now, for the price of a protein target, a barbell, and a scan. Build it in from the first dose. It is far easier to keep muscle than to rebuild it at fifty-five.

Nervous System Regulation and Hormones: Why Your Protocol Isn’t Working

2026-09-26T00:00:00.000Z

There's a woman I see in some version every week. Her labs are on the desk. Her supplement list is long and mostly correct. She strength trains, she eats protein, she's cut the wine, she has the continuous glucose monitor and the sleep tracker, and she is doing everything with a precision that would impress an engineer. And she is still exhausted, still not sleeping through, still holding weight at her middle, still anxious at 3 AM.

When I ask when she last felt genuinely unhurried — not resting, not recovering, but at ease — she can't remember. That is the diagnosis. Not a deficiency, not a dose, not a missing test. A nervous system that has been on duty for so long it has forgotten how to go off it, and a hormone system that is faithfully reporting that state.

This idea — that you cannot supplement, train, or discipline your way past a dysregulated stress response — has moved from the fringes of functional medicine to its center over the past two years, and it's the piece I'd put first if I could reorder how women approach their health.

Why the nervous system comes first

Every hormone I test sits downstream of the autonomic nervous system — the automatic circuitry that decides, moment to moment, whether you are safe enough to digest, repair, and reproduce, or under enough threat to mobilize. That decision is made in the brainstem and hypothalamus before you're conscious of it, and the hypothalamus is also the master switch for the stress axis, the thyroid axis, and the reproductive axis. When it reads "threat," it doesn't just release cortisol. It downregulates thyroid conversion, suppresses ovulation and progesterone, raises blood sugar, slows digestion, and shifts fuel toward storage at the waist.

That is not dysfunction. It's an exquisitely designed survival program. The problem is that it was built for threats that end, and the modern version doesn't — the inbox, the calendar, the news, the mental load of running a household and a career, the 10 PM screen, the alarm at 5:30. The system never gets the "all clear," and the hormonal consequences pile up in exactly the patterns I've spent years describing: the inverted cortisol curve, the crash, the thyroid conversion block, the progesterone that ovulation stopped making.

This is why a technically perfect protocol can fail. Ashwagandha doesn't override a brainstem that reads danger. Progesterone helps but doesn't restore the ovulation that stress suppressed. A thyroid prescription can't unblock a conversion the body is deliberately slowing. The interventions work on a system that is allowed to receive them.

What I mean by regulation — and what I don't

I don't mean relaxation, and I don't mean meditation as one more thing on the list. I've watched women turn breathwork into a performance metric and feel like a failure when their HRV score dropped. That's the same nervous system running the same program with a new object.

Regulation means a nervous system that can move fully into the stress state when a demand appears, and then move fully back out of it when the demand passes. The problem is almost never the going up. It's the coming down — the inability to return to baseline. So the work is not about avoiding stress. It's about restoring the return.

What it looks like in practice

Repeated, small signals of safety. The nervous system learns from repetition, not intensity. A slow exhale that's longer than the inhale, done for two minutes several times a day, does more than a weekly hour-long class. So does eating one meal a day sitting down without a screen, or five minutes outside with nothing to accomplish.
Morning light and a real evening. The stress axis is anchored to the light cycle. Bright light within thirty minutes of waking and dim light after 8 PM are the two most reliable regulators I know, and they cost nothing.
Stop training as though you're in danger. For a woman whose system is stuck on, high-intensity exercise is another threat. Strength training and walking send a different signal — load and recovery — and they build muscle without spiking cortisol. Intensity can come back when the rhythm does.
Eat enough, on a schedule. Skipped meals and aggressive fasting are read by the brainstem as scarcity, which is a threat. Regular meals with protein are one of the strongest safety signals available, and the body will not release weight it believes it may need.
Name what the system is responding to. Sometimes the threat is real and ongoing — a marriage, a job, a caregiving situation — and no amount of breathwork addresses it. Regulation work can make the situation survivable; it can't make it safe. That's a different conversation, and an honest one.
Support, in its place. Magnesium glycinate, L-theanine, phosphatidylserine, and adaptogens matched to the cortisol curve all help a system that's being given a chance to settle. The professional-grade versions are in my Fullscript dispensary. They are the third step, not the first.

How you know it's working

You start falling asleep faster and waking less. Small provocations stop landing as hard. Digestion improves, which is often the first physical sign because the gut is wired directly to the vagus nerve. The 3 AM waking spaces out. And — this is the one women notice with disbelief — the same protocol that wasn't working starts to. The supplements land. The thyroid numbers move. The weight that wouldn't budge begins to.

I still test, and I still treat what the tests show. But I've stopped believing that any woman can optimize her way to health while her nervous system is telling every organ she's under attack. Put the regulation first. Everything else works better on a body that has been told it's safe.

Gut-Skin Axis: Why Adult Acne and Rosacea Start After 40

2026-09-26T00:00:00.000Z

She has a dermatologist and a drawer of products, and her skin is worse than it was at thirty. The redness across her cheeks started a couple of years ago and has been diagnosed as rosacea. The breakouts along her jawline arrived with her forties and don't respond to anything that worked in her teens. Her skin looks dull, reactive, and somehow older than her face. Every treatment has been aimed at the surface. Nobody has asked her about her digestion.

This is the gut–skin axis in a midlife woman, and it has become one of the most active areas of dermatology research for a reason: the skin is often the most visible readout of what's happening in the gut, and in the forties and fifties both of them are being reshaped by the same hormonal shift.

What the gut–skin axis actually is

The gut and the skin are both barrier organs — enormous surfaces where the body meets the outside world, each with its own microbiome and each in constant conversation with the immune system. The research, summarized in reviews from 2021 onward, shows that a surprising number of skin conditions come with an altered gut microbiome, not just an altered skin one: acne, rosacea, atopic dermatitis, psoriasis. The connection runs through the immune system, which the gut microbiome regulates, and through the compounds gut bacteria produce — short-chain fatty acids that calm inflammation, and, when the balance tips, metabolites and bacterial fragments that provoke it.

When the gut lining becomes more permeable — through dysbiosis, low fiber, alcohol, stress, medications — those inflammatory signals reach the bloodstream and the skin responds. The skin is not the problem. The skin is reporting it.

And the axis runs both ways. Skin inflammation and damage feed back to the gut through the same immune circuits. Which is part of why treating the surface alone so often produces a temporary improvement and a relapse.

Why midlife tangles it with hormones

Three things happen at once in perimenopause that land on both organs.

Estrogen declines. Estrogen maintains the gut lining, supports microbial diversity, and drives collagen production in the skin. As it falls, the gut becomes more permeable and less diverse, and the skin loses collagen at a rate that accelerates sharply in the first years after menopause. The dullness and thinning women notice are an estrogen story before they're a skincare story — I covered that side in the Glow Stack piece.

The estrogen-to-androgen ratio shifts. Testosterone declines more slowly than estrogen, so its relative influence grows. That's the jawline acne of the forties — androgen-driven oil production in skin that used to be protected by estrogen. It is also worsened by insulin resistance, which raises androgen activity, which is why the same woman often has the afternoon crashes and the stubborn midsection of a Sugar Sherry.

The gut becomes the estrogen bottleneck. The gut is where estrogen is meant to be cleared. When digestion slows and certain bacteria overproduce the enzyme that reactivates it, estrogen recirculates. This is the Bloated Brenda pattern, and it shows up on the skin as the cyclical, inflamed, hormonally-timed breakouts that dermatology treats with antibiotics — which further disrupt the gut, which worsens the cycle.

What I look at

Before another product, I want to see the gut directly: a comprehensive stool analysis for bacterial balance, inflammation markers, digestive capacity, and permeability. An IgG food sensitivity panel, because the delayed reactions that drive skin inflammation don't show up in a food diary. Fasting insulin, since androgen-driven acne almost always has a blood-sugar component. And the hormone picture — estradiol, progesterone, testosterone, DHEA-S — because the skin is responding to the ratio, not to any single value.

Where to start

Feed the microbiome before you treat the skin. Diversity of plants — thirty different kinds a week is a useful target — plus fermented foods most days. This is the single strongest lever for the short-chain fatty acids that calm skin inflammation from the inside.
Get the gut moving. A daily bowel movement is how estrogen and inflammatory metabolites leave. Fiber, water, magnesium citrate, movement after meals.
Stabilize blood sugar. Protein first, walks after meals, and fewer glucose spikes. Jawline acne often improves within weeks of this alone.
Be careful with the antibiotic cycle. Repeated courses for acne or rosacea can control the surface at the cost of the microbiome that's driving it. That's a conversation to have with your dermatologist, not a reason to stop a prescription on your own.
Targeted support — a well-chosen probiotic, zinc, omega-3s, and gut-lining support where permeability is confirmed — is in my Fullscript dispensary. Which probiotic depends on the stool test; skin-specific strains exist and guessing at them is expensive.
Address the estrogen side. For post-menopausal skin, no topical replaces what estrogen was doing for collagen and the barrier. That belongs in the hormone therapy conversation, alongside everything else it affects.

The skin of a woman in her forties is a map of two organs and one hormonal transition. Read it that way, treat what it's pointing at, and the surface follows — usually faster than the serum ever managed.

Cortisol Crash and Burnout in Women: The Bossy Betty Hormone Archetype

2026-09-14T00:00:00.000Z

She's the one everyone calls. The one who gets it done at work, at home, on the board, in the group chat — and has for years. Then, without a single day off that anyone could point to, something gives. She's not tired the way she used to be tired. She's flat. Small things that would have rolled off her a year ago now land like a punch. She rests and it doesn't take.

That is the Bossy Betty pattern, and of the nine hormone archetypes it may be the one that gets mislabeled most often — as depression, as "just getting older," as a character flaw. It is none of those. It is a stress-hormone system that has been asked to run flat out for too long and has started to downshift on its own.

What's actually happening

Your stress response runs on an axis: the hypothalamus signals the pituitary, the pituitary signals the adrenals, and the adrenals release cortisol. Cortisol is not the villain here. It's what gets you out of bed, holds your blood sugar steady between meals, keeps inflammation in check, and lets you rise to a demand. The system is built for surges followed by recovery.

What it is not built for is a surge that never ends. After enough years of that — a demanding career, caregiving, a marriage under strain, chronic under-sleeping, or all of it at once — the axis stops responding the way it did. Output falls, the daily rhythm flattens, and the brain becomes less sensitive to the cortisol that is there. You'll sometimes hear this called "adrenal fatigue." The adrenals aren't broken; the signaling is. HPA axis dysregulation is the more accurate name, and the distinction matters for how we treat it.

Two things ride along with the crash that make it worse. First, cortisol and thyroid are intertwined — chronic stress pushes thyroid conversion toward reverse T3, an inactive form, so the metabolic slowdown of a Plateau Patty often arrives on the back of a Bossy Betty. Second, the body makes cortisol and progesterone from overlapping raw material and machinery, so a woman deep in this pattern in her forties frequently has the anxiety and sleep changes of low progesterone too.

How to recognize her

Exhaustion that rest doesn't repair. A long weekend, a vacation — she comes back no better.
Flat and "done." Not sad exactly; the drive that defined her is just gone.
Low stress tolerance. A late invoice, a traffic jam, a child's minor crisis — things that used to be nothing now feel like too much.
Crashes after busy periods instead of bouncing back. The week after the big deadline is worse than the deadline itself.
Often: salt cravings, dizziness on standing, a mid-afternoon slump that a nap doesn't fix, and a body that gets sick the moment she finally stops.

Why your labs may say you're fine

A single morning serum cortisol is the test most women get, and it tells us almost nothing about this pattern. Cortisol is a rhythm, not a number. The information is in the shape of the curve across the day — and in this archetype the curve is often low and flat, or has lost the sharp morning rise that should be there. That requires a four-point salivary or dried-urine test, not one blood draw. I also want to see DHEA-S, a full thyroid panel with reverse T3, and ferritin, because iron deficiency mimics this pattern almost perfectly and is far easier to fix.

Where to start

Stop treating rest as a reward. This is the pattern where "I'll slow down after this quarter" has already been said for several years. Recovery is the treatment, not the thing you earn by finishing.
Protect blood sugar. A weak cortisol response means fewer reserves between meals. Protein at breakfast within an hour of waking, and no skipped meals, takes a real load off the system.
Get morning light and go easy on the evening screens. The HPA axis is anchored by the light-dark cycle. Ten minutes outside before 9 AM is one of the highest-return habits for this pattern.
Swap high-intensity exercise for strength and walking for a season. HIIT on a crashed cortisol curve digs the hole deeper. Lift, walk, and come back to intensity when the rhythm recovers.
Adaptogens have real evidence here — ashwagandha and rhodiola in particular — alongside a good B-complex, vitamin C, and magnesium glycinate. The professional-grade versions I use are in my Fullscript dispensary. Which adaptogen, and whether you need one at all, depends on what the curve actually shows.

Her close seconds

Bossy Betty rarely scores alone. Her most common runner-up is Wired Wendy — the same stress system, earlier in its arc, before the crash — or Plateau Patty when the thyroid has started to follow the cortisol down. If your assessment showed one of those as a close second, read it too; the order of operations for repair changes depending on which is driving.

The women who fit this pattern have usually spent a decade being the reliable one. The reliable thing to do now is treat the system that has been carrying you.

Tired but Wired? Cortisol Rhythm Disruption and the Wired Wendy Archetype

2026-09-14T00:00:00.000Z

The alarm goes off and she feels like she's been hit by something. Coffee gets her upright. The morning is a fog, the afternoon is a slog, and then — around nine or ten at night, when the house is finally quiet — she comes alive. Ideas, energy, focus. She gets more done between 10 PM and midnight than she did all day. And then she can't sleep, and the next morning she's hit by something again.

This is Wired Wendy. She is not lazy in the morning or a "night owl" by nature. Her stress hormone is running on the wrong schedule, and everything else — energy, sleep, mood, appetite — is following it.

What's actually happening

Healthy cortisol has a shape. It should surge in the first thirty to forty-five minutes after waking — that spike is what makes you feel awake — then drift down across the day and reach its lowest point around midnight, clearing the way for melatonin and deep sleep. In this archetype the curve is inverted or flattened: low in the morning when it should be high, and rising in the evening when it should be falling.

Here's the part that fools everyone, including doctors. Her total cortisol across the day can be completely normal. If you add up an upside-down curve you get the same number as a right-side-up one. That's why a single morning blood draw comes back fine and why she's told, again, that her labs look good.

What flips the curve? Usually a combination: years of late-night work and screens, caffeine used as a replacement for sleep, evening exercise, blood sugar swings, and a nervous system that has learned to associate nighttime with the only hours that belong to her. The evening cortisol rise is often the body's response to having no other window in which to think.

How to recognize her

Tired all day, wide awake at night. The signature.
A second wind around 10 PM — reliably, almost on a schedule.
Needs caffeine to start the morning, and often a second dose to survive the afternoon.
Sleep that doesn't refresh even when she gets seven or eight hours, because the depth of sleep is compromised by the cortisol that shouldn't be there.
Often: a racing mind at bedtime, waking between 2 and 4 AM, sugar cravings late in the evening, and a stubborn layer of fat at the waist that diet hasn't touched.

Why your labs may say you're fine

Because the test that finds this is rarely ordered. A four-point cortisol test — saliva or dried urine, sampled on waking, at midday, in the late afternoon, and at bedtime — shows the shape of the curve, and the shape is the diagnosis. I pair it with the cortisol awakening response, fasting insulin (the evening sugar cravings usually have a blood-sugar story attached), and a full thyroid panel, since a suppressed morning cortisol and a sluggish thyroid can look identical from the inside.

Where to start

Anchor the morning first. Bright outdoor light within thirty minutes of waking, every day including weekends, is the single most effective lever for restoring the morning spike. This works better than any supplement.
Move caffeine later and end it earlier. Delay the first cup by 60–90 minutes after waking so it doesn't blunt your own cortisol rise; make the last one before noon.
Give the evening a hard edge. Screens off, lights low, and — this is the hard one — no work after 8 PM for two weeks. The night-time productivity is real, but it's borrowed from tomorrow at a brutal interest rate.
Eat a real dinner with protein and slow carbohydrate. The late-evening sugar craving is often blood sugar falling, which triggers a cortisol rise to rescue it. Feed the evening properly and the rise has less reason to happen.
Support the wind-down. Magnesium glycinate, phosphatidylserine, and L-theanine in the evening can help blunt an inappropriate night-time cortisol rise; the professional-grade options are in my Fullscript dispensary. If a stimulating adaptogen like rhodiola is used at all, it belongs in the morning only.

Her close seconds

Wired Wendy and Bossy Betty are the same system at two different points in time — Wendy's inverted curve, left alone long enough, flattens into Betty's crash. The other common pairing is Sugar Sherry, because cortisol and insulin push each other around all day. If either showed up as your close second, the blood sugar work and the cortisol work should happen together.

The good news about this pattern is how responsive it is. Cortisol rhythm is one of the fastest things in the body to retrain — most women feel the morning shift within two to three weeks of anchoring it properly.

Weight Loss Resistance and a “Normal” Thyroid: The Plateau Patty Archetype

2026-09-14T00:00:00.000Z

She tracks her food. She lifts three days a week. She's cut alcohol, tried fasting, gone back to the plan that worked in her thirties. The scale hasn't moved in a year — or it's moving the wrong way. She's cold in rooms where everyone else is comfortable. Her hair is thinning at the part. She reads a paragraph twice. And her doctor, looking at a TSH of 3.8, has told her the thyroid is fine.

This is Plateau Patty. Everything about her is running slower — metabolism, digestion, circulation, cognition — and the number that would explain it is sitting inside a reference range that was never designed to find her.

What's actually happening

The thyroid sets the metabolic rate of nearly every cell in the body. It does that mainly through T3, the active hormone, which the body makes by converting T4 in the liver, gut, and peripheral tissues. TSH — the one number most women get tested — is the pituitary's signal to the thyroid, not a measure of what the tissues are receiving.

So a woman can have a TSH in the conventional "normal" range of roughly 0.5 to 4.5 and still be functionally hypothyroid if her T4 isn't converting to T3, if too much of it is going to reverse T3 (an inactive form the body makes under stress, inflammation, or calorie restriction), or if autoimmune antibodies have been quietly attacking the gland for years. In my practice, the optimal range for TSH sits closer to 0.5 to 2.0, and a large share of symptomatic women live in the gap between optimal and "normal."

Two things push her into this pattern. Chronic stress and dieting both raise reverse T3 — which is why the aggressive calorie cutting she's been doing to fight the plateau is often making it worse. And in perimenopause, estrogen fluctuations change the thyroid-binding proteins in the blood, so a thyroid that was fine at 38 can be underperforming at 46 without any change in the gland itself.

How to recognize her

Weight gain, or total weight-loss resistance, despite consistent habits. The defining feature.
Cold hands and feet when everyone else is comfortable; a low body temperature on waking.
Brain fog and slowed thinking — word-finding, focus, the sense of moving through syrup.
Hair thinning, dry skin, sluggish digestion, brittle nails, and the outer third of the eyebrows thinning.
Often: fatigue that is worst in the morning, puffiness around the eyes and face, a heavier or more irregular cycle, and cholesterol creeping up with no dietary explanation.

Why your labs may say you're fine

Because TSH alone is not a thyroid panel. The panel that finds this pattern includes TSH, free T4, free T3, reverse T3, and both thyroid antibodies (TPO and thyroglobulin). Free T3 and reverse T3 belong together: a low free T3 with a high reverse T3 is a conversion problem, and it will not respond to a thyroid prescription until whatever is driving the conversion block — usually cortisol, inflammation, or iron deficiency — is addressed. Alongside the thyroid I want ferritin, vitamin D, selenium and zinc status, and a look at the gut, because roughly a fifth of T4-to-T3 conversion depends on healthy gut bacteria.

Where to start

Stop cutting calories to break the plateau. This is counterintuitive and it is the most important thing on this list. Under-eating raises reverse T3 and slows you further. Eat enough, with protein at every meal, and let the metabolic rate recover before asking it to burn fat.
Get the full panel. Ask specifically for free T3, reverse T3, and TPO antibodies by name. If your provider won't order them, that is useful information about whether this is the right provider.
Feed thyroid conversion. Selenium (200 mcg), zinc, iron if ferritin is low, and vitamin D are the raw materials. Professional-grade versions are in my Fullscript dispensary.
Lift weights, walk, and skip the punishing cardio for now. Muscle is metabolically active tissue and building it is the sustainable route out of this pattern.
If antibodies are positive, the conversation changes: this is Hashimoto's, an autoimmune condition, and the gut and immune system move to the front of the plan.

Her close seconds

Plateau Patty most often pairs with Bossy Betty — a crashed cortisol curve is the commonest driver of the conversion block — and with Sugar Sherry, since insulin resistance and a slow thyroid reinforce each other and both produce a stubborn midsection. If one of those was your close second, it's probably the reason thyroid-only approaches haven't worked.

The plateau is not a discipline problem. It is a metabolic rate that has been turned down, and metabolic rates can be turned back up — once someone actually measures what's setting it.

Estrogen Dominance Symptoms in Women: The Moody Maven Archetype

2026-09-14T00:00:00.000Z

She can predict it. The week before her period the irritability arrives, then the breast tenderness, then the bloating and the tears over nothing. The period itself is heavy — clots, a second-day flood, sometimes eight days of it. Then it clears and she's herself again for two weeks, until the calendar comes back around. She's been told this is PMS and that PMS is normal. It is common. It is not normal.

This is Moody Maven, and her pattern has a physiology with a name: estrogen dominance. It's one of the most treatable of the nine archetypes, once you understand that the problem is usually not how much estrogen she makes but how well she gets rid of it.

What's actually happening

Estrogen and progesterone are meant to balance each other across the cycle — estrogen builds, progesterone stabilizes and calms. Estrogen dominance means estrogen is high relative to progesterone. That can happen because progesterone has fallen (common from the late thirties on, as ovulation becomes less reliable), because estrogen has risen, or — most often — because estrogen isn't being cleared.

Clearance is a two-step job. The liver processes estrogen into forms that can be excreted, and the gut carries them out. If the liver is overloaded — alcohol, a heavy environmental burden, nutrient shortfalls — or if the gut is sluggish and its bacteria are producing too much of an enzyme called beta-glucuronidase, the estrogen that was packaged for removal gets unpackaged and reabsorbed. It goes around again. The tissue that responds to estrogen — the uterine lining, breast tissue, fibroids — keeps getting the signal to grow.

That's why the Moody Maven story so often includes fibroids, dense or fibrocystic breasts, endometriosis, or a history of being put on the pill to "regulate" a cycle that was actually shouting about clearance.

How to recognize her

Heavy, clotty, or prolonged periods. Soaking through protection hourly, passing clots larger than a quarter, bleeding beyond seven days.
Breast tenderness before the period, sometimes to the point that a seatbelt hurts.
Mood swings and irritability that track the cycle — she can chart them.
PMS that disrupts life, plus fibroids, dense breasts, or endometriosis in the history.
Often: cyclical migraines, water retention and a five-pound premenstrual swing, weight that settles on the hips and thighs, and cycles that are shortening.

Why your labs may say you're fine

A single serum estradiol on a random day tells you almost nothing about a hormone that changes daily. The ratio is what matters, so the useful test is estradiol and progesterone drawn together around day 19 to 21 of a 28-day cycle (about a week after ovulation), when progesterone should be at its peak. Dried-urine hormone testing goes further and shows the estrogen metabolites — which clearance pathway the liver is using and whether it's the protective one. I also look at the gut directly when the history warrants it, since beta-glucuronidase can be measured in a stool test.

Where to start

Fiber, every day, more than you think. Thirty to forty grams is the target. Fiber binds estrogen in the gut and carries it out; a daily bowel movement is non-negotiable for this pattern.
Cruciferous vegetables. Broccoli, cauliflower, Brussels sprouts, cabbage, arugula — their compounds push estrogen down the safer metabolic pathway. Two cups a day, cooked or raw.
Look at alcohol honestly. Even moderate drinking measurably raises circulating estrogen and taxes the same liver pathways that clear it.
Reduce the xenoestrogen load. Plastics with heat, fragranced products, conventional pesticides — these bind estrogen receptors and add to the total signal. You don't need to be perfect; you need to reduce the daily dose.
Targeted support — DIM or calcium-D-glucarate for clearance, magnesium and B6 for the premenstrual symptoms, and in some women cyclical progesterone support. The professional-grade options are in my Fullscript dispensary; which ones fit depends on what the metabolite testing shows.

Her close seconds

Moody Maven's most frequent runner-up is Bloated Brenda, because the gut is where estrogen is meant to leave the body — the two patterns are often the same problem seen from two angles. Anxious Annie is the other: if the imbalance is being driven by falling progesterone rather than excess estrogen, the anxiety and sleep symptoms lead. The distinction changes the plan.

A cycle that announces itself this loudly is not something to be managed with ibuprofen and resignation. It's a signal about clearance, and clearance is something we can measure and fix.

Early Perimenopause Symptoms in Your 40s: The Hot Mama Archetype

2026-09-14T00:00:00.000Z

She thought she had years before any of this. Then the night sweats started — not every night, just enough to wonder. Her cycle, regular her whole life, came at 24 days, then 35, then skipped. She's waking at 3 AM with her heart going. Her patience is thinner than it's ever been and she doesn't recognize the woman who snapped at her daughter over a dish. At 44 she was told she's too young for menopause, and she is. She's in the years before it, which nobody explained to her.

This is Hot Mama, and her pattern is perimenopause onset: the transitional years — usually beginning in the early to mid forties, sometimes the late thirties — when the hormonal system that ran on a steady rhythm for three decades starts rewriting itself in real time.

What's actually happening

Perimenopause is not simply "low estrogen." That's the last chapter. The opening chapters are about instability. Progesterone falls first, because the ovulation that produces it becomes less frequent and less robust — and progesterone was the hormone stabilizing sleep, mood, and the brain's calming GABA system. Estrogen, meanwhile, doesn't decline smoothly; it swings, sometimes higher than it ever was in her thirties, sometimes dropping sharply within the same month.

Every system that relied on those hormones being predictable feels the swings. The hypothalamus, which regulates body temperature, becomes hypersensitive to estrogen drops — that's a hot flash. The brain loses progesterone's steadying effect — that's the 3 AM waking and the new anxiety. Insulin sensitivity shifts, and weight settles at the middle. The changes feel random because the hormone levels are.

The clinical staging system for this, called STRAW+10, defines early perimenopause by a persistent change in cycle length of seven days or more, and late perimenopause by gaps of sixty days or more between periods. Most women are in the early stage for years before anyone names it.

How to recognize her

Hot flashes or night sweats — sometimes subtle at first, a flush at a meeting, a damp pillow.
New sleep disruption, especially 3 AM waking, in a woman who used to sleep well.
Cycles changing length or character — shorter, longer, heavier, lighter, skipped.
Mood and anxiety shifts that feel unfamiliar, like they belong to someone else.
Often: brain fog and word-finding trouble, joint aches with no injury, new heart palpitations, vaginal dryness, and a libido that's changed.

Why your labs may say you're fine

Because the hormones are moving. An estradiol level drawn on Tuesday can be "normal" and bear no relationship to the level that caused the night sweat on Friday. FSH, the test most often used to "rule out" perimenopause, fluctuates too and is frequently normal in early perimenopause. In this pattern I put more weight on the symptom history and cycle tracking than on any single draw, and when I test I'm looking at estradiol and progesterone timed to the cycle, a full thyroid panel (thyroid symptoms and perimenopause symptoms overlap heavily, and both change in the forties), fasting insulin, ferritin, and vitamin D.

Where to start

Track your cycle and your symptoms. Two months of data — cycle days, sleep, hot flashes, mood — is worth more than most lab panels for this pattern and turns a vague complaint into a clinical picture.
Protect sleep with intent. Cool room, earlier protein-inclusive dinner, alcohol off the table for a two-week trial. The 3 AM pattern has its own article and the fixes there apply directly.
Prioritize protein and strength training. This is the decade muscle and bone begin to go; resistance training is not optional in perimenopause.
Steady the blood sugar. Estrogen swings worsen insulin sensitivity. The fewer glucose spikes, the fewer hot flashes and the steadier the mood — many women notice this within a week.
Consider support where it fits. Magnesium glycinate, and for some women black cohosh or cyclical progesterone, can steady the early transition; the professional-grade options are in my Fullscript dispensary. Hormone therapy is a real and often excellent option in this pattern, and it deserves a conversation with someone who prescribes it thoughtfully rather than a blanket yes or no.

Her close seconds

Hot Mama almost always carries a close second, because the transition destabilizes more than one system. Anxious Annie is the most common — the falling progesterone is the shared driver. Moody Maven appears when the estrogen swings run high, and Wired Wendy when the sleep disruption has knocked the cortisol rhythm off its axis. Read your runner-up; it usually tells you which symptom to treat first.

You are not too young, you are not imagining it, and you are not at the mercy of it. This is a transition with a physiology, a staging system, and a real set of tools. The first one is knowing you're in it.

Gut Health and Hormones: Bloating, Estrogen, and the Bloated Brenda Archetype

2026-09-14T00:00:00.000Z

She wakes up with a flat stomach and by dinner she looks five months pregnant. She's cut gluten, then dairy, then most things; some days it helps and some days it doesn't. Her digestion is unpredictable — constipated for three days, then not. And nobody has connected any of that to the PMS, the heavy periods, or the acne along her jaw that showed up at 41.

This is Bloated Brenda, and she is the archetype most likely to have been sent to two different specialists who never spoke to each other. The gut symptoms went to gastroenterology; the hormone symptoms went to gynecology. Her pattern is the place where they meet.

What's actually happening

The gut is a hormone organ. It is where estrogen, once processed by the liver, is meant to be carried out of the body — and it's home to a collection of bacteria, sometimes called the estrobolome, that decide whether it actually leaves. Some of those bacteria produce an enzyme, beta-glucuronidase, that unpackages estrogen the liver has prepared for excretion and sends it back into circulation. In a healthy microbiome that's a small, regulated effect. In an imbalanced one it's a leak that keeps refilling the tank.

So when digestion struggles — slow transit, dysbiosis, low stomach acid, an inflamed or permeable gut lining — hormones recirculate instead of clearing, and the whole system backs up. The bloating, the food reactions, and the estrogen-dominance symptoms are one process. The gut inflammation also raises cortisol and impairs thyroid conversion, which is why this pattern so often drags a second or third archetype along with it.

The traffic runs the other way, too. Falling progesterone in perimenopause slows gut motility; estrogen swings change the gut lining and the microbiome. A woman whose digestion was reliable for forty years and turned unreliable at 45 is usually experiencing her hormones through her gut.

How to recognize her

Persistent bloating, often worse as the day goes on. The signature.
Constipation, irregularity, or food reactions that don't follow a clear rule.
Symptoms that worsen with certain meals — but the list of triggers keeps growing.
Estrogen-dominance symptoms riding along with the gut symptoms: PMS, heavy periods, breast tenderness, hormonal acne.
Often: reflux, fatigue after eating, a history of antibiotics or long-term acid blockers, skin issues, and a growing anxiety about food.

Why your labs may say you're fine

Because the standard workup — a basic metabolic panel, maybe celiac antibodies, maybe an ultrasound — isn't looking at the microbiome or the gut lining. The test that maps this pattern is a comprehensive stool analysis: it measures beta-glucuronidase directly, along with bacterial balance, inflammation markers, digestive enzyme output, and gut permeability. I pair it with an IgG food sensitivity panel, which identifies the delayed reactions that a food diary can't, and with the hormone testing described under Moody Maven, since the two patterns share so much ground. Small intestinal bacterial overgrowth (SIBO) deserves a breath test when the bloating is severe and builds fast after meals.

Where to start

Get a daily bowel movement before anything else. Estrogen can't leave a body that isn't eliminating. Fiber, water, magnesium citrate at night, and movement after meals.
Stop removing foods without a map. Serial elimination shrinks the diet and often shrinks the microbiome with it. Test, then remove the actual triggers, then reintroduce.
Chew, slow down, and eat without a screen. Digestion starts in the mouth and the nervous system; a rushed meal is an under-digested one.
Feed the microbiome with fermented foods and a range of plant fibers — diversity of plants matters more than any single "gut-healthy" food.
Targeted support — a good probiotic, digestive enzymes or betaine HCl where stomach acid is low, and calcium-D-glucarate to inhibit beta-glucuronidase — is in my Fullscript dispensary. Which ones fit depends on what the stool test shows; guessing at probiotics is how women end up with a shelf of them and no improvement.

Her close seconds

Bloated Brenda and Moody Maven are the pairing I see most — the same estrogen-clearance problem, one showing up in the gut and one in the cycle. Plateau Patty follows close behind, because gut inflammation and thyroid autoimmunity travel together. If either was your close second, the gut work comes first; it's the foundation the other systems are built on.

The bloating isn't vanity and it isn't "just IBS." It's your hormones telling you where the bottleneck is. Clear it there, and a surprising number of other symptoms clear with it.

Insulin Resistance Symptoms in Women: The Sugar Sherry Archetype

2026-09-14T00:00:00.000Z

She's fine until about three o'clock. Then the energy drains out of her, the cravings arrive — something sweet, something salty, anything — and she'll fight it or she won't, but either way the afternoon is lost. She gets shaky and irritable if a meal is late. The weight has gone to her middle in a way it never did before, and it's not moving. Her fasting glucose was 96 and her doctor said that's normal.

This is Sugar Sherry. Her energy is tied to her meals because her cells have grown numb to insulin's signal, and the number that would show it years before her glucose changes is one almost no one orders.

What's actually happening

Insulin's job is to move glucose from the blood into the cells. When the cells are exposed to too much insulin for too long — from frequent refined carbohydrate, from chronic stress, from poor sleep, from the hormonal shifts of perimenopause — they start to ignore it. The pancreas compensates by producing more. For years, sometimes a decade, that keeps the glucose in range. Meanwhile the insulin level itself has doubled or tripled, and high insulin is doing its own damage: storing fat at the waist, blocking fat burning, driving cravings, raising blood pressure and triglycerides, and stealing energy from the muscle and brain cells that can't get the fuel.

The crash after lunch is glucose spiking and then overshooting on the way down. The 3 PM craving is the brain calling for a rescue. And in a woman in her forties there's an additional layer: estrogen helps maintain insulin sensitivity, so as it declines and swings, insulin resistance that was mild becomes obvious. This is why the weight gain of perimenopause is so specifically abdominal.

High insulin also interacts with the other archetypes — it pushes cortisol, it lowers the protein that keeps sex hormones in balance, and in younger women it is the engine of PCOS.

How to recognize her

Energy crashes between meals, especially the post-lunch slump.
Irritability or shakiness when hungry — "hangry" is a blood-sugar symptom, not a personality trait.
Carbohydrate and sugar cravings, strongest in the afternoon and evening.
Weight that settles at the midsection and resists diet.
Often: skin tags, darkened skin at the neck or underarms, brain fog after meals, thirst, disrupted sleep, and a family history of type 2 diabetes.

Why your labs may say you're fine

Because fasting glucose is the last thing to change. The pancreas holds glucose in range by pouring out insulin, so glucose can look perfect for years while the underlying problem accelerates. The test that finds this early is fasting insulin — I want to see it under 6 or 7 µIU/mL, though conventional ranges will call anything under 25 normal. Add hemoglobin A1c, triglycerides and HDL (a high ratio between them is a strong insulin-resistance signal), and for many women a continuous glucose monitor for two weeks, which shows in real time which meals are spiking her and which aren't.

Where to start

Protein first, at every meal. Thirty grams at breakfast changes the whole day's glucose curve. Eating protein and vegetables before the carbohydrate on the plate blunts the spike measurably.
Walk after meals. Ten to fifteen minutes after eating — muscles pull glucose out of the blood without needing insulin to do it. This is the highest-return habit for this pattern.
Lift weights. Muscle is the body's biggest glucose sink. More muscle means more places for glucose to go and less insulin required.
Fix sleep before fixing diet. A single short night measurably worsens insulin sensitivity the next day. This pattern is often a sleep pattern first.
Support insulin sensitivity — berberine, myo-inositol, magnesium, chromium, and alpha-lipoic acid all have real evidence, and the professional-grade versions are in my Fullscript dispensary. For some women a GLP-1 medication belongs in the conversation; if it does, it belongs alongside protein and strength training from day one, not instead of them.

Her close seconds

Sugar Sherry travels with Wired Wendy — cortisol and insulin push each other around all day, and the evening cravings usually have both fingerprints on them — and with Plateau Patty, since a slow thyroid and insulin resistance produce the same stubborn middle and reinforce each other. If your close second was Hot Mama, the estrogen shifts are what unmasked this, and steadying blood sugar will steady the hot flashes too.

Insulin resistance is the most reversible pattern of the nine, and the earliest to catch if someone orders the right test. The afternoon doesn't have to be lost.

Post-Menopause Fatigue, Brain Fog, and Muscle Loss: The Depleted Debbie Archetype

2026-09-14T00:00:00.000Z

The hot flashes have mostly settled. Her last period was two years ago. She expected, once the transition was over, to feel like herself again. Instead she feels like a slightly dimmed version of herself: tired in a steady, background way, foggier than she was at fifty, stiff in the mornings, dry-eyed and dry-skinned, losing muscle no matter how she trains, and — this is the part she doesn't say out loud — flat. Her doctor says her labs are appropriate for her age. That's the phrase. Appropriate for her age.

This is Depleted Debbie, and of the nine hormone archetypes she is the one most often told there is nothing to do. The swings of perimenopause have stopped; the steady state that replaced them is low, and low has consequences that are treatable.

What's actually happening

Menopause is defined retrospectively — twelve months after the final period — and what follows is a new hormonal baseline. Estradiol, the strong estrogen of the reproductive years, settles at a small fraction of its former level. Progesterone is close to zero, because there's no ovulation to make it. Testosterone, which women make too and which declines steadily from the thirties, is often at its lowest point. DHEA, the adrenal precursor to sex hormones, has been falling for decades.

Those hormones weren't only running the cycle. Estrogen maintained bone density, skin collagen, the vaginal and bladder tissue, joint lubrication, insulin sensitivity, and the brain's energy metabolism. Testosterone maintained muscle, motivation, and libido. Progesterone was calming the nervous system and supporting sleep. Remove them together and the result is the cumulative depletion this archetype describes — not one dramatic symptom, but a general dimming across every system they touched.

There's a second layer that makes the depletion deeper than it needs to be. After the ovaries retire, the adrenal glands are meant to pick up some of the hormone production. A woman who arrives at menopause on a crashed cortisol curve — the Bossy Betty story — has adrenals with nothing to spare, and her post-menopause depletion is correspondingly worse.

How to recognize her

Steady, low-grade exhaustion — not the crash of burnout, but a permanent lower ceiling.
Brain fog and word-finding difficulty that didn't resolve when the hot flashes did.
Dryness — skin, eyes, mouth, vaginal tissue — and new urinary urgency or recurrent UTIs.
Muscle loss and joint stiffness despite exercising; strength that was easy to keep is now hard to build.
Often: low mood without an obvious cause, absent libido, thinning hair, rising cholesterol and blood pressure, a bone density scan that came back "osteopenia," and sleep that is shallow rather than interrupted.

Why your labs may say you're fine

Because "appropriate for age" is a population average, not a treatment target. Yes, estradiol in the teens and a testosterone near the floor are typical after menopause. They are also the reason for every symptom on the list above. The useful workup measures where she actually is — estradiol, testosterone (free and total), DHEA-S, a full thyroid panel with antibodies, fasting insulin, ferritin, vitamin D, and a bone density scan if she hasn't had one — and then asks what optimal would look like for her, rather than whether she matches a reference range built from women who feel the same way she does.

Where to start

Strength training is the treatment, not a hobby. Two to three sessions a week, progressively heavier, is the single most protective intervention for muscle, bone, insulin sensitivity, and mood in this pattern. Walking is not a substitute.
Protein: roughly 1.2 to 1.6 grams per kilogram of body weight daily, spread across meals. Post-menopausal muscle is harder to build and needs more raw material to do it.
Treat the dryness locally. Vaginal estrogen is low-dose, local, safe for the great majority of women, and transforms tissue symptoms that no amount of "accepting it" will fix. This deserves to be asked about by name.
Have the hormone therapy conversation properly. For many post-menopausal women, hormone therapy — estrogen, progesterone where indicated, sometimes testosterone — is the most effective tool available, with the best evidence for those who start within roughly ten years of their last period. It is neither mandatory nor dangerous by default. It requires an individualized assessment with someone who prescribes it thoughtfully.
Foundational support — vitamin D with K2, magnesium, omega-3s, creatine (which has real evidence for muscle and cognition in post-menopausal women), and DHEA where levels warrant it — is in my Fullscript dispensary.

Her close seconds

Depleted Debbie's usual companions are Bossy Betty — the adrenals that were meant to take over production having been spent in the decade before — and Plateau Patty, since thyroid function commonly slides in the same years and produces overlapping symptoms. Sugar Sherry appears when the loss of estrogen has tipped insulin resistance into the open. Read your close second; in this archetype it often names the system that's most fixable first.

"Appropriate for your age" is a description, not a plan. The years after menopause can be some of the strongest and clearest of a woman's life — but that happens by design, not by waiting.

Low Progesterone and Anxiety in Your 40s: The Anxious Annie Archetype

2026-09-14T00:00:00.000Z

She was never an anxious person. Then, somewhere around 42, she started waking at 3 AM with her heart pounding over nothing. A background hum of dread showed up in the week before her period and stopped leaving when the period came. She's more reactive than she's ever been. She's been offered an SSRI twice. She isn't against medication — she just can't shake the feeling that something changed in her body, not in her head, and that nobody's looked there.

This is Anxious Annie, and the change she's sensing has a name: low progesterone. It is the first hormone to fall in the years leading to menopause, and it happens to be the one that was keeping her calm.

What's actually happening

Progesterone is made after ovulation, in the second half of the cycle. Its reputation is as the pregnancy hormone, but its effect on the brain is the part that matters here. The body converts progesterone into a metabolite called allopregnanolone, which acts directly on the brain's GABA receptors — the same receptors that anti-anxiety medications and alcohol act on. Allopregnanolone is the body's own tranquilizer. It steadies mood, deepens sleep, and takes the edge off the stress response.

From the late thirties on, ovulation becomes less reliable. Some cycles are anovulatory — no egg, no progesterone at all. Cycles that do ovulate often produce less. The estrogen side may still be running strong, so the ratio tips: plenty of the hormone that stimulates, less of the hormone that soothes. The nervous system feels that ratio as anxiety, irritability, a racing mind at night, and a stress response that fires faster and settles slower.

Research from the SWAN study and others has found that the years of the menopausal transition carry a genuinely elevated risk of new depressive and anxiety symptoms, and that lower allopregnanolone tracks with worse mood in that window. This isn't a weakness of character arriving at forty. It's neurochemistry losing a stabilizer.

How to recognize her

New or worsening anxiety in a woman without a prior anxiety history, typically from the late thirties on.
A racing mind at bedtime and 3 AM waking, often with a pounding heart.
PMS that has become premenstrual dread — the emotional symptoms lead, and they've intensified.
Cycles shortening to 24 or 25 days, with spotting before the period; both are classic low-progesterone signs.
Often: heavier periods (progesterone was restraining the lining), new heart palpitations, tension headaches, a shorter fuse, and being told her thyroid is fine.

Why your labs may say you're fine

Because progesterone is rarely tested, and when it is, it's usually drawn on the wrong day. A level pulled in the first half of the cycle will be low in everyone; it's meaningless. The informative draw is around day 19 to 21 of a 28-day cycle — about a week after ovulation — when progesterone should be at its peak; a level under about 10 ng/mL at that point tells us ovulation was weak or absent. Alongside it I want estradiol from the same draw (for the ratio), a full thyroid panel, ferritin, and — because the symptoms overlap so completely — a look at the cortisol rhythm. Anxiety at 3 AM can be low progesterone, a cortisol surge, or a blood sugar drop, and the three respond to different things.

Where to start

Track the cycle. Cycle length, spotting, and the timing of the anxiety across the month. If the anxiety is worst in the second half and eases with the period, that is a progesterone signature.
Protect ovulation. Under-eating, over-training, and chronic stress all suppress it. This is the archetype where the punishing 5 AM workout and the intermittent fasting may be actively producing the symptom.
Stabilize the evening. An earlier dinner with protein and slow carbohydrate, no alcohol (it hits the same GABA receptors, then rebounds), and a genuine wind-down. The 3 AM waking has its own article; those steps apply here.
Support the calming chemistry. Magnesium glycinate, L-theanine, and vitamin B6 support GABA function and progesterone production; chasteberry (vitex) has evidence for improving luteal-phase progesterone in some women. The professional-grade versions are in my Fullscript dispensary.
Consider progesterone itself. Cyclical oral micronized progesterone, taken in the second half of the cycle or nightly, is one of the most effective and best-tolerated interventions for this pattern, and it's frequently the thing that makes the SSRI unnecessary. It deserves a real conversation, not a reflexive prescription for something else.

Her close seconds

Anxious Annie almost always shares a border with Hot Mama — falling progesterone is where perimenopause begins, so the two patterns are frequently one story at two stages. Moody Maven appears when the estrogen side of the ratio is running high, and Wired Wendy when the nighttime anxiety has become a cortisol pattern in its own right. The close second here usually tells you whether to lead with progesterone, with estrogen clearance, or with cortisol.

Anxiety that arrives on a schedule, in your forties, in a body that was calm for four decades, is worth a hormone panel before it's worth a diagnosis. Very often it has one, and very often it's fixable.

Perimenopause, Menopause, Postmenopause: The Map Nobody Handed You

2026-08-24T00:00:00.000Z

Here is something that will sound like a technicality and isn’t. Menopause is one day. It is the day that marks twelve consecutive months without a period, and you can only identify it looking backward. Everything before is perimenopause. Everything after is postmenopause.

Almost nobody uses the words this way, including plenty of clinicians, and the imprecision costs women real time. A 44-year-old with erratic cycles and 3 AM waking is told she is “too young for menopause,” which is technically true and completely unhelpful, because she is squarely in perimenopause and there is a great deal worth doing.

So let me give you the actual map.

The staging system your chart doesn’t mention

There is a formal framework for this, developed by reproductive endocrinologists and revised in 2011: the Stages of Reproductive Aging Workshop, usually shortened to STRAW+10. It divides the transition into stages based on cycle patterns and hormone markers rather than age.

I bring it up not to be academic but because it makes one thing obvious: this is a staged biological process with a described sequence, not a vague fog you enter at some point in your forties. If your clinician has never referenced anything like it, that tells you something about how the transition is being managed.

Early perimenopause: the years that get missed

The first thing that changes is usually not your period length. It is progesterone.

Progesterone is produced after ovulation, by the corpus luteum. As ovulation becomes less consistent — which starts happening years before cycles look irregular — progesterone production becomes less consistent with it. Meanwhile estrogen is still being produced, and often erratically, sometimes at levels higher than you had at 30.

That combination is the signature of early perimenopause: relatively unopposed estrogen with declining progesterone. And it produces a symptom picture almost nobody connects to hormones:

Sleep that breaks in the second half of the night — progesterone’s metabolite allopregnanolone acts on the same GABA receptors as anti-anxiety medication, so when it becomes erratic, so does your ability to stay asleep
New anxiety in a woman with no anxiety history
Heavier or longer periods
Breast tenderness that got worse, not better
A shorter cycle — 24, 25 days where it used to be 28

Notice what is not on that list: hot flashes. Which is exactly why this stage gets missed. The woman is 41, still cycling more or less on schedule, and she has no vasomotor symptoms, so nobody — including her — thinks hormones. She gets offered an antidepressant for the anxiety and a sleep aid for the sleep, and the actual driver goes unaddressed for years.

If I could change one thing about how this transition is managed, it would be this: stop waiting for hot flashes to start the conversation.

Late perimenopause: the part everyone recognizes

The marker here is a skipped cycle — specifically, a gap of 60 days or more. Once that happens you are generally in the late stage, and this is typically the most symptomatic stretch of the whole arc.

Estrogen is now not just erratic but declining, and the swings can be dramatic — high one month, low the next. Your body is not adapting to a new level so much as being asked to function on a moving target.

This is where hot flashes and night sweats usually arrive. It is also where the symptoms women rarely attribute correctly cluster:

Joint pain that appeared out of nowhere — estrogen quietly supports connective tissue and inflammatory regulation. There is a clinical term, menopausal arthralgia, and most women have never heard it.
Cognitive change — word-finding pauses, walking into rooms. Estrogen acts throughout the brain, including on neuronal glucose metabolism. This one frightens women more than anything else on the list, and I want to say clearly: research following women through the transition generally shows cognition recovering as hormones stabilize afterward. It is a feature of the transition, not a trajectory.
Body composition shifting toward the midsection, without any change in habits.
Palpitations, migraines, dry eyes, itchy skin, tinnitus, frozen shoulder. All documented. All routinely investigated as separate problems by separate specialists.

Menopause: the single day

Twelve months with no period. Average age in the U.S. is around 51, with a normal range roughly 45 to 55. Before 45 is early menopause; before 40 is premature ovarian insufficiency, and that one warrants a proper workup rather than reassurance.

You cannot know it in advance and you cannot know it in the moment. You know it a year later. Which is a strange thing to build a diagnosis around, and it is part of why the language confuses everyone.

Postmenopause: the stage that actually determines your next thirty years

Here is what I most want women to understand, because it is the opposite of what the culture communicates.

The story we are told is that menopause is the hard part and postmenopause is relief — symptoms settle, and you are through it. Symptoms often do settle. But the first five to ten years after your final period are when the structural changes happen fastest, and they happen quietly.

Bone. Loss accelerates sharply in the years immediately around and after the final period. A woman can lose a meaningful percentage of her bone density in that window and feel absolutely nothing. There are no symptoms of osteoporosis until something breaks.

Cardiovascular. Women’s cardiovascular risk changes markedly after menopause. Lipids shift, vascular function changes, and the protection that estrogen provided is gone.

Skin and collagen. The research here is striking — the steepest collagen loss is concentrated in the earliest postmenopausal years, which is why women describe looking noticeably different within about eighteen months and are not imagining it.

Genitourinary tissue. Vaginal dryness, urinary urgency, recurrent UTIs, discomfort with sex. Unlike hot flashes, this one does not improve with time — it progresses. It is also highly treatable, and it is the symptom women are least likely to raise.

The part I want to be direct about: this is precisely when most women stop being monitored. Symptoms quieted down, so the appointments stopped. Meanwhile bone density and cardiovascular risk are changing on a timeline nobody is watching. If you are two years past your final period and feeling fine, that is exactly the moment to get a baseline — not five years from now when something has already happened.

Why staging changes what you do

Every stage has a different priority, which is why “menopause advice” as a single category is nearly useless.

Early perimenopause is largely a progesterone and cycle-tracking conversation. It is also the best window to build the muscle and bone you will be drawing on later — the woman who starts strength training at 42 is in a different position at 62 than the woman who starts at 55.

Late perimenopause is symptom management and decision-making about hormone therapy, ideally with real information rather than the residual fear left over from a study most people have never actually read.

Postmenopause is structural. Bone, heart, muscle, genitourinary tissue, cognition. The symptoms may be quieter; the stakes are higher.

What to actually do with this

Figure out where you are. Cycle length and pattern over the last year tell you more than any single lab. Hormone levels in perimenopause fluctuate so much that a one-time draw can be genuinely misleading — two women with identical symptoms can have opposite results depending on the day.

Then get the things measured that actually track the stage-specific risks: a full thyroid panel rather than TSH alone, ferritin, vitamin D, fasting insulin, a lipid panel, and a bone density baseline earlier than standard guidelines suggest if you are heading into or past the transition. See why standard panels miss so much.

And stop accepting “you’re too young for that” as an answer. If you are 42 with erratic sleep, new anxiety, and a cycle that shortened, you are not too young. You are early — which is the best place to be.

Frequently Asked Questions

How long does perimenopause last?

It varies widely. Four to eight years is common, and some women move through it in two while others take a decade or more. The early stage is typically the longest and the least recognized.

Can a blood test tell me what stage I’m in?

Not reliably during perimenopause, because levels swing so much day to day. FSH is more informative once cycles have stopped. Your cycle pattern over time is the better indicator.

I had a hysterectomy — how do I know?

Without a period to track, staging relies on symptoms and, in some cases, hormone testing. If your ovaries were left in place they generally keep functioning; if they were removed, menopause happened immediately, which is a different and more abrupt transition.

Do symptoms just stop after menopause?

Many do settle. Vasomotor symptoms persist for years in a substantial share of women, and genitourinary symptoms typically progress rather than resolve. The structural changes — bone, cardiovascular — continue regardless of how you feel.

References

Brincat M, et al. “A study of the decrease of skin collagen content, skin thickness, and bone mass in the postmenopausal woman.” Obstetrics & Gynecology, 1987. View source

Regulatory status was checked against FDA materials current at the time of publication and is actively changing.

What the July FDA Peptide Vote Actually Changed (and What It Didn’t)

2026-08-24T00:00:00.000Z

On July 23 and 24, an FDA advisory committee did something people who follow this closely did not expect. It recommended six of seven peptides for the compounding list — over the written objections of the agency’s own scientists, who had recommended against all seven.

Reports from the room described an audible gasp when the first tally was read. This panel had rarely, if ever, voted against FDA staff’s written recommendation.

It was a real event. It is also being described online in ways that are simply wrong, and the errors are the kind that cost people money. So here is what happened.

What was actually voted on

The Pharmacy Compounding Advisory Committee considered seven peptides for the 503A Bulks List — the roster of substances that compounding pharmacies may prepare against an individual prescription.

The results, each voted separately in free base and acetate forms:

BPC-157 — recommended, 8–6 with one abstention (reviewed for ulcerative colitis)
KPV — recommended, 8–6 with one abstention (wound healing and inflammatory conditions)
TB-500 — recommended, 8–6 with one abstention (wound healing)
MOTS-c — recommended, 7–5 with two abstentions (obesity and osteoporosis)
Semax — recommended, 8–5 with one abstention (selected neurologic uses)
Epitalon — recommended (insomnia)
Emideltide, better known as DSIP — rejected, the only one

Look at those margins. Not one was a landslide. Every vote carried abstentions. This was a genuinely divided panel, and that matters when you read someone describing it as vindication.

The three separate legal events people keep collapsing into one

This is the part worth getting right, because almost every confused conversation traces back to it.

Event one: removal from Category 2. On April 15, 2026, twelve peptides came off the FDA’s Category 2 restricted list, largely because the nominations were withdrawn. That group included BPC-157, TB-500, MOTS-c, injectable GHK-Cu, Melanotan II, Semax, PEG-MGF, DSIP, Epitalon, KPV, LL-37, and DiHexa. Removal from a prohibition list is not permission. It removes a barrier; it does not open a door.

Event two: the July advisory vote. A recommendation. Non-binding. The FDA is free to disagree with it, and the Secretary of Health and Human Services would still need to formally approve any additions.

Event three: actual placement on the list. This requires formal rulemaking — a proposed rule, a public comment period, and a final rule. That process realistically runs into 2027 and beyond.

Nothing became legal to compound in July that was not legal in June. Six recommendations, zero changes to what a pharmacy can dispense today.

Why the panel overruling FDA scientists matters both ways

I find this genuinely interesting, and I do not think it means what either side is claiming.

The FDA’s career scientists opposed all seven, citing thin human trial data along with unresolved questions about impurity and immunogenicity. Those are not made-up concerns. Most of these compounds have substantial animal literature and essentially no human trials, which is exactly what I have written about each of them individually.

The panel — which included representatives from industry, academia, state government, pharmacy boards, and clinical practice — disagreed. Reasonable people can look at the same evidence base and weigh access against uncertainty differently.

What I would resist is treating the vote as proof these compounds work. It is a recommendation about whether pharmacies should be permitted to prepare them for individual patients under prescription. That is a question about regulatory pathways, not about efficacy. A peptide does not become better supported because a committee voted 8–6.

What this means if you are considering peptides

Availability may change, in either direction. If rulemaking proceeds, more compounds become legitimately available through licensed pharmacies. If it stalls, the current situation persists. Either way, nothing about your options changed this summer.

Be very cautious with anyone marketing on this news. “FDA-approved” is not what happened. Nor is “now legal.” Any seller using that language is either misinformed or counting on you being misinformed, and neither is a good sign about the rest of their operation.

The gray market is still the gray market. An enormous online trade sells these compounds labeled “for research use only, not for human consumption.” That disclaimer is the legal architecture that lets them ship. It also means no prescriber, no sterility requirements for injectables, no pharmacist verification, and no recourse if something goes wrong. A certificate of analysis tells you about a tested sample. It tells you nothing about the sterility of the vial in your hand.

Notice which ones weren’t on the docket. Injectable GHK-Cu came off Category 2 in April but was not among the seven reviewed in July. Neither were CJC-1295, Ipamorelin, Sermorelin, Thymosin Alpha-1, or SS-31. Their status is unchanged and unaddressed.

Important: None of the peptides discussed here is an FDA-approved drug, and none was added to the 503A Bulks List by the July vote. This article is educational and is not medical advice or a recommendation to use any of these compounds. I do not prescribe or dispense peptide therapies. Regulatory status described here is current as of publication and is actively changing.

My honest read

I have written in detail about most of these compounds, and my position has not moved. The mechanisms are interesting. The animal data on several is substantial and consistent. The human data is thin to absent. Those three things are all true at once, and a committee vote does not resolve the tension between them.

What the vote does suggest is that a regulated pathway may eventually exist — which, whatever you think of the compounds, is better than tens of thousands of people injecting unregulated product they ordered online. Supervision, screening, and pharmacy-grade sterility are improvements even when the underlying evidence stays uncertain.

In the meantime, the advice I would give has not changed: get your hormones, thyroid, ferritin, and metabolic markers actually assessed first. A peptide layered on top of an unaddressed foundation is an expensive way to not solve the problem.

Frequently Asked Questions

Does this mean BPC-157 is now legal?

No. The vote was a non-binding recommendation. Formal rulemaking must happen before anything changes, and that realistically runs into 2027.

Why was DSIP the only rejection?

The panel weighed each compound separately on its own evidence and safety profile. DSIP fell short by a single-vote margin, which reflects how divided the committee was overall rather than a clear verdict.

Are these peptides FDA-approved now?

No, and this is the most common misunderstanding. The 503A Bulks List governs what compounding pharmacies may prepare from bulk substances. It is an entirely different thing from drug approval.

What about GHK-Cu, CJC-1295, or the others I’ve read about?

Injectable GHK-Cu came off Category 2 in April but was not part of the July review. Several others were never on either list. Their status is simply unchanged.

References

FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026. View source
“FDA advisory committee nominates six peptides for pharmacies to compound.” NCPA, July 31, 2026. View source
“FDA Panel Backs 6 Peptides for Compounding.” AJMC, 2026. View source
“Bulk-list bound? PCAC backs majority of peptides in two-day public meeting.” McDermott Will & Emery, 2026. View source

Regulatory status was checked against FDA materials current at the time of publication and is actively changing.

It’s Not All in Your Head. It’s in Your Receptors.

2026-08-24T00:00:00.000Z

A woman comes in at 46. No psychiatric history. Successful, functional, not a worrier. And for the past eighteen months she has been waking at three in the morning with her heart pounding for no reason she can identify, snapping at people she loves, and crying in her car before meetings.

She has been told she is stressed. She has been offered an antidepressant. Nobody has mentioned her hormones.

I want to be careful here, because there is a version of this conversation that becomes irresponsible — the version that tells women all mental health symptoms are hormonal and psychiatric care is unnecessary. That is wrong and it is dangerous. But the opposite error is just as common, and women are living inside it: treating a hormonally driven mood change as though it appeared from nowhere.

The receptor-level explanation

Start with progesterone, because it is the piece almost nobody explains.

Progesterone is metabolized into a compound called allopregnanolone. Allopregnanolone is a positive allosteric modulator at the GABA-A receptor — the same receptor system targeted by benzodiazepines. It is, functionally, one of your body’s own anti-anxiety compounds.

Progesterone is produced after ovulation. As ovulation becomes irregular in perimenopause — which begins years before your cycles look irregular — allopregnanolone production becomes irregular with it.

Sit with that. A calming input your nervous system has relied on monthly since adolescence starts arriving unpredictably. Not gone, which might be easier to adapt to. Unpredictable.

That is why perimenopausal anxiety so often has a specific quality women describe the same way: it comes in waves, it does not attach to anything, and it feels physical before it feels emotional. Heart first, thought second.

Your nervous system did not become fragile. One of its regulators started arriving on an unreliable schedule.

Estrogen, serotonin, and the depression window

Estrogen’s relationship with mood runs through different machinery. It influences serotonin synthesis, receptor density, and reuptake, along with dopamine and norepinephrine signaling. It also affects BDNF, involved in neuronal maintenance.

The epidemiology here is worth knowing, because it is stronger than most women realize: the menopausal transition is associated with elevated risk of depressive symptoms, including in women with no prior history. Researchers describe it as a window of vulnerability — comparable in structure to the postpartum period, which is another moment of rapid hormonal change with well-recognized psychiatric risk.

We take postpartum depression seriously. We screen for it. Somehow the same logic has not transferred to a transition that lasts years rather than months.

Women with a history of PMS, PMDD, or postpartum depression appear to be at higher risk during perimenopause — which makes mechanistic sense. Those conditions mark sensitivity to hormonal change rather than to any particular level. Perimenopause is change, sustained.

The cognitive piece, and the fear underneath it

Brain fog gets discussed as an inconvenience. In my experience it is the symptom that frightens women most, and they rarely say so out loud.

The word-finding pauses. Walking into a room with no idea why. Reading the same paragraph three times. More than one woman has told me, quietly, that she has wondered whether she is watching the beginning of dementia.

Here is what I tell them, and it is worth saying plainly: estrogen acts throughout the brain, including on neuronal glucose metabolism, and neuroimaging research has documented measurable changes in brain energy metabolism across the menopausal transition. The fog is a brain adapting to a changing hormonal environment. Studies following women through the transition generally find cognitive performance recovers as hormones stabilize afterward.

It is a feature of the transition. Not a trajectory.

That said — if cognitive symptoms are severe, progressive, or accompanied by other neurologic changes, that deserves proper evaluation rather than reassurance from a blog post.

What a real workup looks like

This is where functional medicine earns its keep, and it is less exotic than the phrase suggests. It is mostly refusing to accept a symptom as a diagnosis.

Before concluding that a woman in her forties has developed anxiety or depression, I want to know:

Full thyroid panel — not TSH alone. Free T3, free T4, reverse T3, and antibodies. Thyroid dysfunction produces anxiety, depression, and cognitive change almost indistinguishable from primary psychiatric illness, and it is dramatically more common in women in exactly this age band.
Ferritin, not just hemoglobin. Iron deficiency without anemia is common in still-cycling women, especially with the heavier periods of early perimenopause, and it produces fatigue, low mood, and poor concentration.
Vitamin D. Receptors sit in brain regions involved in mood regulation, and it participates in the steps that produce serotonin and dopamine. It is also required for calcium absorption, which matters for a woman losing bone — so it is worth knowing even setting mood aside. Most standard panels skip it unless someone asks.
B12. Required for the methylation that builds serotonin, dopamine, and norepinephrine. Deficiency produces depression, poor concentration, and memory complaints before anemia shows on a blood count, which is why checking a CBC and calling it done misses it. Metformin, acid-reducing medications, and plant-based eating all deplete it.
Fasting insulin and glucose. Blood sugar instability produces afternoon irritability and anxiety that gets read as psychological.
Sleep, including apnea screening. Sleep apnea is substantially underdiagnosed in women because it often presents as fatigue and insomnia rather than loud snoring. No mood intervention works well on top of it.
Hormonal status appropriate to her stage — interpreted against her cycle pattern, not from a single draw.
Medication review. A number of common medications affect mood.

I have watched a woman’s “anxiety” resolve on iron repletion. That is not a story about the power of supplements. It is a story about what happens when nobody checks.

What actually helps

Address the hormonal driver. If declining and erratic progesterone and estrogen are driving the picture, that is the conversation to have — with real information about hormone therapy rather than the residual fear from a twenty-year-old study most people have never read in full.

Protect sleep like it is treatment, because it is. Sleep deprivation independently produces anxiety and depressive symptoms. The perimenopausal 3 AM waking has its own physiology worth understanding — see why that hour specifically.

Strength training. Not for the body composition, though you get that too. The mood and cognitive evidence for resistance training in midlife women is genuinely good, and it is one of the few interventions that acts on bone, muscle, insulin sensitivity, and mood at once.

Protein and blood sugar stability. A woman running on coffee until two in the afternoon is riding a glucose curve all day, and the crashes at the bottom of it feel exactly like anxiety — shaky, irritable, suddenly tearful over nothing. Protein at breakfast flattens that curve. It is the least interesting recommendation I make and one of the ones women notice fastest.

And keep psychiatric care on the table. This is important. If a woman is significantly depressed, treating her hormones while she waits for a slow intervention to work is not a kindness. Antidepressants, therapy, and hormonal support are not competing options — they address different parts of the same picture, and the right answer is often more than one.

Please read this part: if you are having thoughts of harming yourself, this is not the moment for a root-cause workup. Reach out to a crisis line or your physician today. In the U.S. you can call or text 988. Depression during the menopausal transition is real and treatable, and getting immediate support does not mean giving up on finding the underlying cause — it means staying safe while you do.

What I want you to take from this

If you developed anxiety at 44 with no history of it, something changed. That something has a mechanism, and it is measurable.

You are allowed to ask for the full thyroid panel. You are allowed to ask about progesterone. You are allowed to say “I want to understand why this started” before you agree to manage it indefinitely.

Sometimes the answer is still that you need psychiatric care, and that is a legitimate and good answer. But it should be an answer arrived at, not assumed.

Frequently Asked Questions

Can perimenopause really cause anxiety with no prior history?

Yes. The allopregnanolone mechanism explains why — a GABA-modulating compound your nervous system relied on monthly starts arriving unpredictably. New-onset anxiety in the forties is common and has a physiological basis.

Should I take hormones instead of an antidepressant?

That is a decision for you and your physician, and it is not necessarily either-or. What matters is that the hormonal contribution gets evaluated rather than skipped.

Will the brain fog go away?

For most women, cognitive performance recovers as hormones stabilize after the transition. Severe or progressive symptoms warrant proper evaluation rather than waiting.

My doctor says my thyroid is fine — should I push?

Ask which markers were actually run. TSH alone is not a full thyroid evaluation, and “normal” on a lab report is a statistical range, not a statement about how you feel. See what standard panels leave out.

References

Bromberger JT, et al. “Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition (SWAN).” Archives of General Psychiatry, 2010. View source
“Correlation between allopregnanolone levels and depressive symptoms during late menopausal transition and early postmenopause.” PubMed, 2017. View source
“Decreased GABA+ Levels in the Medial Prefrontal Cortex of Perimenopausal Women: A 3T 1H-MRS Study.” PubMed, 2022. View source
Mosconi L, et al. “Increased Alzheimer’s risk during the menopause transition: A 3-year longitudinal brain imaging study.” PLOS ONE, 2018. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

The Nine Hormone Archetypes: Which One Is Yours?

2026-08-24T00:00:00.000Z

Two women arrive with the same complaint: exhausted, gaining weight, sleeping badly.

One needs her cortisol rhythm addressed before anything else. The other needs blood sugar work and would be made worse by the adrenal protocol. Same three symptoms. Nearly opposite starting points.

This is why generic hormone advice fails so reliably, and why women end up convinced they are the problem. She read the same article you did, followed it exactly, and got nothing — because it was written for a pattern that is not hers.

So I stopped thinking in symptoms and started thinking in patterns. Nine of them.

Why patterns instead of symptoms

Symptoms are the end of the story. Fatigue is what you notice; it is not what is happening. Half a dozen different hormonal situations produce fatigue, and the intervention that resolves one will do nothing for another.

A pattern is the shape underneath — which systems are struggling, in what relationship to each other, and therefore what to address first. Sequence matters as much as substance. The right intervention in the wrong order is one of the most common reasons women conclude nothing works.

The nine

You will probably recognize yourself in one within a sentence or two. Most women do.

Bossy Betty — the estrogen-dominant pattern

Heavy periods, breast tenderness that got worse rather than better, PMS that now starts two weeks out, and a mood that turns on a schedule. Often carrying weight through the hips and thighs. This pattern frequently appears in early perimenopause, when progesterone starts declining while estrogen is still going strong — sometimes stronger than it was at thirty.

Wired Wendy — the cortisol-driven pattern

Tired all day, alert at 10 PM. Falls asleep and then wakes at three. Runs on caffeine and pushes through, and has been complimented her whole life on how much she handles. The word she uses is usually wired, and she is right.

Plateau Patty — the metabolic stall

Doing everything she did at 35 and the scale has not moved in a year. Same effort, same discipline, and the results quietly stopped matching the work. This is the pattern most likely to be told to try harder, and the one where trying harder makes it worse.

Moody Maven — the progesterone-deficient pattern

Anxiety that arrived without a history of it. Irritability that surprises her. Rage that comes out of nowhere and then embarrasses her. Sleep that breaks in the second half of the night. There is a receptor-level explanation for all of it, and it is not a character flaw.

Hot Mama — the vasomotor pattern

Hot flashes, night sweats, sheets to change. The pattern everyone associates with menopause, which is ironic given how many women have every other pattern and never get taken seriously because they are not having flashes.

Bloated Brenda — the gut-hormone pattern

Bloating that arrives by afternoon regardless of what she ate. Foods she has eaten for twenty years suddenly causing trouble. Skin that got reactive at the same time her digestion did. Gut and hormones are in constant conversation, and this pattern is that conversation going badly.

Sugar Sherry — the blood sugar pattern

Crashes at three. Cannot skip meals without becoming a different person. Craves carbohydrates in the afternoon specifically. Falls asleep after lunch. Weight settling around the middle. Insulin sensitivity commonly shifts through the menopausal transition, and this is what that feels like from the inside.

Depleted Debbie — the adrenal exhaustion pattern

Past wired and into empty. Getting up is hard. Recovery from anything — a workout, a hard week, a cold — takes far longer than it used to. Often a woman who ran on Wired Wendy for years before arriving here.

Anxious Annie — the nervous system pattern

A body stuck in threat detection. Heart racing for no reason. Startles easily. Cannot settle even when there is nothing to settle about. Overlaps with the progesterone pattern but has its own shape, and it responds to different things.

Recognizing yourself in one of these is not a diagnosis. It is a starting point — which is exactly what most women have never been given.

What knowing your pattern actually changes

What you do first. Wired Wendy and Depleted Debbie both need adrenal support, but the same protocol at the wrong stage can flatten one and help the other. Order matters.

What to ask for. Sugar Sherry needs fasting insulin, which is routinely omitted from standard panels even though it shifts years before glucose does. Bloated Brenda may need stool testing. Bossy Betty needs hormones interpreted against her cycle, not a single random draw. Walking in knowing what to request changes the appointment.

What to stop doing. This one gets underrated. The fasted morning workout that is genuinely good for one pattern is actively counterproductive for another. Knowing your pattern tells you what to stop as much as what to start.

Why previous attempts failed. Most women I meet have tried plenty. Not randomly — they tried what worked for a friend, or what an article recommended. When you see the pattern, the failures usually make sense in retrospect, and that is genuinely relieving. It was not discipline. It was a mismatch.

Most women are not one pure type

Worth saying, because naming nine patterns can make biology sound more orderly than it is. Plenty of women are primarily one pattern with a strong secondary. Wired Wendy and Sugar Sherry travel together constantly — cortisol and blood sugar are directly linked. Bossy Betty often shades into Moody Maven as perimenopause progresses.

What matters is the dominant pattern, because that is where the first intervention goes. The assessment is built to show you your strongest match and how close the runners-up are, which is genuinely useful information.

What you get, and what you don’t

The assessment gives you a pattern, a picture of how your nine systems compare, and a clear first step. It takes about three minutes.

It is not a diagnosis, and I would be suspicious of any online quiz claiming to give you one. It cannot see your labs, your history, or your medications. What it can do is replace “something is wrong and I do not know where to start” with a specific, named place to start — and give you language for the next conversation with a clinician.

That shift, from vague to specific, is most of what women are missing.

Frequently Asked Questions

What if I match two archetypes?

Common, and the assessment shows you how close your top matches are. Your dominant pattern is where the first intervention goes; the secondary usually gets easier once the primary is addressed.

Do I need labs first?

No. The assessment is symptom-based and works as a starting point. It will tell you which labs are worth requesting, which makes the eventual testing far more useful.

I don’t have periods anymore — does it still apply?

Yes. The assessment handles that, and the patterns remain meaningful postmenopause. Some, like the blood sugar and adrenal patterns, become more relevant rather than less.

What happens after I get my result?

You get a breakdown of your pattern by email and the option to walk through it with me on a complimentary call. No obligation attached to either.

Which Peptide Protocol Fits You? (And Whether One Should)

2026-08-24T00:00:00.000Z

I get some version of this question weekly now: “I’m interested in peptides — where do I start?”

And the honest answer is that the question, as asked, cannot be answered. Saying you are interested in peptides is like saying you are interested in pills. It describes a delivery format, not a goal.

So I built something that asks better questions.

Why “peptides” isn’t a category you can shop

A peptide is a short chain of amino acids. That is a size classification, not a function. Insulin is a peptide. So is oxytocin. So is semaglutide.

Which means the compounds sold under this heading have almost nothing in common with each other. One is being studied for tendon repair, another for skin collagen, another for insulin sensitivity, another has large randomized trials and FDA approval. Grouping them because they share a molecular shape is like grouping aspirin with chemotherapy because both are small molecules.

The practical consequence: a woman researching “peptides” encounters a wall of marketing that treats them as interchangeable, and has no way to tell which one relates to her actual problem — or whether any of them do.

The seven protocols, in plain terms

The Wolverine stack (BPC-157 + TB-500) is the repair pairing — the one people ask about for a specific injury, a stubborn tendon, or post-surgical recovery. For women, it comes up most often around joint pain that appeared out of nowhere in the forties, which has more to do with estrogen and connective tissue than most people realize.

The Glow stack adds GHK-Cu, a copper peptide associated with collagen synthesis. Worth knowing up front: for facial skin specifically, the topical form has better human evidence than the injection. I would rather tell you that than sell you the more expensive option.

The Klow stack adds KPV and is the one that fits when inflammation is the through-line — gut symptoms and reactive skin arriving together, which is more than coincidence.

CJC-1295 + Ipamorelin prompts your own pituitary to release growth hormone in natural pulses. Dosed at night, because that is when your largest natural pulse happens. Improved sleep is what women report first, usually well before anything else.

Epithalon is the pineal and circadian one, taken as short cycles a few times a year rather than daily. The research base is narrower than its marketing implies, and I say so in the assessment.

SS-31 targets mitochondrial membrane structure and is the one compound here with genuine human clinical trials — though those studied diagnosed mitochondrial disease, not everyday fatigue. That gap matters.

MOTS-c is a peptide your own mitochondria produce, studied for insulin sensitivity and metabolic flexibility. It maps onto the metabolic shift many women feel through perimenopause. It is not a weight-loss drug.

There is also a GLP-1 track — semaglutide and tirzepatide — which sits in a different category entirely, with large randomized trials behind it.

Anyone who can describe seven protocols without once telling you which is unproven is selling, not advising.

What the assessment does differently

Six questions, about two minutes. It asks what you are actually dealing with — recovery, skin, gut, energy, metabolism, or sleep — what else is going on, where you are hormonally, what foundations you already have in place, what you are realistically willing to do, and a short safety screen.

Then it shows your closest match and a runner-up, with the honest evidence picture for each.

Three things it does that I have not seen elsewhere:

It will refuse to show you a protocol. If you indicate pregnancy, trying to conceive, a cancer history, or certain thyroid cancer history, you get no match list at all — you get an explanation of why, and a conversation instead. Several of these compounds influence cell migration, blood vessel formation, or telomerase activity. A quiz that cheerfully recommends peptides to someone with a cancer history is a quiz you should distrust.

It checks your foundation first. If you mark that hormones have not been assessed, protein is not deliberate, or you are not strength training, the results lead with that — ahead of any protocol. Because a peptide layered on top of unaddressed hormones, inadequate protein, or untreated sleep apnea is a Band-Aid on something it cannot reach. I would rather lose the sale than watch that happen.

It collects nothing. No email, no name, no storage. You get your result on the screen and can save or print it. I built it that way on purpose.

The part I say to everyone

Peptides are downstream. Every one of these compounds works on tissue you already have, using machinery that is already running. If the machinery is under-resourced, the signal has nothing to act on.

Which means the order goes: assess hormones, thyroid, ferritin, vitamin D, and fasting insulin. Correct the foundations — protein, resistance training, sleep. Re-evaluate, because a meaningful share of what brought you here resolves right there. Then consider a peptide for what remains.

Women who do it in that order get results that hold. Women who skip to the peptide usually end up disappointed by an expensive intervention aimed at the wrong problem.

Important: Most peptides discussed here are investigational compounds that are not approved by the U.S. Food and Drug Administration for the uses described, and human clinical trial data for most is limited. They are available only as compounded medications through a licensed prescribing provider. I do not prescribe or dispense peptide therapies. This article and the assessment are educational only — not medical advice, and not a recommendation to use any product.

Frequently Asked Questions

Is the assessment a prescription or recommendation?

Neither. It is educational, it collects nothing, and its most useful output is often telling you to address something else first.

What if I get a safety-gated result?

It means something in your history warrants a real conversation rather than a list. That is not a dead end — it means the right starting point is someone who can look at your whole history.

Can I take a peptide alongside hormone therapy?

Often they are considered together, and that combination should be designed deliberately by the provider managing both.

How do I know a peptide is legitimate?

If it is sold “for research use only, not for human consumption,” it sits entirely outside pharmacy regulation — no prescriber, no sterility requirement, no recourse. That disclaimer is the whole legal architecture that lets it ship, and it should tell you everything.

Sermorelin: The Oldest Growth Hormone Peptide, and Why It Still Comes Up

2026-08-04T00:00:00.000Z

Sermorelin has been in clinical use longer than almost anything else on the peptide menu, and it carries a piece of history the newer options don’t: it was once an FDA-approved drug.

The approval that came and went

Sermorelin was approved decades ago under the brand name Geref, used primarily in pediatric growth hormone deficiency. It was later withdrawn from the market — a commercial decision rather than a safety one, as recombinant growth hormone became the dominant treatment. Today it exists as a compounded medication.

That distinction matters when you’re evaluating claims. Sermorelin has a longer human track record than most peptides discussed in this series. But a past approval for childhood growth deficiency is not evidence for anti-aging or body-composition use in a 48-year-old woman, and anyone presenting it that way is stretching.

How it works

Sermorelin is a fragment of growth hormone releasing hormone — the natural signal your hypothalamus sends to tell the pituitary to release growth hormone. Rather than supplying growth hormone from outside, it asks your own gland to produce it, in the pulses your body already uses.

Two consequences follow. First, your natural feedback loops stay intact, which is the main safety argument for secretagogues over synthetic HGH. Second, it only works if your pituitary can still respond — the signal needs a functioning receiver.

Sermorelin vs. CJC-1295 + Ipamorelin

This is the practical question, since both sit on the same menu.

Sermorelin is a single compound acting on one pathway, with a short duration of action. CJC-1295 + Ipamorelin pairs a longer-acting GHRH analog with a secretagogue working through a separate receptor, producing a stronger combined signal.

Neither is simply better. Sermorelin is the gentler, more conservative option with the longer history — often a reasonable starting point for someone new to this category. The combination is the more potent one. Which fits depends on your goals, your labs, and what your prescribing provider makes of both.

A past approval for childhood growth deficiency tells you a compound has been used in humans. It doesn’t tell you what it does for a woman in perimenopause.

Why midlife women ask about it

Growth hormone output declines steadily with age, and that decline overlaps with perimenopause in a way that compounds. Women describe the same cluster: muscle that’s harder to keep, fat redistributing to the midsection, recovery that takes days instead of a night, and sleep that no longer restores.

Sleep deserves emphasis, because it’s both cause and consequence. Your largest natural growth hormone pulse happens during deep slow-wave sleep. Fragmented sleep suppresses that pulse, and reduced growth hormone worsens the recovery and body-composition picture that makes sleep harder still. It’s a loop, which is why sermorelin is dosed at night and why improved sleep quality is what women most often notice first.

What has to come first

The same thing I say about every growth hormone peptide: it supports the tissue you’re building. If you aren’t doing resistance training and eating adequate protein, there is nothing for the signal to act on. And if your sex hormones are the actual driver of what you’re experiencing — which in perimenopause they usually are — a growth hormone peptide addresses a different axis entirely.

Assess hormones, thyroid, insulin sensitivity, ferritin, and IGF-1 first. Then decide.

Frequently Asked Questions

Is sermorelin the same as HGH?

No. HGH supplies the hormone directly and overrides your feedback loops. Sermorelin prompts your own pituitary to release it in natural pulses.

Is it weaker than CJC-1295 + Ipamorelin?

It produces a more modest signal, acting on one pathway rather than two. Whether that is a drawback or a feature depends on what you’re trying to accomplish.

Why at night and on an empty stomach?

To align with your body’s own largest growth hormone pulse during deep sleep. Elevated insulin from a recent meal blunts the release.

How soon would I notice something?

Sleep changes are usually reported first, sometimes within weeks. Body composition changes track over months and depend heavily on training and protein.

References

Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology, 1998. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

Tesamorelin: The Growth Hormone Peptide With an Actual FDA Approval

2026-08-04T00:00:00.000Z

Tesamorelin occupies unusual territory. Nearly everything else discussed in this series is investigational. Tesamorelin is an FDA-approved drug, marketed as Egrifta — but the approval is narrower than the way it’s usually marketed, and understanding that gap is the whole point of this article.

What it’s actually approved for

Tesamorelin is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy — a condition in which visceral fat accumulates around the organs. It went through full clinical trials for that indication and demonstrated meaningful, measurable reduction in visceral adipose tissue.

That is a real approval built on real data. It is also a specific population. When tesamorelin is prescribed to a perimenopausal woman for midsection changes, that is an off-label use — legal and common in medicine, but it means the evidence supporting it is inferred rather than direct.

Visceral fat, and why it’s the right target

Not all abdominal fat is equivalent. Subcutaneous fat sits under the skin. Visceral fat sits deeper, wrapped around the organs, and behaves like an active endocrine tissue — producing inflammatory signals and driving insulin resistance. It is the fat most strongly linked to cardiometabolic risk.

Here is why this lands for midlife women. As estrogen declines, fat distribution shifts. Fat that once sat on hips and thighs relocates toward the abdomen, and a meaningful share of that is visceral. Women describe it as their body changing shape without their habits changing at all — and they’re describing something real.

Tesamorelin works as a growth hormone releasing hormone analog, prompting the pituitary to release growth hormone in pulses. Growth hormone has a particular effect on visceral fat metabolism, which is the mechanism behind the trial results.

“My body changed shape and I didn’t change anything” is not a failure of discipline. It is what declining estrogen does to fat distribution.

How it compares to the other options

Versus sermorelin or CJC-1295 + Ipamorelin: all three work through growth hormone release. Tesamorelin is distinguished by having dedicated clinical trial data specifically on visceral fat.

Versus the GLP-1 medications: different tools for different jobs. GLP-1s produce substantial total weight loss through appetite regulation. Tesamorelin targets a specific fat compartment without appetite suppression. If your concern is overall weight, that’s a GLP-1 conversation. If your labs show metabolic risk concentrated in visceral fat while your total weight is reasonable, tesamorelin becomes the more precise question.

What to measure first

Visceral fat should be assessed, not assumed from the mirror. Waist circumference is a reasonable proxy; body composition scanning is better. Alongside it: fasting insulin, HbA1c, a lipid panel, liver enzymes, and sex hormones appropriate to your stage.

The reason matters. If insulin resistance is driving visceral accumulation and the insulin resistance is itself downstream of a hormonal transition, then addressing hormones, resistance training, and protein intake changes the terrain that any peptide would be working against.

Frequently Asked Questions

Will it help me lose weight overall?

It is not a general weight-loss drug. The evidence concerns visceral fat specifically, and total weight change in the trials was modest.

Is it better than sermorelin or CJC-1295 + Ipamorelin?

For visceral fat specifically it has the most direct evidence. For general growth hormone support the others are reasonable alternatives.

What happens if I stop?

Trial data in the approved population showed visceral fat returning after discontinuation. This is maintenance, not cure.

Can I combine it with a GLP-1?

They act differently and are sometimes considered together, but the combination needs deliberate design and monitoring by your prescribing provider — particularly around glucose metabolism and protein intake.

References

Falutz J, et al. “Effects of tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials.” Journal of Clinical Endocrinology & Metabolism, 2010. View source
Stanley TL, et al. “Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.” 2012. View source
Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology, 1998. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

Glutathione: The Master Antioxidant, and Honest Limits of the Injectable Form

2026-08-04T00:00:00.000Z

Glutathione is not a peptide in the sense the rest of this series uses the word — it’s a tripeptide antioxidant your body manufactures continuously, in every cell. It is often called the master antioxidant, and for once the nickname is earned. It also generates more overstated marketing than almost anything else on a wellness menu, so let’s separate the two.

What glutathione actually does

Three roles matter:

Neutralizing oxidative stress. Glutathione directly quenches free radicals and regenerates other antioxidants, including vitamins C and E, back to their active forms.
Phase II liver detoxification. Your liver processes toxins in stages. In the second, glutathione binds to processed compounds so they can be excreted. Without adequate glutathione, that step bottlenecks — and intermediates from phase I can be more reactive than the original substance.
Immune function. Lymphocytes depend on adequate glutathione to replicate and function.

Levels decline with age and are depleted by chronic illness, inflammation, alcohol, medications, and sustained stress.

The women’s health angle

There’s a genuine reason this comes up for midlife women rather than being generic wellness advice.

Your liver metabolizes estrogen. That process runs through phase I and phase II pathways, and the detoxification machinery that clears estrogen metabolites is the same machinery glutathione supports. Some estrogen metabolites are more reactive than others, and clearing them efficiently is part of why estrogen metabolism is a real clinical topic rather than a marketing one.

Estrogen also influences antioxidant defenses directly. Its decline through the menopausal transition is associated with increased oxidative stress — part of the picture behind the changes in skin, energy, and cardiovascular risk that arrive in the same window.

The same liver pathways that clear environmental compounds also clear your estrogen metabolites. That is not a marketing angle. It is the reason this molecule belongs in a hormone conversation.

The honest part: does injecting it work?

Here I have to be direct, because the gap between marketing and evidence is wide.

Oral glutathione is poorly absorbed — largely broken down in digestion. That is the argument for bypassing the gut, and it is a legitimate argument. But bypassing digestion establishes that the molecule reaches the bloodstream. It does not establish that it reaches the cells where it does its work, or that clinical benefit follows.

The human trial evidence for injectable glutathione in healthy adults seeking energy, detoxification, or general wellness is limited. It is used in some specific clinical contexts with more support, but the wellness applications largely outrun the data.

On skin lightening specifically — a common marketing claim — the FDA has issued warnings about injectable products promoted for that purpose. This is not an indication with established safety and efficacy behind it.

What I’d consider first

Glutathione status can be supported through routes with better evidence and lower cost: adequate protein supplying cysteine, sulfur-rich vegetables, N-acetylcysteine, selenium, and the B vitamins that methylation depends on. Addressing the things depleting glutathione — alcohol, poor sleep, chronic inflammation — usually moves the needle further than adding more.

None of that makes injectable glutathione worthless. It makes it a later consideration rather than a first one.

Frequently Asked Questions

Why is oral glutathione considered poorly absorbed?

It is largely broken down during digestion. This is the reasoning behind injectable and liposomal forms.

Does it help with skin brightening?

The FDA has warned about injectable products marketed for skin lightening. This is not an established, approved use.

What about NAC instead?

N-acetylcysteine supplies cysteine, typically the limiting building block for glutathione production. It has a longer record and is far less expensive.

Would it help with estrogen metabolism?

Glutathione is genuinely involved in phase II detoxification, which is part of estrogen clearance. Whether supplementing it improves outcomes is a separate question the evidence has not settled.

References

Richie JP Jr, et al. “Randomized controlled trial of oral glutathione supplementation on body stores of glutathione.” European Journal of Nutrition, 2015. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

Thymosin Alpha-1: The Immune Peptide and the Thymus Nobody Talks About

2026-08-04T00:00:00.000Z

Most people couldn’t point to their thymus. It sits behind the breastbone, it is largest in childhood, and it begins shrinking in adolescence — a process called thymic involution. By midlife it is substantially replaced by fatty tissue.

That matters, because the thymus is where T cells mature and learn to distinguish threat from self. Thymosin Alpha-1 is a synthetic version of a peptide that gland produces.

What it does

Thymosin Alpha-1 is an immune modulator rather than an immune stimulant, and the distinction is not semantic. Research describes it influencing T cell maturation and function, dendritic cell activity, and the balance of inflammatory signaling — nudging a dysregulated response toward normal rather than simply amplifying it.

It has a longer clinical history than most peptides on this menu. Under the name Zadaxin it is approved in a number of countries outside the United States, used in contexts including hepatitis B and C and as an adjunct in certain immune-compromised states. It has been studied in sepsis and in cancer immunotherapy contexts.

In the US it remains investigational and is available only as a compounded medication.

Why women in midlife ask about it

Two reasons come up repeatedly. The first is recurrent infection — the woman who catches everything, whose colds last three weeks, whose dormant viruses reactivate under stress. The second is chronic inflammatory or post-viral illness that hasn’t resolved.

There’s also a hormonal dimension worth naming. Estrogen influences immune function substantially, which is part of why autoimmune conditions are so much more common in women and why many women notice immune changes through the menopausal transition. Thymic involution running alongside estrogen decline means two immune-relevant systems shifting at once.

An immune system that has become confused about self is a different problem from an immune system that is underperforming. The same intervention is not automatically right for both.

The autoimmune caution

This deserves its own section, because it is the most important thing on this page and it’s routinely glossed over.

Autoimmune conditions — Hashimoto’s, rheumatoid arthritis, lupus, psoriasis, MS — are overwhelmingly more common in women, and Hashimoto’s in particular is extremely common in the population I work with. In autoimmunity, the immune system is not weak. It is misdirected.

Thymosin Alpha-1 is described as modulating rather than stimulating, and there is reasoning that modulation could help rather than harm in autoimmunity. But the human evidence in autoimmune populations is limited, and any immune-active compound in someone with existing autoimmunity requires careful thought, coordination with the physician managing that condition, and honest acknowledgment of uncertainty.

If you have an autoimmune diagnosis, this is not a peptide to approach casually.

What to rule out first

Recurrent infection and persistent fatigue have common explanations that deserve investigation before an immune peptide: iron deficiency, low vitamin D, poorly controlled blood sugar, undiagnosed thyroid disease, sleep apnea, and chronic under-recovery. Each of these impairs immune function measurably, and each is cheaper and more direct to address.

Frequently Asked Questions

Is it approved anywhere?

It is approved in a number of countries outside the US under the name Zadaxin. In the US it remains investigational.

Is it safe with Hashimoto’s?

That requires a specific conversation with a provider who knows your case. Immune-active compounds in autoimmune disease need individual assessment, not a general answer.

How does it differ from KPV?

KPV, in the Klow stack, is studied for inflammatory signaling in gut and skin tissue. Thymosin Alpha-1 acts more broadly on T cell function and immune regulation.

Would it help with long-COVID-type symptoms?

It has drawn research interest in post-viral and immune-dysregulation contexts, but evidence there is early. Treat confident claims with suspicion.

References

Dominari A, et al. “Thymosin alpha 1: A comprehensive review of the literature.” World Journal of Virology, 2020. View source
“Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials.” 2024. Reviews outcomes across more than 30 trials and 11,000 subjects. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

Semax + Selank: The Brain Fog Stack, and What Perimenopause Is Doing to Your Head

2026-08-04T00:00:00.000Z

Of everything women describe to me about perimenopause, cognitive change is the one that frightens them most. Not hot flashes. The word-finding pauses. Walking into a room without knowing why. Reading a paragraph three times. Many women quietly wonder whether they’re watching early dementia.

They usually aren’t. And that context is where any conversation about Semax and Selank has to begin.

What these two are

Both were developed in Russia and have been used clinically there for decades — a history that explains why the published literature is substantial in Russian sources and thin in Western ones.

Semax is a fragment of ACTH, modified so it no longer carries the hormonal activity of the parent molecule. Research describes effects on BDNF — brain-derived neurotrophic factor, involved in the growth and maintenance of neurons — and on attention and cognitive performance. It has been used in Russia in stroke recovery and cognitive disorders.

Selank is derived from tuftsin, an immune-related peptide. It has been studied as an anxiolytic, with research describing effects on GABA signaling and on serotonin metabolism, reportedly without the sedation or dependence associated with benzodiazepines.

Combined, the intended profile is focus without agitation, calm without sedation. That’s the appeal, and it’s worth noting the combination is used far more than it has been formally studied as a combination.

The evidence, stated plainly

The Russian clinical literature is real and spans decades. It has also seen limited independent replication in Western trials, and much of it is difficult to evaluate against the standards typically applied here. That doesn’t make it wrong. It does mean the confidence level should be lower than the marketing suggests.

Perimenopausal cognitive change is real, physiological, and for most women temporary. That is the most important sentence on this page.

What is actually happening to your brain in perimenopause

This is the part women are rarely told.

Estrogen is not only a reproductive hormone. It acts throughout the brain — on the hippocampus, on glucose metabolism in neurons, on serotonin and dopamine signaling. Brain imaging research has shown measurable changes in brain energy metabolism across the menopausal transition.

Which means the fog is not imagined and not a character flaw. It is a brain adapting to a changing hormonal environment. Studies following women through the transition generally find that cognitive performance recovers as hormones stabilize post-menopause — the fog is a feature of the transition rather than a permanent decline.

Anxiety follows a similar logic. Progesterone’s metabolite allopregnanolone acts on GABA receptors — the same system targeted by anti-anxiety medication. As progesterone becomes erratic, so does that calming input. Women who have never been anxious describe new anxiety in their forties, and this is a large part of why.

What I’d look at before a nootropic

For brain fog and new anxiety in midlife, the highest-yield investigation is unglamorous: a full thyroid panel (not TSH alone), ferritin, B12, vitamin D, fasting insulin, sleep quality including apnea screening, and hormonal status appropriate to your stage. Low ferritin and undiagnosed thyroid disease each reproduce this symptom picture almost exactly, and both are common in women who are still cycling. Start with how to tell thyroid from hormones.

If those are addressed and cognitive symptoms persist, a nootropic conversation becomes reasonable rather than premature.

Frequently Asked Questions

Are these like Adderall?

No. They are not stimulants and don’t work through that mechanism. Nor are they a substitute for evaluation if attention problems are significant.

Is Selank addictive?

The research interest in it stems partly from reports of anxiolytic effect without the dependence associated with benzodiazepines. Long-term human data is limited.

Will perimenopausal brain fog go away?

For most women, cognitive performance recovers as hormones stabilize after the transition. It is not typically a permanent decline — though persistent or worsening symptoms deserve proper evaluation.

Can I use these with an antidepressant or anti-anxiety medication?

That needs review by the provider managing those medications. Compounds affecting serotonin and GABA signaling are not to be layered casually.

References

“Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia.” PubMed, 2008. Note: much of the Semax and Selank literature is published in Russian, which limits independent verification. View source
“Decreased GABA+ Levels in the Medial Prefrontal Cortex of Perimenopausal Women: A 3T 1H-MRS Study.” PubMed, 2022. View source
Mosconi L, et al. “Increased Alzheimer’s risk during the menopause transition: A 3-year longitudinal brain imaging study.” PLOS ONE, 2018. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

PT-141: The Desire Medication That Works in the Brain, Not the Body

2026-08-04T00:00:00.000Z

Low sexual desire is one of the most common things women raise in a consultation and one of the least often addressed. It gets attributed to stress, to relationship dynamics, to being tired, to age — and then the conversation ends. PT-141 is worth understanding because it is one of very few pharmacological options that exists specifically for this, and because it works in a way most people assume it doesn’t.

Brain, not blood flow

The assumption is usually that a desire medication works like the erectile dysfunction drugs — on blood flow to genital tissue. PT-141 does not.

Bremelanotide, its pharmaceutical name, is a melanocortin receptor agonist. It acts on melanocortin pathways in the central nervous system involved in sexual arousal and desire. It is targeting the wanting, not the mechanics.

That distinction matters clinically, because for many women the problem was never mechanical. Desire itself had gone quiet, and no amount of blood flow addresses that.

What the FDA approval actually covers

This is the part to read carefully.

Bremelanotide was approved by the FDA in 2019 under the brand name Vyleesi, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Each word carries weight. Acquired means desire was previously present and declined. Generalized means it isn’t situation-specific. And premenopausal is the one that matters most for the women reading this.

The approval does not extend to postmenopausal women. Which means that for a woman in perimenopause or beyond — a large share of the women asking about it — use would be off-label, and the trial evidence supporting it was generated in a different population.

It is dosed as needed rather than daily, via a small subcutaneous autoinjector, with labeling limits on how often it may be used. Nausea is the most commonly reported side effect, and it can raise blood pressure transiently, which makes cardiovascular history part of the screening.

Desire that faded gradually over years is telling you something. A medication that restores it without asking why is treating the smoke alarm.

What deserves investigating first

Low desire in midlife is rarely a single-cause problem, and most of the causes are treatable:

Hormonal. Declining estrogen and testosterone both affect desire. Vaginal dryness and discomfort with sex — genitourinary syndrome of menopause — create avoidance that reads as low desire but is actually anticipated pain, and it is very treatable.
Medications. SSRIs are a leading pharmacological cause of reduced desire and are widely prescribed to women in exactly this age group.
Thyroid, iron, and sleep. Each reduces desire through simple depletion.
Exhaustion and load. The least medical and often the most relevant. Desire requires some surplus capacity, and midlife frequently offers none.
Relationship context. Worth naming honestly rather than medicalizing around.

A woman whose desire declined because of untreated vaginal atrophy, an SSRI, and four years of broken sleep does not primarily have a melanocortin problem.

Where it fits

PT-141 is most reasonable for the woman who has genuinely addressed the rest — hormones assessed and supported, vaginal symptoms treated, medications reviewed, sleep and thyroid handled — and who still finds that desire simply does not arrive. That woman exists, and for her a treatment that acts on desire directly is a legitimate option rather than a shortcut.

It is a poor fit as a first move, because a first move should be finding out what changed.

Frequently Asked Questions

Is it like Viagra for women?

No. Those medications work on blood flow. PT-141 acts on central nervous system pathways involved in desire.

Do I take it daily?

No — it is used as needed ahead of anticipated activity, with labeled limits on frequency.

Can postmenopausal women use it?

The FDA approval covers premenopausal women. Use beyond that is off-label and should be an explicit, informed conversation with a prescribing provider.

What if I’m on an SSRI?

Then reduced desire may well be medication-related, and reviewing that with your prescriber comes before adding anything new.

References

Kingsberg SA, Clayton AH, Portman D, et al. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT).” Obstetrics & Gynecology, 2019. View source
Simon JA, Kingsberg SA, Portman D, et al. “Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.” Obstetrics & Gynecology, 2019. View source
“Bremelanotide: First Approval.” Drugs, 2019. Approved June 2019 as Vyleesi for HSDD in premenopausal women. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

BPC-157 on Its Own: The Gut Peptide That Became a Recovery Peptide

2026-08-04T00:00:00.000Z

BPC-157 is the most-discussed peptide in the world right now, and most of that discussion is about tendons and joints. Which is slightly odd, because it started somewhere else entirely.

Where it came from

BPC stands for Body Protection Compound. The sequence was identified from a protein found in human gastric juice — part of the system by which the stomach protects itself from its own acid. Researchers at the University of Zagreb isolated it in the 1990s and have published on it extensively since.

The original research was about the gut: protection of the stomach lining, healing of intestinal tissue, effects on inflammatory bowel models. The tendon and ligament findings came later, and those are what made it famous.

Why the gut application still matters most for many women

If you came to this article because of joint pain, the Wolverine stack is likely the more relevant read — BPC-157 is usually paired with TB-500 for musculoskeletal goals.

BPC-157 on its own tends to be the conversation when the gut is the target. In animal research it has been associated with protection and repair of the intestinal lining, effects on tight junction integrity — the seals between the cells lining your intestine — and protection against NSAID-induced gut damage. That last one is worth pausing on, because a great many women take ibuprofen regularly for cycle pain, headaches, or joint aches, and chronic NSAID use is genuinely hard on the gut lining.

Gut symptoms that appear or worsen in your forties often aren’t a new gut problem. They’re your gut responding to a hormonal change.

The hormone-gut connection

Estrogen and progesterone influence gut motility, the microbiome, intestinal permeability, and mast cell behavior. As those hormones become erratic in perimenopause, many women experience new or worsening bloating, irregularity, reflux, or food reactivity — often having eaten the same way for twenty years without trouble.

There is also a loop worth understanding: a subset of your gut bacteria produces enzymes that influence how estrogen is recirculated versus excreted. Gut health affects estrogen levels, and estrogen affects gut health. Treating one while ignoring the other is why so many women get partial results.

The research, honestly

The BPC-157 evidence base is large, consistent, and almost entirely preclinical. Animal studies repeatedly show accelerated healing across tissue types with a favorable safety profile in those models. Human trial data is essentially absent.

That is a genuinely unusual position: an enormous body of animal work and almost no human work. It is why the compound generates both real scientific interest and justified caution, and why anyone describing it as proven is misrepresenting it.

What comes first for gut symptoms

A peptide is not a substitute for finding out what is wrong. For persistent gut symptoms I’d want to know about celiac status, thyroid function, whether there is bacterial overgrowth, what the diet and stress picture looks like, whether NSAIDs or other medications are involved, and where hormones sit. Comprehensive stool testing has a place when the picture warrants it.

BPC-157 may support the lining. It does not answer why the lining was damaged.

Frequently Asked Questions

Should I take it alone or in the Wolverine stack?

Broadly: gut-focused goals tend toward BPC-157 alone; musculoskeletal repair tends toward the pairing with TB-500. Your prescribing provider decides based on your case.

Is oral or injectable better for gut issues?

There is an argument that oral delivery keeps the compound where the gut damage is, and an argument that injection ensures systemic availability. The available forms depend on your prescriber and pharmacy.

Is it safe?

Animal studies show a favorable safety profile, but large human trials have not been done. That is the honest answer, and it is why supervision matters.

Can it undo NSAID damage?

Animal research has examined protection against NSAID-induced gut injury. Extrapolating to humans is speculative — and reducing NSAID use where possible is the more direct intervention.

GHK-Cu: Injection or Cream? The Copper Peptide, and Which Form the Evidence Supports

2026-08-04T00:00:00.000Z

GHK-Cu is unusual among the compounds discussed here, for a reason that should change how you approach it: this is the one where the topical form has the stronger human evidence, not the injectable.

That inverts the usual assumption — that injecting something must be the serious version and the cream is the consumer version. For this molecule, the opposite is closer to true.

What GHK-Cu is

GHK is a naturally occurring tripeptide — glycine, histidine, lysine — that binds copper with high affinity. It circulates in your plasma, and its levels decline substantially between your twenties and your sixties.

The copper is not incidental. Copper is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin into functional structure. GHK acts partly as a delivery vehicle, bringing copper where it’s needed for tissue remodeling.

What the research describes

GHK-Cu is one of the most-studied molecules in skin science. Laboratory and cosmetic research has associated it with:

Stimulating collagen and elastin synthesis in skin fibroblasts
Supporting wound healing and tissue remodeling
Antioxidant and anti-inflammatory activity
Improvements in skin density, firmness, fine lines, and photodamage in topical studies
Interest in hair follicle support

Injection vs. cream

The topical cream has the strongest human evidence, from cosmetic trials measuring skin parameters directly. It acts where you apply it, which for a skin goal is precisely the point. It is also the lower-risk option — no injection, no systemic copper exposure.

The injection is chosen when the goal is systemic tissue support rather than the skin on your face — broader repair, or as part of the Glow stack alongside BPC-157 and TB-500. The human evidence for injectable GHK-Cu is thinner and draws more on general tissue-repair reasoning than on direct trials.

If your goal is facial skin quality, the cream is the evidence-backed choice and I’d start there. If your goal is systemic repair with skin as one component, the injectable enters the conversation. Some protocols use both, targeting different things.

Research suggests women lose a striking share of their skin collagen in the first years after menopause. No cream reverses that alone — but knowing the cause changes what you do about it.

The estrogen story underneath

Skin is an estrogen-responsive organ. Estrogen receptors are abundant in it, and estrogen supports collagen synthesis, skin thickness, hydration, and wound healing.

Which is why skin change in midlife is not gradual in the way people expect. Research indicates the steepest collagen loss occurs in the years immediately following menopause. Women describe looking different within eighteen months, and they are not imagining it.

Any serious approach to midlife skin has to include the hormonal question, adequate protein and the micronutrients collagen synthesis requires, and sun protection — which remains the single highest-yield intervention for skin aging regardless of what else you do.

Frequently Asked Questions

Which should I choose?

For facial skin quality, the topical cream has the better human evidence. For systemic tissue repair, the injectable is the relevant form. Your goal decides.

Can I use both?

Some protocols do, targeting different objectives. That should be designed with your prescribing provider rather than assembled independently.

How long until I see a change?

Collagen remodeling is inherently gradual. Topical cosmetic studies typically measure change over weeks to months, not days.

Does it work with retinoids or vitamin C?

Layering actives is a real consideration and depends on formulation — some combinations are best applied at different times of day. A dermatology-informed routine is worth building deliberately.

Is there a copper safety concern?

With systemic use, yes, it deserves attention — particularly for anyone with a copper metabolism disorder. Topical exposure is far more limited.

Epithalon: The Telomere Peptide, the Pineal Gland, and What the Evidence Actually Supports

2026-08-04T00:00:00.000Z

Of everything on the longevity peptide menu, Epithalon carries the boldest claim: that it acts on telomeres, the protective caps at the ends of your chromosomes that shorten each time a cell divides. That claim deserves a careful look, because it is simultaneously the most interesting thing about this peptide and the most overstated thing in its marketing.

What Epithalon is

Epithalon (also written Epitalon) is a synthetic four-amino-acid peptide — alanine, glutamate, aspartate, glycine. It was developed as a synthetic version of Epithalamin, an extract of the pineal gland studied in the Soviet Union and later Russia beginning in the 1970s under Professor Vladimir Khavinson.

The pineal gland matters here. It is the small structure deep in the brain that produces melatonin and helps govern circadian rhythm. Pineal function changes with age, and the original hypothesis behind this research was that supporting the pineal gland might influence the pace of aging more broadly — not just sleep.

The telomere claim, examined

Telomeres shorten with each cell division. When they get critically short, the cell stops dividing. Telomerase is the enzyme that can lengthen them, and it is largely switched off in most adult cells. The published Epithalon research reports telomerase activation and telomere elongation in human cell cultures, alongside animal studies reporting extended lifespan and effects on circadian and hormonal rhythm.

Here is the honest framing, which you will rarely see on a supplier's website. Most of this work comes from a single research group, published over several decades, much of it in Russian-language journals, with limited independent replication in Western laboratories. That does not make it wrong. It does mean the evidence base is narrower than the confident language around this peptide implies. Cell-culture telomerase activity is also a long way from a demonstrated clinical benefit in a living woman.

There is a second consideration worth naming plainly: telomerase activation is not a uniformly good thing. Cancer cells rely on telomerase to divide indefinitely. Researchers in this area have not established what long-term telomerase modulation means for cancer risk in humans. Anyone selling you telomere lengthening as a pure upside is skipping the part of the biology that requires the most caution.

"Promising in cell culture" and "proven in women" are separated by decades of research that have not yet been done.

The cycling protocol — and why it is unusual

Epithalon is not taken continuously. The standard approach is a short course — commonly around ten consecutive days — repeated only a few times a year, often at roughly four-month intervals.

That is a genuinely different rhythm from most peptides, and it comes directly from the original research design rather than from a marketing decision. It also means the total exposure over a year is small compared to a daily protocol, which is part of why the cost per cycle is structured the way it is.

Why women in midlife ask about it

In practice, the women I hear from about Epithalon are rarely chasing immortality. They are usually interested in something more concrete:

Sleep and circadian rhythm. The pineal-melatonin connection is the most mechanistically plausible part of this story, and disrupted sleep is one of the defining complaints of perimenopause.
The feeling of accelerated aging. Many women describe the perimenopausal transition as aging faster for a few years — skin, recovery, energy, sleep all shifting at once. That experience is real, and it is largely an estrogen story.
Preventive framing. Women who are doing the foundational work well and want to know what else exists.

If sleep is your primary reason for interest, I would point out something inexpensive first: the perimenopausal sleep pattern has its own well-described physiology, and addressing that directly often produces more change than any peptide would. Start with why so many women wake at 3 AM.

How I think about it clinically

Epithalon sits in a category I would call "interesting, unproven, low-priority." It is not where I would spend a woman's first dollar or her first six months of effort. Hormonal assessment, sleep architecture, muscle mass, insulin sensitivity, and inflammation all have far stronger evidence behind them and far more room to move.

The women for whom a longevity peptide conversation makes sense are the ones who have already built that foundation — who are strength training, eating enough protein, sleeping reasonably, and have had their hormones and metabolic markers actually looked at. If that is not yet you, the highest-yield work is upstream of anything on this page.

Frequently Asked Questions

Is Epithalon the same as melatonin?

No. Melatonin is the hormone the pineal gland produces. Epithalon is a synthetic peptide developed from a pineal extract, studied for effects on pineal function and circadian rhythm rather than as a melatonin substitute.

Why is it dosed as a short cycle a few times a year?

That schedule comes from the original research protocols rather than from continuous-use logic. It means yearly exposure is relatively low compared with daily peptides.

Will it make me live longer?

There is no human evidence supporting that claim, and anyone who tells you otherwise is selling something. The lifespan data comes from animal studies.

What would you look at first instead?

Sleep architecture, hormone status, muscle mass, and metabolic markers — in that order for most women in midlife. Those have real evidence and real leverage.

References

Khavinson VK, Bondarev IE, Butyugov AA. “Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells.” Bulletin of Experimental Biology and Medicine, 2003. Note: the substantial majority of epithalon research originates from this single group; independent replication in humans is lacking. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

SS-31: The Mitochondrial Peptide With Real Clinical Trial Data

2026-08-04T00:00:00.000Z

If you have read the rest of this series, you know my recurring caution: most peptides marketed for longevity rest on animal data and enthusiasm. SS-31 is the exception worth knowing about, because it has been through genuine human clinical trials under a different name — elamipretide — in rare mitochondrial disease.

What SS-31 targets, and why that is unusual

Your mitochondria are the structures inside your cells that convert food and oxygen into usable energy. They have an inner membrane, densely folded, where most of that energy production happens. That membrane contains a distinctive lipid called cardiolipin.

Cardiolipin does something specific: it helps hold the energy-producing protein complexes in the right shape and the right arrangement. When cardiolipin is damaged — by oxidative stress, by age, by disease — those complexes lose efficiency. Energy output drops and free radical production rises, which damages more cardiolipin. It is a self-reinforcing loop.

SS-31 is a small peptide designed to concentrate in the inner mitochondrial membrane and bind cardiolipin. Rather than adding fuel or supplying an antioxidant broadly, the concept is structural: stabilize the membrane environment so the existing machinery works properly again. That is a more targeted mechanism than almost anything else in this category.

The clinical trial history

Under the name elamipretide, this peptide has been evaluated in human trials for primary mitochondrial myopathy and for Barth syndrome, a rare genetic disorder that directly involves cardiolipin. It has also been studied in other conditions where mitochondrial dysfunction is central.

The results have been mixed rather than uniformly positive — some endpoints met, others not — which is itself informative. Real drug development produces complicated results. What matters for our purposes is that this compound has been through rigorous evaluation in defined patient populations, which sets it apart from peptides whose entire evidence base is preclinical.

The important caveat: those trials studied people with specific diagnosed mitochondrial diseases. They did not study healthy midlife women with fatigue. Extrapolating from one to the other is a leap, and it should be labeled as one.

Evidence in rare mitochondrial disease is not the same as evidence in everyday midlife fatigue. It is a reason to take the mechanism seriously, not a reason to assume the benefit transfers.

The midlife energy question

Mitochondrial function does decline with age, and it is one of the more coherent explanations for why energy in your forties feels categorically different from energy in your twenties. For women there is an added layer: estrogen influences mitochondrial biogenesis and antioxidant defense, so the perimenopausal decline is not just a reproductive event — it touches cellular energy production too.

That said, I want to be careful here, because "mitochondrial dysfunction" has become a catch-all explanation in wellness marketing. Before attributing fatigue to mitochondria, the ordinary causes deserve to be ruled out first, and in my experience they explain most cases: thyroid function, iron and ferritin, B12 and vitamin D, sleep apnea, blood sugar instability, and the hormonal shifts of perimenopause itself. Low ferritin alone reproduces almost the entire fatigue picture and is remarkably common in women who are still cycling. Start with what "normal" labs actually mean before reaching for a cellular explanation.

Where it fits

Of the longevity-oriented peptides, SS-31 has the most credible mechanism and the most serious research history. That earns it a place in the conversation. It does not earn it a place ahead of the workup.

The sequence I would suggest for any woman drawn to this: get the ordinary causes of fatigue properly investigated, address hormonal status, build the muscle and sleep foundation, and then — if fatigue persists in a body that has been genuinely optimized — a mitochondrial conversation becomes reasonable rather than speculative.

Frequently Asked Questions

Is SS-31 the same as elamipretide?

Yes. SS-31 is the research designation; elamipretide is the name used in pharmaceutical development. It has also appeared as MTP-131 and Bendavia.

How is it different from CoQ10 or NAD precursors?

Those supply substrates or cofactors for mitochondrial reactions. SS-31 targets the structure of the inner membrane itself by binding cardiolipin. Different point of intervention.

Would it help general fatigue?

That has not been established. The human trials studied diagnosed mitochondrial disease, not everyday fatigue. Anyone claiming otherwise is extrapolating well beyond the data.

Why is a course so expensive relative to other peptides?

It is dosed as a multi-vial protocol rather than a single vial, so a full course involves substantially more material than most peptide protocols.

References

Karaa A, et al. “Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy (MMPOWER).” Neurology, 2018. View source
Karaa A, et al. “A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy (MMPOWER-2).” 2020. View source
Karaa A, et al. “Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.” Neurology, 2023. Note: MMPOWER-3 did not demonstrate a significant benefit across a genotypically diverse population. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

MOTS-c: The Peptide Your Mitochondria Make — and Why It Interests Midlife Women

2026-08-04T00:00:00.000Z

MOTS-c stands apart from most peptides in this series for a structural reason: your body already makes it. It is encoded not in the DNA in your cell nucleus, but in your mitochondrial DNA — the small separate genome your mitochondria carry. That places it in a class called mitochondrial-derived peptides, and it means MOTS-c is part of a signaling conversation between your mitochondria and the rest of your body.

What the research describes

MOTS-c was identified relatively recently, and the research to date has focused on metabolism. In animal and cellular studies it has been associated with:

Improved insulin sensitivity and glucose handling in skeletal muscle
Activation of AMPK, a cellular energy sensor that also responds to exercise and to fasting
Resistance to diet-induced weight gain in rodent models
Metabolic flexibility — the ability to switch efficiently between burning glucose and burning fat

Human levels of MOTS-c appear to decline with age, and exercise appears to raise them — which is where the phrase "exercise mimetic" entered the conversation.

About that phrase

"Exercise mimetic" is a genuine term in the research literature, describing compounds that activate some of the same molecular pathways exercise does. It is also the single most misused phrase in peptide marketing.

Activating AMPK is not the same as exercising. Exercise loads your skeleton, which is how bone density is maintained. It builds muscle through mechanical tension. It improves cardiac output, balance, coordination, mood, and sleep. It produces adaptations across a dozen systems simultaneously. No peptide replaces that, and for women in midlife — when bone and muscle are both under hormonal pressure — the parts a peptide cannot replicate are precisely the parts that matter most.

The honest framing is that MOTS-c may share a signaling pathway with exercise. It is not a substitute for it.

A peptide can share a pathway with exercise. It cannot load your skeleton, and in midlife that is the part you cannot afford to skip.

Why perimenopausal metabolism makes this relevant

Here is the part that makes MOTS-c genuinely interesting for this audience rather than just for athletes.

Insulin sensitivity commonly declines through the menopausal transition. Estrogen influences how muscle takes up glucose and where the body stores fat, so as estrogen becomes erratic and then declines, many women experience a real metabolic shift — fat redistributing toward the midsection, blood sugar becoming less stable, energy dipping in the afternoon — without changing a thing about how they eat or train. Being told to simply eat less and move more at that moment is both unhelpful and slightly insulting, because the terrain genuinely changed.

A peptide studied specifically for insulin sensitivity and metabolic flexibility lands right on that problem. Whether it delivers in humans is an open question — the research is early and largely preclinical. But the reason women keep asking about it is not marketing. It is that the mechanism maps onto something they are actually experiencing.

What I would want to know first

If insulin resistance is the concern, it should be measured rather than assumed. Fasting insulin, fasting glucose, HbA1c, and a lipid panel give a far clearer picture than symptoms alone — and fasting insulin in particular is frequently omitted from standard panels even though it often shifts years before glucose does.

From there, the interventions with the strongest evidence in perimenopausal women are unglamorous and effective: resistance training, adequate protein, addressing sleep, and evaluating whether hormonal support is appropriate. If a woman has done that work and metabolic markers remain stubborn, a conversation about metabolic peptides becomes reasonable. Before that, it is a shortcut around the thing that would actually work.

Frequently Asked Questions

Is MOTS-c a weight loss drug?

No. It is studied for insulin sensitivity and metabolic signaling, not appetite regulation, and it should not be compared to the GLP-1 medications. If weight is the goal, see the semaglutide and tirzepatide comparison for what the approved options actually do.

Does exercise raise my own MOTS-c?

Research suggests exercise increases circulating levels, which is part of why the exercise connection is drawn in the first place.

Can I take it alongside strength training?

The premise of this article is that strength training is the non-negotiable part and the peptide is the optional part — not the reverse.

How does it compare to SS-31?

Both concern mitochondria, but differently. SS-31 targets the structure of the inner mitochondrial membrane. MOTS-c is a signaling molecule affecting metabolic pathways throughout the body.

References

Lee C, et al. “The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance.” Cell Metabolism, 2015. View source
Kim SJ, et al. “The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity.” Physiological Reports, 2019. View source
“MOTS-c Functionally Prevents Metabolic Disorders.” PubMed, 2023. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

Semaglutide for Women: What It Does, What It Costs You, and What to Protect

2026-08-04T00:00:00.000Z

Semaglutide changed the conversation about weight in a way nothing before it did. It is genuinely effective, it is FDA-approved, and unlike most of what I write about in this series, it rests on large randomized trials rather than preliminary research. What it does not come with — at least not in most of the marketing — is an honest account of what a woman in midlife needs to protect while taking it.

How it works

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after eating; it signals to the pancreas, slows gastric emptying, and acts on appetite centers in the brain. Semaglutide is a modified version engineered to resist rapid breakdown, so a single weekly injection maintains that signal continuously.

The practical result is that the constant negotiation with hunger quiets down. Women frequently describe it as the disappearance of "food noise" — the background mental chatter about eating — and that description tells you something important. This is a neurological and hormonal intervention, not a willpower supplement.

It is approved under different brand names for different purposes — type 2 diabetes and chronic weight management — and an oral tablet form is now available as well. Which formulation fits depends on the indication being treated.

What the trials show

In the pivotal weight-management trials, semaglutide at the full dose produced average weight reduction in the range of fifteen percent of body weight over roughly sixteen months, with substantial improvements in blood pressure, lipids, and glycemic markers. Separately, cardiovascular outcome research has shown benefit in defined populations — a meaningful finding, because it suggests the drug does more than move a number on a scale.

What midlife changes about the calculation

This is the part that gets left out, and it is the part I care most about.

Muscle. Rapid weight loss always costs some lean mass, not only fat. In a woman in perimenopause, that cost lands on a body already losing muscle for hormonal reasons — estrogen supports muscle maintenance, and its decline accelerates the natural sarcopenia of midlife. Powerful appetite suppression layered on top of that means eating substantially less protein at exactly the moment you need more of it. The scale will look excellent while your body composition quietly moves in the wrong direction.

Bone. This follows directly. Muscle pulls on bone, and that mechanical stress is a primary driver of bone density. Meanwhile, estrogen decline is already accelerating bone loss, and fat tissue itself produces a small amount of estrogen that decreases as body fat falls. Researchers studying bone in midlife women have described exactly this convergence — menopause, rapid weight loss, and reduced loading arriving together — as a genuine concern. Women aged fifty to sixty-four use these medications at the highest rate of any group, which is precisely the group where this matters.

Hair, gallbladder, and GI. Hair shedding is commonly reported and usually reflects the rapid weight loss rather than the drug itself. Rapid weight loss also raises gallstone risk. Gastrointestinal side effects — nausea, constipation, reflux — are the most common reason women stop.

Fertility. Women who were not ovulating regularly sometimes begin ovulating again as insulin sensitivity improves. Unplanned pregnancy is a real possibility, and these medications are not to be used in pregnancy.

The scale can look excellent while your body composition moves in exactly the wrong direction. In midlife, what you lose matters as much as how much.

The protective protocol

None of the above is an argument against these medications. It is an argument for using them with a plan. The protective measures are consistent and well established:

Protein becomes non-negotiable and has to be deliberate, because appetite is suppressed. Most women in this situation need to plan protein rather than wait to feel like eating it.
Resistance training two to three times weekly. This is the single strongest lever for preserving both muscle and bone during weight loss. Cardio does not substitute.
Baseline bone assessment. Standard screening guidelines often do not recommend a bone density scan until sixty-five, which may be too late for a woman starting significant weight loss in her fifties. It is worth asking about.
Track body composition, not just weight. A scale cannot tell you what you lost.
Address hormones in parallel. Treating perimenopausal metabolic change without evaluating the hormonal shift driving it means treating a symptom.

A note on compounded versions

The compounded semaglutide market that grew during the drug shortages has been narrowing substantially as regulators have tightened oversight, and the FDA has moved to further restrict large-scale compounding of these ingredients. If you are currently using a compounded version, it is worth asking your provider directly which pharmacy produces it and what their plan is if availability changes — and worth knowing that compounded products are not FDA-approved even when the active ingredient shares a name.

Frequently Asked Questions

Will I regain the weight if I stop?

Trial data shows substantial regain after discontinuation for most people. These medications treat an ongoing condition rather than curing it, which is a conversation worth having before starting rather than after.

Can I take it with hormone therapy?

They address different systems and are frequently considered together in midlife. That combination should be designed by the provider managing both.

How does it compare to tirzepatide?

They differ meaningfully in mechanism and in head-to-head results — see the direct comparison, which includes a finding specific to women.

Is the food noise reduction permanent?

It generally tracks with being on the medication. Most people report it returning after stopping.

Tirzepatide for Women: The Dual-Receptor Difference and What It Means in Midlife

2026-08-04T00:00:00.000Z

Tirzepatide is the newer of the two dominant metabolic medications, and the difference between it and semaglutide is not a matter of dosing or branding. It acts on two receptors instead of one, and the clinical consequences of that turn out to be substantial — particularly, as it happens, in women.

Two incretins, not one

Your gut releases several hormones in response to food. Two matter here: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Semaglutide acts on the GLP-1 receptor alone. Tirzepatide acts on both.

The GLP-1 arm does what you would expect: slows gastric emptying, supports insulin release, and reduces appetite signaling. The GIP arm is more interesting and less intuitive. GIP receptors are found in fat tissue and in the brain, and the current understanding is that adding GIP activity influences how the body handles fat storage and energy, while also appearing to moderate some of the nausea associated with GLP-1 activity alone.

It is approved under separate brand names for type 2 diabetes and for chronic weight management, and it also carries an approval for moderate-to-severe obstructive sleep apnea in adults with obesity — a condition substantially underdiagnosed in women, whose sleep apnea often presents as fatigue and insomnia rather than the classic loud snoring picture.

The head-to-head data — and the finding for women

The two medications have been compared directly in a randomized trial running seventy-two weeks in adults with obesity and without diabetes. Tirzepatide produced greater average weight reduction — roughly twenty percent versus roughly fourteen percent — along with greater reduction in waist circumference and a larger proportion of participants reaching the higher weight-loss thresholds.

The detail worth pausing on: the response was larger in women than in men on both drugs, and the gap between the two medications was substantial in women as well. Women in that trial averaged meaningfully greater reduction than men on either treatment. That is an unusual and useful piece of sex-specific data in a field where women's results are too often buried in a pooled average.

Sex-specific results are rare in metabolic research. When a trial reports them and the difference is this large, it deserves more than a footnote.

The contraception interaction women are rarely told about

This one deserves its own section because it has real consequences and it is routinely omitted.

Tirzepatide can reduce the effectiveness of oral contraceptives, an effect attributed to delayed gastric emptying altering absorption. The product labeling advises using a non-oral contraceptive method or adding a barrier method for a defined period after starting the medication and after each dose increase. Non-oral methods — an IUD, implant, injection, patch, or ring — are not affected in the same way.

Layer onto that the fertility effect common to this class: women with insulin resistance who were ovulating irregularly may begin ovulating predictably again as metabolic health improves. A woman who assumed her fertility was low, taking a medication that reduces oral contraceptive reliability, is in a situation she should have been warned about. These medications are not to be used in pregnancy.

What to protect in midlife

Everything I wrote about semaglutide and muscle and bone applies here, and arguably more so, because greater weight loss means a greater absolute amount of lean tissue at stake. The protective measures are the same and they are not optional:

Deliberate protein intake, planned rather than driven by appetite — because appetite is exactly what has been suppressed
Resistance training two to three times weekly, as the primary defense for both muscle and bone
Baseline bone density assessment before significant weight loss, particularly for women in or past the menopausal transition
Body composition tracking rather than scale weight alone
Parallel hormonal evaluation, since perimenopausal insulin resistance has a hormonal driver that a metabolic medication does not address

On compounded tirzepatide

The compounded tirzepatide market has been contracting as the shortage that permitted it resolved and regulatory oversight tightened. Regulators have also raised specific concerns about compounded products that combine the active ingredient with added vitamins, since those combinations were never studied. If you are using a compounded version, ask which pharmacy produces it and what happens to your supply if the rules change. Compounded is not the same as FDA-approved, even when the ingredient name matches.

Frequently Asked Questions

Is tirzepatide simply better than semaglutide?

It produced greater weight loss in the head-to-head trial, but "better" depends on tolerance, cost, coverage, and what you are treating. See the full comparison.

Does the GIP component reduce nausea?

Both medications commonly cause gastrointestinal effects. In the head-to-head trial, discontinuation due to GI side effects was somewhat lower with tirzepatide.

What if I have sleep apnea?

Tirzepatide carries an approval in that indication for adults with obesity, which may factor into the choice. Sleep apnea is frequently missed in women — it is worth raising if you have unexplained fatigue.

Do I need to change my birth control?

If you use oral contraceptives, this needs a direct conversation with your prescribing provider before starting and at each dose increase.

Semaglutide vs. Tirzepatide for Women: An Honest Comparison

2026-08-04T00:00:00.000Z

This is the question I hear more than any other about metabolic medication, and most of the answers online compare the two drugs as though the patient were a generic adult. Women in midlife are not a generic adult, and several of the deciding factors are different for us. Here is the comparison as I would actually walk through it.

The mechanism difference

Semaglutide is a GLP-1 receptor agonist. It acts on one incretin pathway — slowing gastric emptying, supporting glucose-dependent insulin release, and reducing appetite signaling in the brain.

Tirzepatide acts on two receptors: GLP-1 and GIP. The GIP arm engages receptors in fat tissue and the brain, and appears to influence how the body handles fat storage and energy in ways the GLP-1 pathway alone does not.

That is not a marketing distinction. It is a different pharmacology, and it shows up in the outcomes.

Head-to-head: what the trial found

The two were compared directly in a seventy-two-week randomized trial in adults with obesity and without diabetes. Tirzepatide produced greater average weight reduction — approximately twenty percent versus approximately fourteen percent — greater waist circumference reduction, and roughly double the proportion of participants reaching the most substantial weight-loss threshold. Gastrointestinal side effects leading to discontinuation were somewhat more common with semaglutide.

The finding most coverage skipped: the results broke down differently by sex. Women averaged greater reduction than men on both medications, and the difference between the two drugs held in women as well. If you have been reading trial averages and quietly wondering whether they describe you, this is one of the rare cases where the sex-specific data was reported — and it favored women on both.

Most metabolic trial results are reported as a pooled average that hides the difference between men and women. When the breakdown exists, it is worth reading.

Where semaglutide has the stronger case

Greater weight loss is not the only thing that matters, and there are real reasons a woman might land on semaglutide:

A longer track record and a larger body of cardiovascular outcome research in defined populations.
Formulation options, including an oral tablet form for those who would rather not inject.
No oral contraceptive interaction of the kind labeled for tirzepatide — a meaningful consideration for a woman in her thirties or forties using the pill.
Coverage and access, which vary and sometimes decide the question regardless of preference.

Where tirzepatide has the stronger case

Greater weight reduction in direct comparison, with the sex-specific data favoring women.
An obstructive sleep apnea indication in adults with obesity — relevant because sleep apnea is substantially underdiagnosed in women, often presenting as fatigue and insomnia rather than loud snoring.
Somewhat lower discontinuation due to gastrointestinal effects in the head-to-head data.
Greater improvement across several cardiometabolic measures in that trial.

The four questions that actually decide it for women

In practice, the comparison narrows quickly once you ask the right things:

1. Do you use oral contraceptives? If yes, tirzepatide requires a plan — the labeling advises a non-oral or backup method after starting and after each dose increase. This alone reshapes the decision for many premenopausal women.

2. Where are you in the menopausal transition? If you are perimenopausal or postmenopausal, muscle and bone protection move to the center of the plan regardless of which drug you choose — and the drug producing more weight loss puts more lean tissue at stake, not less.

3. Is fatigue part of your picture? If unexplained fatigue is prominent, sleep apnea deserves evaluation, and that may point toward one option over the other.

4. What has actually been measured? Fasting insulin, HbA1c, thyroid panel, ferritin, vitamin D, and sex hormones. Perimenopausal insulin resistance has a hormonal driver, and treating the metabolic downstream while ignoring the hormonal upstream is why many women get partial results and conclude nothing works.

What is identical between them

The parts that matter most in midlife do not differ by drug:

Both cost you lean muscle alongside fat unless you actively protect it — deliberate protein and resistance training two to three times weekly, not optional.
Both raise the bone question in women already losing bone to estrogen decline. A baseline bone density assessment is worth asking about before significant weight loss, since standard guidelines often do not suggest one until sixty-five.
Both can restore ovulation in women with insulin resistance, making unplanned pregnancy a genuine possibility. Neither is used in pregnancy.
Both carry the same boxed warning regarding thyroid C-cell tumors and the same contraindications.
Both are associated with weight regain after stopping for most people. These treat an ongoing condition rather than curing it.
Neither addresses the hormonal shift underneath perimenopausal metabolic change.

The landscape is still moving

Two things worth knowing if you are deciding now. First, oral options have expanded considerably — both an oral semaglutide tablet and a newer once-daily oral GLP-1 taken without food or water restrictions are now approved, though oral options have generally produced less weight loss than the injectables. Second, the compounded market that made these medications cheaply available during the shortages has been contracting sharply as the shortages resolved and regulators tightened oversight. If your current access depends on a compounded product, that is worth a direct conversation about continuity.

My actual answer

For most women in midlife the more useful question is not which drug, but what surrounds it. A medication chosen carefully and taken inside a plan that protects muscle, protects bone, addresses hormones, and tracks body composition rather than scale weight will outperform the theoretically superior drug taken alone. The reverse is also true, and it is the more common story.

Frequently Asked Questions

Which produces more weight loss?

Tirzepatide, in the direct head-to-head trial — roughly twenty percent versus roughly fourteen percent over seventy-two weeks, with women responding more strongly than men on both.

Can I switch from one to the other?

Switching is done, but dose escalation and tolerance have to be managed by your prescribing provider — the doses are not interchangeable.

Do either help hot flashes?

Some early research has looked at vasomotor symptoms alongside weight loss in menopausal women, but the evidence is limited. Hormone therapy has far stronger evidence for that specific symptom.

What should I have tested before starting either?

At minimum: fasting insulin and glucose, HbA1c, a full thyroid panel, ferritin, vitamin D, lipids, and sex hormones appropriate to your stage. See why standard panels often miss the picture.

The Wolverine Stack: BPC-157 + TB-500 for Recovery, Repair & Resilience in Women

2026-08-04T00:00:00.000Z

If you've heard whispers about a "Wolverine" peptide protocol in wellness circles, here's what's actually behind the name: a pairing of two of the most-discussed repair peptides in regenerative medicine — BPC‑157 and TB‑500. In this guide, I'll walk you through what these peptides are, what the research actually shows, and why women — especially in the perimenopausal years — are increasingly asking about them.

What Is the Wolverine Peptide Stack?

Peptides are short chains of amino acids — think of them as precise biological messengers that tell specific tissues what to do. The Wolverine stack combines two of them:

BPC‑157 ("Body Protection Compound") — a peptide sequence derived from a protective protein found in gastric juice, studied extensively in animal models for tendon, ligament, muscle, and gut-lining repair.
TB‑500 — a synthetic version of Thymosin Beta‑4, a naturally occurring peptide involved in cell migration, blood vessel formation, and wound healing.

The nickname comes from the superhero famous for rapid healing — a nod to why these two are so often paired together. BPC‑157 appears to act locally on injured tissue and the gut lining, while TB‑500 is thought to work more systemically, helping repair cells migrate to where they're needed. Together, they're the foundation of most modern recovery-focused peptide protocols.

Why Women Are Asking About Repair Peptides

Most peptide content online is written for male athletes. But the women asking about the Wolverine stack usually aren't chasing a deadlift PR — they're navigating something different:

New-onset joint pain in perimenopause. As estrogen declines, so does its quiet protective effect on collagen, connective tissue, and inflammation. "Menopausal arthralgia" is real, common, and rarely explained to women.
Slower recovery from workouts. The strength training we need in midlife for bone and muscle can feel harder to bounce back from.
Nagging soft-tissue injuries — tennis elbow, plantar fasciitis, shoulder issues — that linger for months.
Gut issues that flare with hormonal shifts. BPC‑157's origins in gastric protection make it one of the most interesting peptides for gut-lining integrity.

Declining estrogen changes how women's connective tissue repairs itself. That's not weakness — it's physiology. And physiology can be supported.

What the Research Shows (and What It Doesn't)

I want to be straightforward with you, because this is where much of the internet isn't. The evidence base for BPC‑157 and TB‑500 is promising but early. In animal studies, BPC‑157 has repeatedly demonstrated accelerated healing of tendons, ligaments, muscle tears, and intestinal tissue, along with anti-inflammatory effects. Thymosin Beta‑4 has been studied in wound healing and cardiac and corneal repair models, with some early-phase human research.

What we don't yet have are large randomized human trials for either peptide. Neither is approved by the FDA; both are available only as compounded medications through a licensed prescribing provider. Anyone who tells you these peptides are "proven" is overstating the science — and anyone selling them without medical oversight should be a red flag.

What I can tell you from the functional medicine vantage point: when repair peptides are used thoughtfully — in the right patient, at the right time, alongside hormonal assessment, nutrition, and strength work — many women report meaningful improvements in recovery time, joint comfort, and gut symptoms. That clinical picture is why interest keeps growing, and why supervision matters.

How the Wolverine Stack Is Used

The stack is generally given as a single combined subcutaneous injection — a tiny insulin-style needle, self-administered at home after training from the prescribing provider. Protocols are individualized, but a typical course runs several weeks, timed around an injury, a surgical recovery window, or a period of intensive training. Because BPC‑157 is also studied for its effects on the gut lining, women exploring it often have GI symptoms in the picture as well.

This is also where the "women's health" part matters: before considering any peptide, it's worth knowing what your hormones, inflammation markers, and recovery capacity actually look like — the piece I focus on in my functional medicine work. A peptide layered on top of unaddressed perimenopausal hormone shifts, poor sleep, or under-eating is a Band-Aid. Layered on top of a solid foundation, it can be a genuine accelerant.

Who Might Be a Candidate — and Who Isn't

Women who tend to do well with a supervised Wolverine protocol are typically dealing with a specific soft-tissue injury, post-surgical recovery, stubborn tendon issues, or gut-lining concerns — and already have (or are building) the foundations: adequate protein, strength training, sleep, and hormonal support where needed.

It's not the right fit for women looking for a shortcut around those foundations, for anyone with active malignancy, or during pregnancy and breastfeeding. Because TB‑500 influences cell migration and blood-vessel formation, cancer history is a firm stop-and-evaluate point in any responsible screening process.

Frequently Asked Questions

Does the injection hurt?

Most patients are surprised — it's a very fine, short needle into the fatty tissue of the abdomen, similar to what millions of people use daily for insulin. Discomfort is minimal.

How quickly do women notice a difference?

It varies with the tissue involved. Gut-related benefits are often reported earliest, sometimes within a couple of weeks; tendon and joint changes are slower, tracking with the natural timeline of connective-tissue turnover.

Can I take the Wolverine stack with hormone therapy?

Often they are considered together — which is precisely why peptides belong inside a medically supervised plan with a licensed prescribing provider, rather than purchased online from an unregulated source.

Is there a version with skin benefits?

Yes — adding the copper peptide GHK‑Cu creates what we call the Glow stack, and adding KPV for inflammatory and skin-barrier support creates the Klow stack.

CJC-1295 + Ipamorelin: What Every Woman Should Understand Before She Starts

2026-08-04T00:00:00.000Z

Of all the peptides women ask me about, this pairing generates the most excitement — and the most confusion. CJC‑1295 + Ipamorelin is often described as "growth hormone therapy," which isn't quite right, and that distinction turns out to matter enormously for how it works, who it suits, and what to expect.

Secretagogues, Not Replacement

Here's the core concept. Synthetic human growth hormone (HGH) delivers the hormone directly, overriding your body's own regulatory feedback. These two peptides do something fundamentally different — they ask your pituitary to do its job:

CJC‑1295 is an analog of growth hormone releasing hormone (GHRH) — the upstream signal that tells the pituitary to release GH. Its modifications extend its activity well beyond that of natural GHRH.
Ipamorelin is a growth hormone secretagogue acting through a separate receptor pathway (the ghrelin/GHS receptor). It's prized for its selectivity — stimulating GH release with minimal impact on cortisol and prolactin, which older secretagogues affected considerably.

Because they work through two different mechanisms, the combination produces a stronger, more physiologic release than either alone — and critically, it stays pulsatile, following the rhythm your body already uses. Your natural feedback loops remain in place.

Growth hormone decline isn't a disease. But how a woman ages through it — muscle, sleep, recovery, body composition — is very much a moving target.

What Happens to Growth Hormone in a Woman's Midlife

Growth hormone secretion peaks in adolescence and declines steadily thereafter — a phenomenon sometimes called somatopause. The overlap with perimenopause is what makes this clinically interesting for women. In the same decade, many women experience:

Loss of lean muscle mass despite unchanged training
Shifting fat distribution toward the midsection
Fragmented sleep, particularly less deep slow-wave sleep
Slower recovery and more persistent soreness
Changes in skin thickness and elasticity

Estrogen and progesterone changes drive much of this. But growth hormone and the sleep architecture that governs it are part of the same system — and sleep disruption itself suppresses GH pulses, creating a loop that's hard to exit.

Why Timing and Sleep Are Central

Your largest natural GH pulse happens during deep slow-wave sleep, typically in the first part of the night. That's why this stack is dosed at bedtime, on an empty stomach — elevated insulin from a recent meal blunts GH release. It's also why improved sleep quality is the most commonly reported early effect women describe to me, often before any change in body composition.

That sequence makes physiologic sense: better deep sleep supports GH pulses, which supports recovery and lean tissue, which supports metabolic health. The peptide isn't creating something foreign — it's nudging a rhythm that midlife disrupted.

What This Stack Is Not

I want to set expectations honestly, because the marketing around GH peptides is often reckless:

It is not a weight-loss drug. Women expecting GLP‑1-style results will be disappointed. GH influences body composition and visceral fat over months, not the appetite regulation that drives rapid weight change.
It is not a replacement for hormone therapy. If declining estrogen and progesterone are driving your symptoms, a GH secretagogue addresses a different axis entirely.
It is not a substitute for resistance training and protein. GH supports the tissue you're building. If you're not giving your body a reason to build muscle and the amino acids to build it with, there's nothing for the signal to act on.
It is not FDA-approved for anti-aging or body composition. These are investigational compounded peptides used off-label, available only through a licensed prescribing provider.

Where It Fits in a Woman's Protocol

CJC‑1295 + Ipamorelin belongs after the foundational work, not instead of it. Before anyone considers it, it's worth seeing where your sex hormones, thyroid, insulin sensitivity, inflammatory markers, and IGF‑1 actually sit — and whether you're eating enough protein and lifting anything heavy. That foundational assessment is the part I focus on. Women who start here — foundation first — get results that hold. Women who start with the peptide often end up disappointed by an expensive placebo for an unaddressed problem.

For women whose primary concern is visceral abdominal fat specifically, Tesamorelin — a GHRH analog with dedicated clinical research in that area — may be the better-matched choice, and it's a distinction worth understanding. Sermorelin is another GHRH-based option with a longer track record in clinical use.

Frequently Asked Questions

How is it administered?

A small nightly subcutaneous injection with a fine insulin-style needle, self-administered at home after training from the prescribing provider, typically before bed on an empty stomach.

How long before I notice anything?

Sleep changes are often the first thing women report, sometimes within the first weeks. Body composition and recovery changes track over months and depend heavily on training and nutrition.

Are protocols cycled?

Often, yes. Cycling is used to help preserve pituitary responsiveness. Any specific schedule is set by the prescribing provider, alongside lab monitoring.

Can I use this with hormone therapy or a GLP-1?

In many cases these are considered complementary rather than competing — but combinations need to be designed deliberately, with attention to insulin sensitivity and adequate protein intake. That's a conversation for your prescribing provider.

Will this raise my cortisol?

Ipamorelin's appeal is precisely its selectivity — it was developed to stimulate GH with minimal cortisol and prolactin effect compared to earlier secretagogues.

References

Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology, 1998. View source
Harlow SD, et al. “Executive Summary of the Stages of Reproductive Aging Workshop + 10.” Journal of Clinical Endocrinology & Metabolism, 2012. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

The Glow Stack: Where Recovery Science Meets Radiant Skin

2026-08-04T00:00:00.000Z

Here's a truth most dermatology counters won't tell you: the most dramatic skin changes of a woman's life aren't about skincare at all — they're about hormones. Estrogen is one of your skin's most important structural allies, and as it declines through perimenopause, collagen goes with it. The Glow stack — BPC‑157, TB‑500, and the copper peptide GHK‑Cu — approaches skin and tissue quality from the inside, which is exactly where the problem starts.

What Is the Glow Peptide Stack?

The Glow stack builds on the classic Wolverine repair combination (BPC‑157 + TB‑500) and adds a third peptide with a very different specialty:

BPC‑157 — studied in animal models for repair of gut lining, tendon, ligament, and muscle tissue, with anti-inflammatory activity.
TB‑500 (Thymosin Beta‑4) — involved in cell migration and wound healing, helping repair processes reach the tissues that need them.
GHK‑Cu — a naturally occurring copper-binding peptide, one of the most-researched molecules in skin science, associated with collagen and elastin synthesis, skin remodeling, and antioxidant defense.

The result is a single compounded injectable designed around a simple idea: repair the body's tissues and the visible tissue you face the world with — your skin.

GHK-Cu: The Copper Peptide Your Body Is Losing

GHK‑Cu deserves its own spotlight. This tripeptide circulates naturally in your plasma — but here's the part that matters for midlife women: its levels decline dramatically between your twenties and your sixties. That decline runs in parallel with the changes women notice in skin firmness, elasticity, and healing speed.

In laboratory and cosmetic research, GHK‑Cu has been associated with:

Stimulating collagen and elastin production in skin fibroblasts
Supporting wound healing and tissue remodeling
Antioxidant and anti-inflammatory activity at the cellular level
Improvements in skin density, firmness, and fine lines in topical cosmetic studies

Much of the strongest human data comes from topical use in cosmetic trials, while injectable use draws on broader tissue-repair research. That's why GHK‑Cu is generally available in two forms — this injectable stack for systemic support, and a topical GHK‑Cu cream for targeted skin application. For some women, the answer is one or the other; for others, it's both.

Perimenopausal skin change isn't a skincare failure. It's an estrogen story — and it deserves a strategy that starts deeper than the surface.

The Hormone–Collagen Connection Nobody Explains

Estrogen receptors are abundant in skin. Estrogen supports collagen synthesis, skin thickness, hydration, and wound healing — which is why research suggests women lose a striking share of their dermal collagen in the years immediately following menopause, with the steepest decline early on.

This is the context that matters most for any woman considering the Glow stack. If your hormonal foundation is crumbling, a peptide alone is asking one worker to rebuild a house while the foundation is still sinking. The most durable results come from sequencing: assess and support hormones, secure protein intake and micronutrients (collagen is built from raw materials), then consider peptide support. That's functional medicine — root cause first, accelerants second.

Beyond Skin: What Else This Stack May Support

Because the Glow stack keeps the full Wolverine repair duo on board, its potential reach extends past the mirror: joint and tendon comfort, workout recovery, gut-lining support, and post-procedure healing. It draws particular interest among women recovering from cosmetic procedures — microneedling, laser, surgery — where both systemic repair and collagen remodeling are the goal. Any such use should be coordinated directly with the treating provider.

Who the Glow Stack Is For

The women who gravitate toward this protocol are typically in their late 30s through 60s and are noticing accelerating skin changes alongside slower recovery — often right as perimenopause begins rewriting the rules. They're not looking for vanity; they're looking for congruence — to look as strong and vital as they're working to feel.

It's not appropriate during pregnancy or breastfeeding, with active malignancy, or with certain copper-metabolism disorders (a specific consideration for GHK‑Cu). A comprehensive medical intake with a licensed prescribing provider comes first.

Frequently Asked Questions

How is the Glow stack taken?

As a small subcutaneous injection using a fine insulin-style needle, self-administered at home after in-office training. Protocol length is individualized.

Injectable GHK-Cu vs. the topical cream — which is better?

They do different jobs. Topical GHK‑Cu has the strongest cosmetic evidence for the skin it touches; the injectable form is chosen for systemic tissue support. Your goals and your prescribing provider decide the route — and sometimes both are used.

When do women typically notice skin changes?

Collagen remodeling is inherently gradual. Most protocols run in cycles measured in weeks to a few months, with skin texture and firmness changes emerging over that horizon rather than overnight.

What if inflammation and gut issues are my bigger concern?

Then you may be a better fit for the Klow stack, which adds KPV — a peptide fragment studied for inflammatory and skin-barrier conditions.

The Klow Stack: A Four-Peptide Approach to Inflammation, Gut Lining & Skin

2026-08-04T00:00:00.000Z

Some women come to me with a gut problem. Some come with a skin problem. A surprising number have both — and no one has ever connected the two for them. The Klow stack is the peptide combination that comes up most often when inflammation itself is the through-line: BPC‑157, TB‑500, GHK‑Cu, and the peptide that gives this stack its "K" — KPV.

What Is the Klow Peptide Stack?

Klow is the most comprehensive of the combination protocols, layering four peptides into a single compounded injection:

BPC‑157 — studied for repair of the gut lining, tendon, ligament, and muscle, with anti-inflammatory effects in animal models.
TB‑500 (Thymosin Beta‑4) — involved in cell migration and wound healing.
GHK‑Cu — the copper peptide associated with collagen synthesis, tissue remodeling, and antioxidant activity.
KPV — a three-amino-acid fragment of alpha‑MSH, studied specifically for its anti-inflammatory signaling.

If Wolverine is about repair and Glow is about repair plus skin quality, Klow is about repair, skin, and quieting the inflammatory noise underneath both.

KPV: Small Peptide, Specific Job

KPV is remarkably small — just three amino acids (lysine, proline, valine) clipped from the tail of alpha‑melanocyte‑stimulating hormone, a molecule your body already uses in immune regulation. What makes KPV interesting to researchers is that it appears able to enter cells and interfere with inflammatory signaling pathways from the inside, rather than only acting at the cell surface.

The research attention has clustered in two places, and they're precisely the two places midlife women most often struggle:

Inflammatory conditions of the intestine — where preclinical work has examined KPV's effect on colitis models and intestinal barrier function.
Inflammatory skin conditions — including interest in eczema, psoriasis, and acne, where alpha‑MSH biology is already relevant.

Gut and skin aren't separate systems having separate problems. They're two surfaces of the same immune conversation.

The Gut–Skin Axis: Why This Combination Makes Sense

The gut–skin axis is one of the most clinically useful concepts in functional medicine. Your intestinal barrier, microbiome, and immune system are in constant dialogue, and skin often reflects that conversation. It's why so many women with rosacea, eczema, or unexplained flushing also describe bloating, irregularity, or food reactivity — and why treating the skin alone so often plateaus.

For women, hormones add a third voice. Estrogen and progesterone influence gut motility, microbiome composition, mast cell behavior, and skin barrier function. During perimenopause — when those hormones swing rather than glide — I frequently see previously stable gut and skin conditions destabilize at the same time. Women are told these are two coincidental new problems. They usually aren't.

The Klow stack is built for that convergence: BPC‑157 and KPV oriented toward the gut lining and inflammatory signaling, GHK‑Cu and TB‑500 oriented toward tissue repair and skin remodeling.

What Klow Doesn't Replace

I'll be blunt, because it matters clinically: a peptide stack is not a substitute for finding out why you're inflamed. Anyone considering Klow should be doing the investigative work alongside it — comprehensive stool analysis where indicated, hormone assessment, food-reactivity and nutrient evaluation, and a genuine look at sleep and stress physiology. That root-cause work is where I spend my time with patients. Peptides can shift the terrain; they don't answer the question of what put you there.

Nor is Klow a treatment for diagnosed inflammatory bowel disease or an autoimmune skin condition. If you carry one of those diagnoses, this is a conversation to have jointly with your gastroenterologist or dermatologist — not a swap for the care they're providing.

Who Might Be a Candidate

The women who ask about Klow are usually dealing with a stubborn combination — digestive symptoms that haven't fully resolved with dietary work, plus reactive or inflamed skin, plus the recovery slowdown and joint aches that so often arrive alongside perimenopause. They've usually done the elimination diets and the expensive serums. What they haven't had is a strategy that treats the inflammation as one problem instead of four.

Frequently Asked Questions

Should I start with Wolverine, Glow, or Klow?

It depends on what's loudest. Isolated injury or recovery: Wolverine. Skin and collagen priority: Glow. Active inflammation across gut and skin: Klow. That triage belongs in a clinical conversation, not on a menu.

How is it administered?

A small subcutaneous injection with a fine insulin-style needle, self-administered at home after training from the prescribing provider. Protocols are typically run in defined cycles rather than indefinitely.

Can I use this while on other medications?

Possibly — but interactions and underlying diagnoses have to be reviewed first by a licensed prescribing provider. Bring your full medication and supplement list to that conversation.

Is there an oral form of KPV?

KPV is available in other delivery forms in some settings; the version discussed here is the injectable four-peptide combination. Which form fits you is a clinical decision based on whether the target is systemic or gut-localized.

"Your Labs Are Normal" — Why You Can Feel Terrible With a Perfect Blood Panel

2026-07-05T00:00:00Z

It might be the sentence I hear most often from new patients: "My doctor ran everything and said it's all normal — but I feel awful."

Both things can be true, and understanding why changes how you advocate for yourself.

"Normal" is a statistical statement, not a health statement

A standard reference range is built from the population that gets tested at that lab — which skews toward people who had a reason to be tested. Falling inside that range means you're not a statistical outlier. It doesn't mean you're at your optimal, and it says nothing about your trajectory. A ferritin of 18 and a ferritin of 90 are both "normal," and they can feel like two different lives.

The question standard panels don't ask

Conventional screening is designed to catch disease. It's genuinely good at that, and I'm glad it exists. But "do you have a disease?" and "why are you exhausted, foggy, and gaining weight on the same routine that used to work?" are different questions. The second one usually lives in patterns across markers, in optimal-versus-normal gaps, and in tests that aren't on the default panel at all.

Markers worth a second look

A few examples of where "normal" hides useful information:

Thyroid: A TSH alone can look fine while free T3, free T4, and thyroid antibodies tell a more complete story.
Iron: Ferritin at the low end of normal is strongly associated with fatigue and hair changes in menstruating women.
Blood sugar: A normal fasting glucose can coexist with a fasting insulin that's quietly climbing — often years of warning you'd want to have.
B12: Bottom-quartile "normal" B12 can still be functionally low, especially alongside certain medications.
Sex hormones: A single-day estradiol or progesterone draw in perimenopause is a snapshot of a moving target; timing and pattern matter more than any one number.

None of this means your doctor did anything wrong — they answered the question their tools are built to answer. It means that if you feel unwell with normal labs, the next step isn't to doubt yourself. It's to ask a better-shaped question.

How to advocate at your next appointment

Bring symptoms as patterns with timelines, not adjectives: "waking at 3 AM five nights a week since January" gets a different response than "tired." Ask for your actual numbers, not just the verdict. And ask where in the range you fall — "normal" at the 3rd percentile is a finding.

Feeling terrible with perfect labs isn't a contradiction. It's a sign the investigation stopped one layer too early.

References

Verdon F, et al. “Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial.” BMJ, 2003. Improvement was seen in women with ferritin at or below 50 µg/L — a range routinely reported as normal. View source
Harlow SD, et al. “Executive Summary of the Stages of Reproductive Aging Workshop + 10.” Journal of Clinical Endocrinology & Metabolism, 2012. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

Waking at 3 AM, Every Night: The Perimenopause Sleep Pattern No One Warns You About

2026-07-12T00:00:00Z

There's a specific kind of insomnia that walks into my practice again and again: falling asleep is easy, but somewhere between 2 and 4 AM, you're suddenly wide awake — mind racing, sometimes warm, sometimes anxious for no reason you can name. By 5 AM you drift off again, just in time for the alarm.

If that's you, you're not imagining a pattern. Middle-of-the-night waking is one of the most consistent early signatures of perimenopause I see, and it often shows up before cycle changes do.

Why 3 AM, specifically?

Two systems intersect in the early morning hours. First, progesterone — which has a calming, sleep-stabilizing effect on the brain — is typically the first hormone to decline in perimenopause. Less of that stabilizing signal means lighter, more fragile sleep architecture in the second half of the night.

Second, cortisol begins its natural pre-dawn rise around 2–3 AM. In a well-regulated system, you sleep through it. In a stressed or hormonally shifting system, that rise is steeper and earlier — enough to tip a lightly sleeping brain into full wakefulness. Add a blood sugar dip from an early dinner or an evening glass of wine, and the wake-up becomes almost scheduled.

The wine question

I'll say the unpopular thing gently: alcohol is the single most common aggravator of this pattern I see. It sedates you into the first half of the night, then rebounds — fragmenting exactly the sleep window that's already vulnerable. You don't have to quit; run a two-week experiment without it and let your own sleep data make the argument.

Where to start

Protect the pre-dawn window with an earlier, protein-inclusive dinner or a small protein-and-fat snack before bed if dinner is early — this smooths the overnight glucose curve.
Get bright light within 30 minutes of waking. Morning light anchors the cortisol rhythm, which makes the pre-dawn rise less likely to overshoot.
Cool the room more than you think you need. Thermoregulation gets twitchier in perimenopause; 65–67°F is a better target than "comfortable."
Track before you treat. A simple wearable can show you whether the problem is falling asleep, staying asleep, or waking early — three different problems with three different fixes. I like the ring-style trackers for this because there's no screen in bed.

On the supplement side, evening magnesium glycinate and, for some women, glycine or L-theanine can support sleep continuity — the professional-grade options I use are in my Fullscript dispensary. But if the 3 AM pattern is entrenched, the more useful step is figuring out which system is driving it, because progesterone-driven waking, cortisol-driven waking, and glucose-driven waking respond to different things.

The 3 AM wake-up feels random, but it's one of the most decodable symptoms in perimenopause. Once you know which of the three drivers is yours, the nights get boring again — in the best possible way.

References

“Correlation between allopregnanolone levels and depressive symptoms during late menopausal transition and early postmenopause.” PubMed, 2017. View source
Harlow SD, et al. “Executive Summary of the Stages of Reproductive Aging Workshop + 10.” Journal of Clinical Endocrinology & Metabolism, 2012. View source
Bromberger JT, et al. “Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition (SWAN).” Archives of General Psychiatry, 2010. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

Why You Crash at 3 PM (and Why Coffee Makes It Worse)

2026-07-20T00:00:00Z

You know the moment. It's 2:47 PM, your calendar says you have three more hours of real work, and your brain has quietly left the building. So you reach for coffee number three — and by 9 PM you're exhausted and wired, staring at the ceiling.

For high-achieving women in their 40s, the afternoon crash is one of the most common complaints I hear in practice — and one of the most misread. It gets blamed on discipline, on lunch, on "just getting older." In my experience, it's usually a physiology story with three chapters.

Chapter one: your cortisol curve is flattening

Cortisol is supposed to follow a strong daily rhythm — highest within an hour of waking, then a smooth taper toward evening. Years of chronic output pressure can flatten that curve: mornings feel groggy, afternoons collapse, and evenings bring a strange "second wind" right when you should be winding down.

If that pattern sounds familiar, the afternoon crash isn't the problem. It's the symptom.

Chapter two: blood sugar is amplifying it

A lunch that's mostly refined carbohydrate — the desk salad with sweet dressing and no real protein counts — produces a glucose spike and a compensatory dip about two hours later. That dip lands at, you guessed it, 3 PM. Two practical moves I give nearly every patient:

Anchor lunch with 30+ grams of protein. Protein blunts the glucose curve, which blunts the crash.
Walk for 10 minutes after eating. Working muscle pulls glucose out of the bloodstream without an insulin surge.

Chapter three: perimenopause changes the math

Estrogen and progesterone both influence how your brain responds to cortisol and insulin. As they begin to fluctuate — often starting in the early 40s, years before periods change — the energy stability you used to take for granted requires more deliberate support. This is why the strategies that worked at 35 stop working at 44. You didn't change. Your endocrine context did.

What about that third coffee?

Caffeine after roughly noon works against you twice: it borrows energy from your evening sleep, and in a flattened-cortisol pattern it can push the "wired and tired" cycle further. I don't take coffee away from my patients — I move it. One to two cups, finished by late morning, works with your rhythm instead of against it.

Where supplements fit (and where they don't)

Supplements are the third lever, not the first — food, light, and sleep timing come before any capsule. That said, two categories I use often in practice, under individualized guidance:

Magnesium glycinate in the evening, which many of my patients find supports sleep quality and stress resilience. You can find the professional-grade brands I use in my Fullscript dispensary.
Adaptogens such as rhodiola or ashwagandha, which some women find helpful for stress-related fatigue — but which should be matched to your cortisol pattern, not chosen off a listicle.

A caution worth repeating: "adrenal support" blends sold online often contain stimulants or glandulars that can make a dysregulated pattern worse. If you're going to supplement, test first or work with someone who can read your pattern.

The afternoon crash is information. It's your physiology telling you which system needs attention — and once you know whether yours is a cortisol story, a blood sugar story, or a perimenopause story (often it's all three), the fix becomes specific instead of generic.

References

Verdon F, et al. “Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial.” BMJ, 2003. View source
Lee CG, et al. “Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study.” Journal of Clinical Endocrinology & Metabolism, 2009. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

Is It Your Thyroid or Your Hormones? How Functional Medicine Finds the Answer

2026-07-25T00:00:00Z

There's a particular kind of frustration I hear in a first appointment, and it usually arrives with a folder of lab results. The story goes like this: exhausted for a year, gaining weight, losing hair, cold when everyone else is comfortable, thinking through fog. She looked up her symptoms — thyroid, obviously. She asked her doctor to check. The TSH came back normal. Case closed, symptom by symptom re-assigned to stress, age, or "doing too much."

Or the mirror-image story: she's in her mid-40s, so everything gets attributed to perimenopause — while an actual thyroid condition smolders untested underneath.

Both stories share the same root problem. The thyroid system and the sex-hormone system produce almost identical symptom lists, they interact with each other constantly, and standard practice usually investigates only one of them — briefly. Let's fix that.

Why the symptoms overlap so completely

Your thyroid sets the metabolic rate of essentially every cell in your body — brain, skin, hair follicles, gut, heart, muscle. Estrogen and progesterone modulate many of the same tissues, especially the brain. So when either system falters, the output looks the same from the outside: fatigue, weight gain, low mood, brain fog, hair changes, temperature intolerance, sleep problems, cycle changes.

A few clues lean one direction — cold intolerance, outer-eyebrow thinning, constipation, and puffiness lean thyroid; night sweats, cycle shortening, and 3 AM waking lean perimenopause — but I want to be honest: symptom lists alone cannot reliably separate these. Anyone who tells you they can diagnose you from a checklist is guessing. The separation happens through complete testing, interpreted in context.

The problem with "we checked your thyroid"

When most doctors say they checked your thyroid, they mean they ran a TSH — thyroid-stimulating hormone. TSH isn't a thyroid hormone at all; it's the pituitary's request signal to the thyroid. It's a genuinely useful screening test, and I'm not here to trash it. But using TSH alone has three blind spots that matter enormously for women:

Blind spot one: it says nothing about conversion. Your thyroid mostly produces T4, a storage form, which your body must convert into T3 — the form that actually does the work in your cells. Stress, chronic dieting, inflammation, and certain nutrient shortfalls can all impair that conversion. A woman can have a beautiful TSH, adequate T4, and low free T3 — and feel every bit of it. TSH-only testing will never see her.

Blind spot two: it misses smoldering autoimmunity. Hashimoto's thyroiditis — the autoimmune condition that is far and away the most common cause of low thyroid in women — can produce elevated thyroid antibodies for years before TSH drifts out of range. Those years are frequently symptomatic. Testing antibodies (TPO and thyroglobulin antibodies) identifies the process early, when lifestyle and nutritional interventions have the most room to help.

Blind spot three: "normal" is a wide, wide range. Standard TSH ranges accommodate a large population spread. Many clinicians — including a good number in conventional endocrinology — note that the optimal zone for how patients actually feel is considerably narrower than the full lab range. Sitting at the far edge of normal is a finding worth discussing, not a conversation-ender.

A complete thyroid picture

When I evaluate a thyroid, I want five numbers, together, on the same day: TSH, free T4, free T3, TPO antibodies, and thyroglobulin antibodies (in some cases reverse T3 adds useful context). None of these are exotic or expensive tests. The pattern across them tells the story a lone TSH can't: Is the gland underproducing? Is production fine but conversion poor? Is there an autoimmune process? Each pattern points to a different intervention.

Now add the hormone layer — because they talk to each other

Here's what makes midlife the perfect storm, and why "thyroid or hormones" is usually the wrong question: these systems directly influence each other.

Estrogen affects the proteins that carry thyroid hormone through your bloodstream — meaning the estrogen turbulence of perimenopause can change how much free, usable thyroid hormone reaches your tissues, even when the gland's output is unchanged. Cortisol, elevated by the chronic stress that tends to peak in these same years, suppresses the T4-to-T3 conversion and can blunt tissue response to thyroid hormone. And perimenopause itself is a stress amplifier — broken sleep raises cortisol, which impairs thyroid function, which deepens fatigue, which erodes the exercise and sleep that would help. The systems don't fail in isolation; they pull on each other.

This is also the age when Hashimoto's incidence climbs — so it is genuinely common for a woman to be experiencing early autoimmune thyroid disease and perimenopause simultaneously, with each being told the other's symptoms belong to it.

How functional medicine approaches the puzzle

The functional medicine difference isn't secret tests — it's completeness and context. In practice, the workup for this symptom picture looks like:

The full thyroid panel above — all five markers, together
Sex hormones interpreted against your cycle and stage — estradiol, progesterone, FSH, and testosterone, read as a pattern over time rather than a single-day verdict (one draw in perimenopause is a snapshot of a moving target)
The amplifiers and impersonators — cortisol rhythm across the day, fasting insulin and glucose, ferritin (iron), vitamin D, and B12. Low ferritin alone can reproduce nearly the entire "thyroid" symptom list and is remarkably common in women who are still cycling.
A real history — symptom timeline, cycle history, stressors, sleep, diet history (including chronic under-eating, which suppresses thyroid function all by itself), and family autoimmune history

Then the findings get read as a system. Sometimes the answer is genuinely thyroid, and appropriate treatment is life-changing. Sometimes it's genuinely perimenopause. Very often it's an interaction — a mildly struggling thyroid that a body could compensate for at 32, colliding with hormonal turbulence and a decade of accumulated stress at 46. Treating any single node of that triangle while ignoring the others is why so many women get partial results and conclude nothing works.

What you can do this week

If this article is your story, three concrete moves:

Request the complete panel. Bring the list: TSH, free T4, free T3, TPO and thyroglobulin antibodies, plus ferritin, vitamin D, B12, fasting insulin. These are standard, insurable labs; you're allowed to ask for them, and "let's be thorough" is a reasonable sentence to say out loud.
Get your actual numbers, not the verdict. "Normal" is the beginning of the conversation. Where in the range? Trending which direction versus last year?
Track your pattern for two weeks — energy by time of day, sleep, cycle, temperature comfort. Pattern data makes any practitioner better at helping you, and it makes dismissal harder.

The fatigue-weight-fog-hair cluster is real, common, and decodable. The women who get answers aren't the ones with rarer conditions — they're the ones whose investigation didn't stop at a single number. Make sure yours doesn't.

References

Verdon F, et al. “Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial.” BMJ, 2003. View source
Harlow SD, et al. “Executive Summary of the Stages of Reproductive Aging Workshop + 10.” Journal of Clinical Endocrinology & Metabolism, 2012. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

Perimenopause Symptoms: What's Normal and What's a Red Flag

2026-07-26T00:00:00Z

Ask most people what perimenopause looks like and you'll get the movie version: a woman in her early fifties fanning herself through a hot flash while her periods wind down. That version exists. But it's the final act of a transition that typically begins in the early-to-mid 40s — sometimes late 30s — and the opening acts look nothing like the movie.

The opening acts look like anxiety that arrived out of nowhere. Sleep that broke for no reason. A brain that suddenly can't hold a name or a word you've used your whole life. Weight settling around your middle despite unchanged habits. Joints that ache like you aged a decade in a year.

Because these early symptoms don't match the movie, most women don't connect them to hormones — and, frankly, neither do many of their doctors. I've lost count of patients who spent years being offered an antidepressant, a sleep aid, and a shrug before anyone said the word "perimenopause." So let's map the territory: what's common, what's expected, and — just as important — what should not be waved off as "just hormones."

What's happening underneath

Perimenopause isn't a smooth decline in hormones. It's turbulence. Progesterone typically falls first and most steadily, taking its calming, sleep-supporting influence with it. Estrogen doesn't simply drop — it swings, sometimes spiking higher than in your 30s before crashing, cycle to cycle and even week to week. Your brain, which has estrogen receptors everywhere — mood circuits, memory circuits, temperature regulation — is riding those swings. That's why the early symptoms are so often neurological and emotional rather than the classic physical ones.

Common and expected (which doesn't mean ignorable)

These are the symptoms I consider consistent with the normal physiology of the transition:

Cycle changes — shorter cycles at first (25–26 days where you used to run 28–30), then variability, skipped months, heavier or lighter flow
Sleep disruption — especially middle-of-the-night waking around 2–4 AM, often the very first sign
New or amplified anxiety and irritability — including a shortened fuse that feels genuinely out of character
Brain fog — word-finding pauses, walking into rooms without the reason, needing lists where you never did
Body composition shift — weight moving to the midsection, even at stable weight
Night sweats and warm flushes — often mild and sporadic years before classic hot flashes
Joint aches and new stiffness — estrogen is anti-inflammatory, and joints notice its swings
Changes in libido, vaginal dryness, more frequent UTIs
Hair thinning and drier skin

"Normal" here means explainable — not mandatory to endure. Every symptom on that list has meaningful support options, from lifestyle architecture to targeted supplementation to hormone therapy where appropriate. The bar for getting help is not "unbearable." The bar is "this is affecting my life."

Red flags: when it's not "just perimenopause"

This section matters most, because perimenopause's biggest danger is that it becomes a basket that catches symptoms belonging to something else. See a doctor promptly — and don't accept a hormonal hand-wave — for any of the following:

Very heavy bleeding — soaking through a pad or tampon every hour for several hours, flooding, or clots larger than a quarter. Common causes like fibroids or polyps are treatable, but heavy bleeding can also cause serious anemia and occasionally signals something that needs ruling out.
Bleeding between periods, after sex, or any bleeding after 12+ months without a period. Post-menopausal bleeding in particular always warrants evaluation. Usually benign — but "usually" is a word to verify, not assume.
Periods that stop before age 40, which merits a real workup rather than a shrug.
Sudden, severe symptoms — drenching night sweats with fever, unexplained weight loss, a racing heart at rest. Overactive thyroid, infections, and other conditions can impersonate perimenopause.
Depression that feels dangerous — hopelessness, or thoughts of harming yourself. Hormonal shifts genuinely can destabilize mood, and that makes real support more urgent, not less. This is a today problem, not a next-physical problem.
New severe headaches, chest pain, or breathlessness — never a hormone-basket symptom.

The pattern in that list: perimenopause explains a lot, but it should be a diagnosis of fit, not a diagnosis of default. When a symptom is extreme, sudden, or escalating, it's earned an investigation.

Why testing is tricky — and still useful

Here's an honest limitation: because estrogen swings so widely in perimenopause, a single blood draw can catch you on a high day or a low day and tell you very little. A "normal estradiol" on Tuesday doesn't rule out the transition. This is why perimenopause is primarily diagnosed by pattern — your age, cycle changes, and symptom cluster — not by one number.

Testing still earns its keep in two ways: ruling out impersonators (thyroid disease, iron deficiency, and blood sugar dysregulation top the list, and all are common in this decade), and establishing baselines that make treatment decisions smarter. The mistake isn't testing — it's letting one snapshot overrule a two-year pattern.

When to act

My rule of thumb is simple: act when symptoms start editing your life. When you're declining evening plans because you know sleep will be broken. When the anxiety is loud enough that you're managing around it. When you've quietly lowered your expectations of your own brain. Those are not signs to wait out — the transition can run four to ten years, and "white-knuckling it" is a long strategy.

And the earlier you address the foundations — sleep architecture, blood sugar stability, strength training, stress load — the smoother the entire transition tends to run. Perimenopause is not a disease. But it is a renegotiation between you and your physiology, and you'll get much better terms if you show up to the table informed.

References

Harlow SD, et al. “Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging.” Journal of Clinical Endocrinology & Metabolism, 2012. View source
Bromberger JT, et al. “Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women’s Health Across the Nation (SWAN).” Archives of General Psychiatry, 2010. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.

Why Can't I Lose Weight? The Hormone Connection Most Doctors Miss

2026-07-27T00:00:00Z

You're doing everything right. You track your food. You show up for workouts you don't always feel like doing. You've cut the wine back, you've tried intermittent fasting, you've done the 1,200-calorie thing that worked in your twenties. And the scale hasn't moved in months — or it's moving in the wrong direction.

At this point, most women do one of two things: they blame themselves, or they push harder. Eat less, train more, sleep less to fit it all in. And in a cruel twist of physiology, for a woman with hormonally driven weight loss resistance, pushing harder often makes the problem worse.

Here's the reframe I offer every patient who sits across from me with this story: if your effort is real and your results are absent, that's not a character flaw. That's data. It tells me something in your physiology is overriding the simple math — and in women over 40, the override is almost always hormonal.

The calorie model isn't wrong. It's incomplete.

Energy balance is real. But the "calories in, calories out" model treats both sides of that equation as things you control directly, and you don't. Hormones control them. Hormones regulate how hungry you are, where your body stores fat, how much energy you burn at rest, how efficiently you build muscle, and — critically — how your body responds to a calorie deficit. Two women can eat identical meals and do identical workouts and get completely different results, because the hormonal terrain those inputs land on is different.

So the useful question isn't "am I disciplined enough?" It's "what is my terrain doing?" In practice, I find weight loss resistance usually traces to one or more of five patterns.

Pattern one: cortisol is running the show

Chronic stress keeps cortisol elevated, and elevated cortisol does three unhelpful things at once. It raises blood sugar (your body thinks you need fuel for an emergency), it promotes fat storage specifically around the midsection, and it increases cravings for quick carbohydrates. This is why the most stressed years of your career often coincide with the appearance of belly fat that diet doesn't touch.

It's also why aggressive dieting backfires here: a severe calorie deficit is a stressor. Add it to an already-maxed stress load and you can raise cortisol further — driving the very storage pattern you're trying to fix. Some of the most dramatic progress I've seen has come from women who ate slightly more, trained slightly less, and slept an hour longer.

Pattern two: insulin resistance, years before diabetes

Insulin's job is to move glucose out of your blood and into your cells. When cells become resistant to that signal, the body compensates by producing more insulin — and insulin is a storage hormone. Chronically elevated insulin essentially locks the door on fat burning.

Here's what most women don't know: fasting glucose stays normal for years while insulin quietly climbs. A standard physical checks glucose and calls it a day. A fasting insulin test, which is inexpensive and widely available, can reveal the pattern a decade earlier. If you've never had your fasting insulin measured, that's one of the first conversations to have.

Pattern three: estrogen and progesterone are shifting

Perimenopause changes your body composition math even when nothing else changes. Declining and fluctuating estrogen shifts fat storage from hips and thighs toward the abdomen, and it reduces insulin sensitivity — so the same breakfast produces a bigger glucose response at 47 than it did at 37. Meanwhile, falling progesterone disrupts sleep, and poor sleep independently raises hunger hormones and cortisol the next day.

This is why "nothing changed but my weight" is such a common perimenopause sentence. Something did change. It just wasn't your behavior.

Pattern four: your thyroid is underperforming — subtly

The thyroid sets your metabolic rate, and even a modest slowdown shows up as gradual weight gain, cold hands, thinning hair, and fatigue. The catch is that standard screening usually checks TSH alone, and a "normal" TSH can coexist with suboptimal thyroid function. A complete picture includes free T4, free T3, and thyroid antibodies — because autoimmune thyroid disease, which is common in women, can smolder for years before TSH moves. (This deserves its own article, and it has one: Is It Your Thyroid or Your Hormones?.)

Pattern five: you're under-muscled, not over-fat

Muscle is your metabolic engine — it's where most of your glucose gets disposed of and a major driver of resting energy burn. Women lose muscle steadily from their 30s onward unless they actively fight for it, and decades of cardio-plus-calorie-cutting accelerates the loss. Less muscle means lower metabolic rate and worse insulin sensitivity, which means weight loss gets harder every year on the same routine.

The fix is direction-changing but simple: prioritize resistance training two to four times a week, and eat enough protein to build with — for most of my patients, that's a target of roughly 100 grams a day, front-loaded at breakfast. Almost every woman I work with is shocked by how far below that she's been eating.

What testing actually looks like

If this article is describing you, here's the panel conversation to have — with your doctor, or with a practitioner trained to look at the full pattern:

Fasting insulin and glucose together (and ideally HbA1c) — to see the insulin-resistance pattern early
Complete thyroid panel — TSH, free T4, free T3, and thyroid antibodies
Cortisol rhythm — not a single morning blood draw, but a pattern across the day
Sex hormones in context — estradiol, progesterone, and testosterone, interpreted against your cycle stage and symptoms rather than a lone reference range
Ferritin and vitamin D — low levels of either sabotage energy and training capacity

None of these are exotic. What's uncommon is running them together and reading them as a system — because the patterns overlap and amplify each other, and treating one while ignoring the others is how women end up doing everything right for years with nothing to show for it.

Where supplements fit

Honestly? Fourth or fifth on the list — after sleep, protein, resistance training, and stress architecture. But a few have consistent supporting roles in my practice: magnesium (most women are under-consuming it, and it participates in blood sugar regulation and sleep), omega-3s, and for some women inositol, which has meaningful research behind it for insulin sensitivity. Quality matters enormously in this category; the professional-grade brands I use clinically are in my Fullscript dispensary. But please hear the order of operations: no capsule out-lifts a barbell or out-regulates a full night of sleep.

The bottom line

Weight loss resistance is a message, not a verdict. When effort stops producing results, your body isn't broken and your willpower isn't weak — a regulatory system is doing exactly what its inputs are telling it to do. Find the pattern, and the same effort that's been failing starts working again. I've watched it happen hundreds of times, and it never stops being satisfying — mostly because of what women say when it does: "I thought it was me."

It was never you. It was your terrain. And terrain can be mapped.

References

Harlow SD, et al. “Executive Summary of the Stages of Reproductive Aging Workshop + 10.” Journal of Clinical Endocrinology & Metabolism, 2012. View source
Lee CG, et al. “Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study.” Journal of Clinical Endocrinology & Metabolism, 2009. View source
Verdon F, et al. “Iron supplementation for unexplained fatigue in non-anaemic women.” BMJ, 2003. View source

Where a compound is investigational, that is stated in the disclosure at the top of this article. Regulatory status was checked against FDA materials current at the time of publication.